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Deutsche Zusammenfassung 
 
TAP („transporter associated with antigen processing“) spielt eine zentrale Rolle in der 
MHC („major histocompatibility complex“) I abhängigen Antigenprozessierung. Dabei 
transportiert TAP proteasomale Degradationsprodukte vom Zytosol ins Lumen des 
Endoplasmatischen Retikulums (ER). Dort werden die antigenen Peptide auf MHC I 
Moleküle geladen. Anschließend werden peptidbeladene-MHC Moleküle an die 
Zelloberfläche transportiert, um ihre antigene Fracht zytotoxischen T-Lymphozyten zu 
präsentieren. Erkennen diese zytotoxischen T-Zellen via dem T-Zellrezeptor virale oder 
onkogene Proteinfragmente, führt dies zur Elimination der virusinfizierten oder 
transformierten Zelle.  
TAP gehört der Familie der ABC („ATP binding cassette“) Transporter an, die die 
Energie der ATP Hydrolyse ausnutzen, um Substrate über Membrane zu transportieren. TAP 
bildet einen Heterodimer bestehend aus TAP1 und TAP2. Jede Untereinheit baut sich aus 
einer N-terminalen Transmembrandomäne (TMD) und einer C-terminalen 
Nukleotidbindungsdomäne (NBD) auf. Die TMDs bilden die Translokationspore und die 
Peptidbindungstasche. Die NBDs binden und hydrolysieren ATP, was den Peptidtransport 
über die Membran antreibt. Die Transmembrandomänen bestehen jeweils aus 10 
Transmembranhelizes, wobei die sechs C-terminalen Transmembranhelizes in Kombination 
mit der Nukleotidbindungsdomäne jeder Untereinheit den Kernkomplex formen, welcher für 
den Peptidtransport ausreichend ist. Wie aus einem Homologiemodell von TAP basierend auf 
der Röntgenkristallstruktur des bakteriellen ABC-Exporters Sav1866 hervorgeht, sind die 
Transmembranhelizes auf der extrazellulären Seite durch kurze Schleifen–helikale α 
verbunden. Die zytosolischen Schleifen (CL) dagegen stellen Verlängerungen der 
Transmembranhelizes dar, die durch eine ca. 10 Aminosäure umfassende, parallel zur 
Membranebene liegende Kopplungshelix (CH) verbunden sind. Interessanterweise bilden 
diese CLs sowohl Kontakte mit der NBD der eigenen (cis-Interaktion) als auch mit der 
gegenüberliegenden Untereinheit (trans-Interaktion). In den NBDs sind vor allem der Q-
Schleife wie auch der für ABC-Exporter einzigartige X-Schleife in diese 
Interdomäneninteraktion involviert. In biochemischen Studien konnte gezeigt werden, dass Deutsche Zusammenfassung 
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die TMDs und NDBs während des Transportvorgangs in einer gekoppelten Art und Weise 
zusammenarbeiten.  
Die zentrale Frage im ABC-Transporterfeld beschäftigt sich momentan damit, die 
Bedeutung dieser Interaktionsschnittstelle aufzuklären und strukturelle Änderungen dieser 
Schnittstelle im Verlauf des Transportvorgangs aufzuklären.  
Die Ziele meiner Doktorarbeit waren (i) den Mechanismus zu entschlüsseln, wie die 
Anwesenheit von gebundenem Peptid in der Peptidbindungstasche an die NBDs übermittelt 
wird. (ii) Desweiteren sollte die Bedeutung dieser Transmissionsschnittstelle aufgeklärt 
werden und (iii) weiterhin strukturelle Veränderungen während des Transportzyklus 
untersucht werden.  
Mit Hilfe eine kleinen, chemischen Protease kovalent an Peptidliganden von TAP 
gebunden, konnte eine bisher nicht beschriebene Interaktionsstelle detektiert werde. Um die 
physikalische Interaktion dieses in der CL1 von TAP1 gelegen Bereichs mit dem Peptid 
nachzuweisen, wurden durch gezielte Mutagenes einzelne Cysteine in cysteinloses TAP 
eingeführt und zusammen mit wt TAP2 mit dem Baculovirusexpressionssystem in 
Insektenzellen exprimiert. Die eingeführten Cysteine hatten keinen Einfluss auf die Faltung 
von TAP, da alle TAP-Varianten in vergleichbaren Mengen exprimiert wurden und die 
Peptidbindung durch diese Mutationen nicht beeinflusst wurde. Allerdings interferierten 
Cysteinsubstitutionen der am stärksten konservierten Aminosäurenreste in diesem Bereich 
(G282C, I284C und R287C) sehr stark mit dem Peptidtransport. Die Entkopplung zwischen 
Peptidbindung und Transport in diesen Mutanten legt nahe, dass diese Region in CL1 von 
TAP1 eine Art Transmitterfunktion einnimmt, indem sie den Beladungszustand der 
Peptidbindungstasche in der TMD an die NBD übermittelt. Die physikalische Nähe des 
Peptids zu diesem Transmitter konnte mittels oxidativer Quervernetzung von Cysteinen in 
dieser Region mit einem Cystein des gebunden Peptids nachgewiesen werden. Neben der 
Position 288 stehen allerdings schwächer die Positionen 284, 285 und 286 in TAP1 in 
Kontakt mit dem gebundenen Peptid. Durch Zugabe von ATP wird die Wechselwirkung mit 
der Position 285 unterbrochen, was auf eine strukturelle Flexibilität von TAP in diesem Deutsche Zusammenfassung 
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Bereich hindeutet. Position 288 dagegen steht sowohl in Anwesenheit sowie in Abwesenheit 
von Nukleotiden (ATP, ADP, AMP-PNP, ATPγS) in Kontakt mit dem gebundenen Peptid. 
Allerdings ging diese Interaktion in Anwesenheit von ADP-AlFx, welches den 
Übergangszustand der Hydrolyse fixiert, verloren. Zusammenfassend zeigen diese 
Ergebnisse, dass der neu identifizierte Bereich als Peptidsensor wirkt, der sich im Verlauf des 
Transportzyklus strukturell reorganisiert und somit als Transmitter zwischen TMD und NBD 
fungiert.  
Um den molekularen Aufbau des CL1 zu entschlüsseln, wurde ein minimal invasiver 
Ansatz gewählt, bei dem die Zugänglichkeit von einzel eingeführten Cysteinen in diesem 
Bereich mittels thiolspezifischer Fluoreszenzfarbstoffen mit unterschiedlicher 
Hydrophobizität analysiert wurde. Die N-terminalen Postionen von CL1 (Q277C, G282C, 
N283C und I284C) zeigten eine hohe Markierungseffizienz für den hydrophilen Farbstoff 
Iodacetamidofluorescein, den amphiphilen Farbstoff BODIPYmaleimid sowie den 
hydrophoben Fluoreszenzfarbstoff Coumarinmaleimid, sodass diese Region exponiert zu 
schein sein. Der C-terminale Bereich von CL1 dagegen (M285C, S286C, R287C und V288C) 
zeigte nur mit Coumarinmaleimid eine hohe Markierungseffizienz, was darauf hinweist, dass 
diese Seitenketten in einer hydrophoben Umgebung sich befinden.  
Um auch kleinste strukturelle Änderungen der CL1 während des Transportvorgangs zu 
identifizieren, wurden Markierungskinetiken mittels BODIPYmaleimid im nukleotidfreien, 
im ATP gebundenen sowie im posthydrolytischen Zustand bestimmt. So ist zum Beispiel die 
Markierungsratenkonstante der Mutante I284C im nukleotidfreien Zustand 100-mal schneller 
als im ATP-gebundenen Zustand und 36-mal schneller als in Gegenwart von ADP. Betrachtet 
man die Ratenkonstante der Markierung, so konnten die CL1-Mutanten in vier Gruppen 
unterteilt werden:  
i.  Seitenketten mit einer langsamen Markierungskinetik für alle getesteten Bedingungen 
(N283C, R287C, V288C)  Deutsche Zusammenfassung 
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ii.  Seitenketten mit eine schnelleren Markierungskinetik im nukleotidfreien Zustand als 
im ATP-gebundenen Zustand (I284C, M285C, S286C)  
iii.  Seitenketten mit eine schnelleren Markierungskinetik in Gegenwart von ATP als im 
nukleotidfreien Zustand (G282C)  
iv.  Seitenketten mit eine schnelleren Markierungskinetik im nukleotidfreien Zustand oder 
in Gegenwart von ADP als im ATP-gebundenen Zustand (Q277C)  
  Neben der Ratenkonstante wurden die einzelnen Mutanten auch nach der 
Markierungseffizienz klassifiziert, wobei diese nicht direkt mit den Ratenkonstanten 
korreliert:  
i.  Seitenketten mit der höchsten Markierungseffizienz im ATP gebundenen Zustand 
(Q277C)  
ii.  Seitenketten mit der höchsten Markierungseffizienz im ADP gebundenen Zustand 
(N283C, R287C, V288C)  
iii.  Seitenketten mit der höchsten Markierungseffizienz im nukleotidfreien Zustand 
(G282C)  
iv.  Seitenketten mit ähnlicher Markierungseffizienz in allen untersuchten Zuständen 
(I284C, M285C, S286C)  
  Die signifikanten nukleotidabhängigen Unterschiede sowohl der 
Markierungseffizienzen als auch der Markierungskinetiken belegen die Vermutung, dass die 
Struktur dieses Peptidsensor in CL1 in einer nukleotidabhängigen Art und Weise verändert 
wird. Somit ist CL1 sowohl an der Signaltransduktion von der TMD zur NBD als auch in die 
entgegengesetzte Richtung beteiligt.  
Um den Effekt der Fluoreszenzmarkierung des CL1 in TAP1 auf die Funktionalität 
des Peptidtransportkomplexes zu adressieren, wurden alle Einzelcysteinmutanten mit Deutsche Zusammenfassung 
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BODIPYmaleimid markiert. Während alle Mutanten eine reduzierte Transportaktivität durch 
die Fluorophormarkierung aufwiesen, blieb die Peptidbindung unverändert. Somit entkoppelte 
diese kovalente Modifikation die Peptidbindung vom Transport, indem die Signalübertragung 
zwischen TMD und NBD gestört wurde.  
Um die Funktion dieser Transmissionsschnittstelle weiter zu studieren und die 
Bedeutung der trans-Interaktion in einem heterodimeren ABC-Halbtransporter zu 
untersuchen, wurde das konserviert Glutamat im X-Schleife von TAP2 durch verschiedene 
Aminosäuren ersetzt. Da all diese X-Schleife Mutanten keinen Einfluss auf die Peptidbindung 
hatten, ist dieser Bereich in TAP2 weder für die Membraninsertion noch für die 
Heterodimerisierung von Bedeutung. Allerdings zeigten alle Mutanten eine verringerte 
Transportaktivität. TAP Komplex mit der E602C Variante wiesen eine um 50% verringerte 
Transportrate auf. Mutationen zu Aspartat oder Alanin reduzierten den Transport um 80% und 
die Einführung eines Arginins an Position 602 führt zum völligen Verlust des 
Peptidtransports. Daraus geht hervor, dass dem hoch konservierte Glutamat des X-Schleifen 
eine Schlüsselrolle in der Translokation zukommt, ohne einen Einfluss auf die Peptidbindung 
zu haben.  
Um Seitenketten in TAP1 zu identifizieren, welche mit dem X-Schleife in TAP2 in 
trans interagieren, wurden mit Hilfe des Homologiemodells des Kern-TAP-Komplexes 24 
Aminosäuren in CL1 und CL2 von TAP1 identifiziert, die E602 in TAP2 umgeben. All diese 
Einzelcysteinmutanten von TAP1 wurden zusammen mit der E602C Mutante von TAP2 
exprimiert. Keine der CL1-Mutationen beeinflussten die Peptidbindung. Dagegen 
interferierten alle CL1-Mutanten ausser Q277C mit dem Peptidtransport. In CL2 ergab sich 
allerdings ein ganz anderes Bild. Nur die R378C Substitution verringerte signifikant 
Peptidbindung und in Folge dessen Peptidtransporter. Zusätzlich hatte die Mutation P375C 
einen staken negativen Effekt auf den Peptidtransport ohne jedoch die Peptidbindung zu 
beeinträchtigen. Daraus kann geschlossen werden, dass CL2 nur eine geringe Bedeutung für 
die Signaltransduktion zwischen TMD und NBD hat. Deutsche Zusammenfassung 
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Zur Verifizierung der aus röntgenkristallographischen  Strukturen vorhergesagten 
trans-Interaktion zwischen zytosolischen Schleifen und dem X-Schleife in der NBD, wurden 
mit Hilfe der Cysteinmutanten Quervernetzungsexperimente durchgeführt. Dabei zeigte sich, 
dass CL1 sowie CL2 von TAP1 mit dem X-Schleife in TAP2 interagieren und damit auch in 
einem heterodimeren ABC-Exporter eine trans-Interaktion zwischen TMD und NBD besteht. 
Die Quervernetzung zwischen CL2 und dem X-Schleife arretiert TAP in einer Konformation, 
in der Peptide nicht mehr binden können. Die Quervernetzung zwischen CL1 und dem X-
Schleife dagegen beeinträchtigt die Peptidbindung nicht, sondern inhibiert ausschließlich den 
Transport. Diese Fixierung verhindert somit strukturelle Änderungen im TAP Komplex, 
sodass die Kommunikation zwischen den Domänen verhindert wird.  
Basierend auf diesen Ergebnissen kann festgestellt werden, dass das Zusammenspiel 
der TMDs und NBDs in TAP ein hoch komplexer und dynamischer Prozeß darstellt. 
Eingeleitet durch die Peptidbindung, welche mittels des Peptidsensors an die NBD signalisiert 
wird, kommt es in Gegenwart von ATP zur Dimerisierung der NBDs. Diese Dimerisierung 
löst weitere konformationelle Änderungen in den TMDs aus, wodurch es zur 
Peptidtranslokation kommen kann. Durch die ATP-Hydrolyse wird der Transporter wieder in 
den Grundzustand versetzt. Den zytosolischen Schleifen (CL1 und CL2) kommt dabei eine 
zentrale Rolle in der Signalübertragung zwischen den Domänen zu. Desweiteren sind sie auch 
an der Peptidbindung und Qualtitätskontrolle beteiligt.  
    Summary 
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Summary 
 
  By translocating proteasomal degradation products into the endoplasmic reticulum 
(ER) for loading of major histocompatibility complex (MHC) class I molecules, the ATP 
binding cassette (ABC) transporter associated with antigen processing (TAP) plays a pivotal 
role in the adaptive immunity against infected or malignantly transformed cells. A key 
question regarding the transport mechanism is how the inter-domain communication and 
conformational dynamics of the TAP complex are connected during the peptide transport. 
 
  To identify residues involved in this processes, we evolved a Trojan horse strategy in 
which a small artificial protease is inserted into antigenic epitopes. After binding, the TAP 
backbone in contact is cleaved, allowing the peptide sensor site to be mapped by mass 
spectrometry. Within this study, the peptide sensor and transmission interface have been 
identified. This region aligns with the cytosolic loop 1 (CL1) of Sav1866 and MsbA. Based 
on a number of experimental data and the homology to the bacterial ABC exporter Sav1866, 
we constructed a 3D structural model of the core TAP complex. According to this model, the 
CL1 and CL2 of TAP1 are extended cytosolic loops connecting the transmembrane helices 
(TMH) 2 and 3, and TMH4 and 5 respectively, and contact both nucleotide binding domains 
(NBDs) of the opposite subunit. In contrast to exporters, the cytosolic loop (named L-loop) of 
BtuCD importer is much shorter, and contacts only one NBD. 
 
  The data confirm that the CL1 of TAP1 functions as signal transducer in ABC 
exporters, because it does not interfere with substrate binding but with substrate transport. 
The peptide contact site identified herein is restructured during the ATP hydrolysis cycle. 
Importantly, TAP showed a structural change trapped in the ATP hydrolysis transition state, 
because direct contact between peptide and CL1 is abolished. By cysteine scanning, the most 
conserved residues within CL1 were identified, which disrupted the tight coupling between 
peptide binding and transport. Together with Val-288, these residues are essential in sensing 
the bound peptide and inter-domain signal transmission. 
 
  To characterize the molecular architecture of CL1, a convenient and minimally 
perturbing approach was used, which combined cysteine substitution in the CL1 region and 
determination of accessibility to thiol specific compounds with different properties. These 
studies revealed that the N-terminal region of CL1 has a good accessibility for hydrophilic 
(iodoacetamidofluorescein, IAF) and amphiphilic probes (BODIPY maleimide, BM), whereas    Summary 
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the C-terminal region is accessible for hydrophobic probe (coumarin maleimide, CM). Kinetic 
studies of fluorescence labeling suggest that this region displayed a different accessibility to 
probes when the protein undergoes distinct conformations (e. g. nucleotide free state), thereby 
reflecting conformational transitions. Fluorescence labeling with BM induces a lost of peptide 
transport, whereas the peptide binding remains unaffected. These results indicate that covalent 
modifications of the CL1 residues influenced the inter-domain communication between 
transmembrane domain (TMD) and NBD.  
 
  The X-loop is a recently discovered motif in the NBD of ABC exporters, which stays 
in close contact to the CLs. Moreover, because the X-loop precedes the ABC signature motif, 
it probably responds to ATP binding and hydrolysis and may transmit conformational changes 
to the CLs. By substitution of the highly conserved Glu-602 of TAP2 with residues that have 
different chemical properties, it was shown for the first time that the X-loop is a functional 
important element, which plays an key role in coupling substrate binding to downstream 
events in the transport cycle. We further verified domain swapping in the TAP complex by 
cysteine cross-linking. The TAP complex can be reversibly arrested either in a binding or 
translocation incompetent state by cross-linking of the X-loop to CL1 or CL2, respectively. 
These results resolve the structural arrangement of the transmission interface and point to 
different functions of the cytosolic loops in substrate recognition, signaling and transport. 
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1. Introduction 
 
1.1  MHC class I antigen presentation pathway 
 
Higher eukaryotic organisms must defend themselves against invaders and malignant 
cells to survive. Therefore, the adaptive immune system has evolved to protect the organism 
against pathogens. The adaptive immune system, developed in jawed vertebrates, allows for 
specific recognition and elimination of antigens that are abundant in body fluids or within 
cells (Flajnik and Kasahara, 2001). The recognition and elimination of mutated or infected 
cells are performed by the cellular immune system, which can be subdivided into the class I 
major histocompatibility complex (MHC) and the class II MHC pathways. MHC class I 
molecules are present on the surface of nearly all nucleated cells, whereas class II molecules 
are restricted to the cells of the immune system, such as dendritic cells, macrophages and B-
cells. 
A main task of the MHC class I-dependent pathway of antigen processing is the 
selection of highly abundant and high-affinity peptides for MHC class I loading and 
presentation to the immune system. Endogenous proteins are constantly degraded by the 
20S/26S proteasome, a multicatalytic protease complex in the cytosol (Rock et al., 1994; 
Coux et al., 1996; Baumeister et al., 1998; Früh and Yang, 1999; York et al., 1999). The 
contribution of the 20S proteasome for the generation of antigenic peptides is further 
strengthened by the observation that proteasomal subunits, LMP2 and LMP7 (low-molecular-
mass polypeptides), are encoded within the MHC locus (Brown et al., 1991; Glynne et al., 
1991; Martinez and Monaco, 1991). The catalytic core of the proteasome is a 20S (700 kDa) 
cylindrical particle composed of 28 subunits arranged in four heptameric rings. The outer 
rings are made up of seven α-subunits; the inner rings are composed of seven β-subunits. 
Whereas the α-subunits are thought to be primarily responsible for structural and regulatory 
functions, the β-subunits harbor the catalytic centers (Fenteany et al., 1995; Löwe et al., 1995; 
Seemüller et al., 1995). Another form of the proteasome is the 26S (1.500 kDa) particle. It 
contains the 20S complex and additional subunits associated with regulation of its activity 
(Rechsteiner  et al., 1993; Peters,  1994). The proteasome produces peptides with a size 
distribution of 3-30 residues with an optimum of 6-11 residues (Ehring et al., 1996; Kisselev 
et al., 1999). This size corresponds in part to the size of antigenic peptides bound to MHC 
class I molecules. During interferon (IFN)-γ stimulation, the three active proteasomal β-
subunits are replaced by LMP2 and LMP7 subunits to build up a so-called Chapter 1    Introduction 
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“immunoproteasome” (Rock and Goldberg, 1999). Immunoproteasomes show a different 
cleavage pattern compared with the proteasomes, thereby generating more peptides with 
hydrophobic and basic C-termini (Rock and Goldberg, 1999), both of them are favored for 
uptake by transporter associated with antigen processing (TAP) into the endoplasmic 
reticulum (ER) and for optimal binding to MHC class I molecules (Buttgereit and Tampé, 
2002). About one-third of newly synthesized proteins are rapidly degraded by proteasomes 
under physiological conditions (Schubert et al., 2000; Turner and Varshavski, 2000). 
However, peptides are also generated, at least in part, by other proteases, such as the IFN-γ-
inducible leucine aminopeptidase (Beninga et al., 1998) or a giant cytosolic protease system, 
the tripeptidyl peptidase II (Glas et al., 1998; Geier et al., 1999). In addition, the remaining 
peptides are processed by cytosolic peptidases like the two aminopeptidases puromycin-
sensitive aminopeptidase and bleomycin hydrolase (Stoltze et al., 2000). Below the length of 
15 amino acids, peptides are exclusively trimmed by tripeptidyl peptidase II, which displays 
both exo- and endopeptidase activity (Reits et al., 2004), and are subsequently translocated 
into the ER lumen by TAP. After further trimming of the peptides by the ER-luminal 
aminopeptidases 1 and 2 (Saric et al., 2002; Serwold et al., 2002; Saveanu et al., 2005) to a 
length of 8-11 residues (Falk et al., 1991; York et al., 2002), they are loaded onto MHC class 
I molecules, a complicated and tightly regulated process, which requires a macromolecular 
peptide-loading complex (PLC) comprised of TAP1, TAP2, tapasin, MHC class I heavy 
chain,  β2-microglobulin, calreticulin, and ERp57 (Ortmann et al., 1997; Antoniou et al., 
2002). Following peptide binding, MHC-peptide complexes are released from the PLC and 
shuttled via the Golgi apparatus to the cell surface where they are scanned by cytotoxic T 
lymphocytes (CTL), which may trigger an adaptive immune response (Figure 1-1). 
The chronic presentation of self-protein-derived peptides does not lead to a stimulation 
of T cells. During the development of the thymus, self-reactive T-cells are deleted. In case of 
malignant transformation or viral infection of the cells, an additional set of peptides is 
presented to the CTL. The intracellular pathways leading to the generation of peptides, their 
binding to MHC molecules, and presentation on the cell surface are called antigen processing 
and presentation (Buttgereit and Tampé, 2002). The recognition of MHC class I molecules as 
“self component” loaded with peptides from “non-self” proteins by CTL leads to apoptosis or 
lysis of malignant or infected cells. This is an essential process of the cellular immune 
response. The pathway of antigen presentation by the MHC class I complex is constitutively 
active in all nucleated cells and is upregulated by inflammatory cytokines. Interference with Chapter 1    Introduction 
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this pathway has evolved as an effective strategy for pathogens to evade immune response, 
leading to chronic or latent infections.  
 
Figure 1-1. Antigen presentation pathway via MHC class I molecules.  
The MHC I heavy chain is co-translationally translocated into the ER, where it folds and assembles with β2-
microglobulin assisted by the immunoglobulin binding protein (BiP) and calnexin. Subsequently, MHC class I 
molecules are recruited into a macromolecular peptide-loading complex (PLC) composed of calreticulin, ERp57, 
tapasin, TAP1 and TAP2. Peptides derived mainly by proteasomal degradation in the cytosol are translocated by 
TAP into the lumen of the ER, where they are loaded onto pre-assembled MHC class I molecules. Kinetically 
stable peptide-MHC complexes can escape the ER quality control and are transported via the Golgi to the cell 
surface. Binding of T-cell receptor and CD8 co-receptor to trimeric MHC class I molecules triggers the killing of 
the target cell (adapted from Schölz and Tampé, 2005). 
  
  TAP translocates peptides generated by the proteasome complex from the cytosol into 
the lumen of the ER. In the ER, peptides are loaded onto the newly synthesized MHC class I 
molecules. Deletion or mutation of TAP severely affects the translocation of peptides into the 
ER (Chen et al., 1996; Seliger et al., 2000; Seliger et al., 2001; Yang et al., 2003). Because 
binding of peptides stabilizes the MHC complex and induces subsequent export to the cell 
surface for presentation to T-cell receptors (Figure 1-1), any defect, which impairs the 
transport of peptides, results in reduced surface expression of MHC class I molecules. Despite 
the physical association of TAP and the MHC class I molecules, it was shown by inhibition of 
binding in cytosol after anti-peptide antibody application that possibly most TAP-transported 
peptides diffuse through the lumen of the ER before being loaded onto MHC class I 
molecules (Hilton et al., 2001). The stable binding of peptides to class I heterodimers releases Chapter 1    Introduction 
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the loaded MHC class I molecules from the assembly complex for transport to the cell surface 
via the Golgi apparatus and the trans-Golgi network. 
 
1.2  Overview of ABC transporters 
 
1.2.1  ABC transporters are ubiquitous and clinically important 
 
  ATP binding cassette (ABC) transporters are a large superfamily of integral membrane 
proteins that carry diverse substrates across cellular membranes. They are present in all 
organisms and contribute to various human diseases and to multidrug resistance in cancer 
cells. In bacteria, they catalyse the uptake of essential nutrients or the extrusion of, among 
others, toxic substances, thus contributing to drug and antibiotic resistance of pathogenic 
microbes (Holland et al., 2003). The human ABC transporters are classified by sequence 
homology into seven subfamilies, designated ABCA to ABCG (Dean et al., 2001). 
  There are 48 ABC proteins in humans and mutations in many are at the root of genetic 
disorders including a bleeding disorder (Albrecht et al., 2005) and a number of eye (Martinez-
Mir et al., 1998) and liver diseases (Jacquemin, 2000), all of which are caused by the failure 
to export a specific ligand across a lipid bilayer, as well as autoimmune diseases caused by 
genetic TAP defects (Table 1-1; Johnsen et al., 1999; Dean et al., 2001; Holland et al., 2003). 
The normal function of some human ABC transporters is to secrete cytotoxic compounds 
(dietary cytotoxics and therapeutic drugs). These transporters (P-glycoprotein, BCRP, and 
MRP1) are highly expressed in the gut, liver and kidneys where they restrict the 
bioavailability of administred drugs. P-glycoprotein and BCRP in particular are also 
expressed in the epithelia of sensitive tissues (for example, the brain and placenta (Schinkel et 
al., 1995; Jonker et al., 2000) and in stem cells (Zhou et al., 2001), where they perform a 
barrier function (Sarkadi et al., 2006). There are also a few atypical ABC proteins, which do 
not transport substrates, but they are either a channel for chloride ions such as the cystic 
fibrosis transmembrane regulator (CFTR; Tabcharani et al., 1991), or function as a regulator 
of a potassium channel such as sulphonyl urea receptor (SUR; Inagaki et al., 1995). Other 
atypical ABC proteins, which do not have transmembrane subunits, are involved in chromatin 
organization (Hirano, 2006), DNA repair, telomere maintenance (Hopfner et al., 2000; 
Obmolova et al., 2000), and mRNA trafficking through the nuclear pore (Kozak et al., 2002). 
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Table 1-1. Clinically relevant and atypical ABC proteins (Linton, 2007). 
ABC Protein  Pseudonym  Ligand(s)/Function Associated  Disease(s) 
ABC1 ABCA1  Cholesterol  Tangier  disease 
ABCR  ABCA4  Retinal  Various eye diseases 
TAP1/2 ABCB2/B3  Peptides  Autoimmune  diseases 
ABC7 ABCB7  Iron  Anemia  and  XLSA 
MRP6 ABCC6  ?  Pseudoxanthoma  elasticum 
ALD ABCD1  vlcFA  Adrenoleukodystrophy 
Sterolin1/2 ABCG5/G8  Sterols  Sitosterolemia 
PGY3/MDR3  ABCB4  Phosphatidylcholine  Liver disease: PFIC3, OC 
BSEP/SPGP  ABCB11  Bile acids  Liver disease: PFIC2 
MRP2  ABCC2  Conjugated bilirubin  Liver disease: D-J syndrome 
MDR1  ABCB1  Hydrophobic drugs  Failure of chemotherapy 
BCRP/MXR ABCG2  Hydrophobic  drugs   
MRP1 ABCC1  Conjugated  drugs  
MRP4 ABCC4  Conjugated  nucleosides   
     
  Atypical ABC proteins   
CFTR  ABCC7  Chloride ion channel  Cystic fibrosis 
SUR  ABCC8  Regulation of KIR channel  PHHI 
SMC1-6   Chromosome  maintenance   
RAD50    DNA, telomere repair   
Elf1p   mRNA  trafficking   
XLSA, X-linked sideroblastomic anemia; PFIC, progressive familial intrahepatic cholestasis; OC, obstetric 
cholestasis; D-J, Dubin-Johnson syndrome; PHHI, persistent hyperinsulinemic hypoglycemia of infancy. 
 
1.2.2  Architecture of ABC proteins 
 
  ABC transporters share a basic domain organization (Figure 1-2). Two transmembrane 
domains (TMDs) provide a passageway for the substrate, while two cytoplasmic nucleotide 
binding domains (NBDs) bind and hydrolyze ATP, providing the energy needed for active 
transport (Higgins, 1992). In ABC importers, TMDs and NBDs are produced as separate 
polypeptide chains, whereas in bacterial exporters, one TMD is fused to a NBD, generating a 
“half-transporter” that can form a homodimer or a heterodimer to generate the complete, 
functional ABC transporter. Many eukaryotic ABC exporters are “full-transporters” that 
feature all four domains in a single polypeptide chain. Archaea and bacteria contain importers 
and exporters, whereas eukaryotes contain only exporters (Beismann-Driemeyer and Tampé, 
2004). Crystal structures of numerous cytoplasmic NBDs have been determined at high 
resolution and have provided insight into the ATP hydrolysis mechanism (for review see Chapter 1    Introduction 
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Davidson and Chen, 2004). However, direct visualization of transmembrane domains is 
required to understand key features such as substrate acquisition and translocation. A key 
problem in obtaining high-resolution structures of full transporters consists of difficulties in 
producing, purifying and crystallizing dynamic membrane proteins. Crystal structures of 
seven complete ABC transporters have recently been determined, providing the molecular 
basis for understanding the transport reaction. Five of the structures are of ABC importers: the 
vitamin B12 transporter BtuCD from Escherichia coli (Locher et al., 2002), the putative 
metal-chelate transporter HI1470/71 from Haemophilus influenzae (Pinkett et al., 2007), the 
molybdate/tungstate transporter ModBC from Archaeoglobus fulgidus, determined in 
complex with its cognate-binding protein ModA (Hollenstein et al., 2007), the maltose 
transporter MalFGK2 from Escherichia coli determined in complex with the maltose-binding 
protein, maltose and ATP (Oldham et al., 2007), and the methionine transporter MetNI from 
Escherichia coli (Kadaba et al., 2008). Currently there are four structures of ABC exporters: 
the Sav1866 protein from Staphylococcus aureus, determined in ATP-bound state (Dawson 
and Locher, 2006), and the MsbA from Escherichia coli, Vibrio cholerae and Salmonella 
typhimurium trapped in different conformations, two nucleotide bound structures and two in 
the absence of nucleotide (Ward et al., 2007). Analyzing the basic architectural features of 
ABC transporters as revealed by these recent structures and the large amount of biochemical 
and functional data obtained so far, a conserved engine and transmission machinery common 
to all ABC transporters has been suggested. According to this model a molecular mechanism 
has been proposed by which binding of ATP flips the TMDs of ABC transporters into an 
outward-facing conformation, whereas dissociation of the hydrolysis products ADP and 
phosphate returns them to an inward-facing conformation (Dawson et al., 2007). 
 Chapter 1    Introduction 
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Figure 1-2. Domain organization and structure of two bacterial transporters.  
(A) Schematic representation of domain organization. Both, ABC importers and exporters contain two TMDs 
and two NBDs. In importers, these are separate subunits, whereas the ABC transporters of eukaryotes are built 
up of either one (TMD-NBD)2 fusion protein (“full-length transporters”) or two TMD-NBD fusion proteins 
(“half transporters”). (B) Structures of ModBC-A and Sav1866. The ABC importer ModBC (left; PDB 
Accession Number: 2ONK) consists of two copies of the ModB subunit (TMD) and two copies of the ModC 
subunit (NBD), whereas the ABC exporter Sav1866 (right; Accession Number: 2HYD) is a homodimer with the 
stoichiometry (Sav1866)2. Note that the TMDs of Sav1866 extend significantly into the cytoplasmic space, 
which is not observed for importers. ABC importers such as ModBC require an external binding protein (in this 
case ModA) that captures the transport substrate and delivers it to ModBC. ModBC-A and Sav1866 have been 
crystallized in distinct functional states: whereas ModBC-A was visualized in the nucleotide-free state, the 
structure of Sav1866 reflects the ATP-bound state. The nucleotide-free state of ModBC-A is coupled to an 
inward-facing conformation of the TMDs, whereas the ATP-bound state of Sav1866 is coupled to an outward-
facing conformation. These two conformations are likely to be present in all ABC transporters and provide the 
structural basis of ATP-driven, unidirectional substrate transport (Dawson et al., 2007). Chapter 1    Introduction 
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1.2.3  Harnessing the power of ATP: structure and arrangement of the NBDs 
 
The NBDs are the motor domains of ABC transporters. They are highly conserved, 
sharing over 25% sequence homology irrespective of whether the sequence is of prokaryotic 
or eukaryotic origin. They convert the chemical energy of ATP hydrolysis into mechanical 
work, which is realized in conformational changes within the TMDs. The NBDs are between 
200 and 300 amino acids in length and contain a number of characteristic motifs found in all 
ABC proteins. The most prominent motifs are the Walker A and B motifs as well as the C 
loop (ABC signature). The Walker A motif has the consensus sequence GxxGxGKS/T (x = 
any amino acid) and the Walker B motif the consensus sequence φφφφD (φ = any 
hydrophobic amino acid). Walker A and B motifs are 5-9 amino acid long and are separated 
from each other by 90-120 amino acids (Walker et al., 1982). The C-loop is located between 
the Walker A and B motifs and has the consensus sequence LSGGQ. In contrast to the Walker 
A and B motifs, which are also present in other ATP- and GTP-binding proteins, the C-loop is 
exclusively found in ABC proteins, though trimeric G proteins contain a related motif 
(GGQR/K/Q) (Manavalan et al., 1995). Other conserved amino acids and motifs present in 
NBDs include the glutamate residue C-terminal to the Walker B motif which acts as the 
general or catalytic base (Moody et al., 2002; Smith et al., 2002), the Q-loop which contains a 
conserved glutamine that contacts the γ-phosphate of ATP via a water molecule (Hung et al., 
1998), the Pro-loop which contains a conserved proline and together with Q-loop connects the 
arm I and arm II of the NBDs (Schmitt et al., 2003), as well as the D-, H-, and X-loop (Figure 
1-3). The D-loop is located within the NBD-NBD dimer interface, has the consensus sequence 
SALD, and interacts with the highly conserved histidine of the H-loop at the dimer interface 
providing an explanation of the mechanism for communication between monomers (Smith et 
al., 2002; Chen et al., 2003; Zaitseva et al., 2005). The highly conserved histidine of the H-
loop not only participates in ATP hydrolysis, but also forms essential hydrogen bonds in the 
so-called catalytic diad together with the conserved glutamate (Zaitseva et al., 2005). The X-
loop, which contains a short sequence TEVGERG conserved in ABC export proteins only, 
has an apparent function in communication between the intracellular loops of the TMDs with 
the NBDs (Dawson and Locher, 2006).  
All NBDs adopt a similar fold that consists of two subdomains (arms). Arm I 
(catalytic domain) is an F1-ATPase-like domain and contains the Walker A and B motifs. The 
α-helical arm II (signaling domain), which is specific for ABC proteins, is thought to act as 
the signaling domain. Arm II lies perpendicular to the catalytic arm I and contains the Q-, X-, Chapter 1    Introduction 
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and C-loop (Abele and Tampé, 2004). The hinge region connecting arm I and arm II is 
located between the Q-loop and the Pro-loop (Hung et al., 1998; Schmitt et al., 2003). Both, 
their general fold and the arrangement of the NBDs in ABC transporters are conserved. The 
arrangement is called “head-to-tail” or “Rad50-like” after the structure of the Rad50 protein in 
which it was first visualized (Hopfner et al., 2000). The key feature is that the two NBDs 
present their conserved sequence motifs at the shared interface. Within an NBD-NBD dimer, 
two ATP molecules are bound. The binding of a single ATP molecule is mainly accomplished 
by residues from the Walker A and Walker B motifs, the Q-loop, and the H-loop of one NBD 
and of residues from the C-loop of the second NBD (Figure 1-3B). Since the ATPase site of 
each NBD is complemented by residues from the second NBD within an NBD dimer, the 
function of the second NBD is to shield the nucleotide from the solvent and to fix the γ-
phosphate of the ATP (Beismann-Driemeyer and Tampé, 2004). The counterion of ATP 
(usually Mg
2+, Na
+ in the MJ0796 (E171Q) mutant) interacts with the conserved S/T residue 
from the Walker A motif, the Q-loop glutamine, and the β- and γ-phosphates of ATP. These 
interactions are proposed to help tether the two NBDs together (Smith et al., 2002). 
Arm I
Arm II
AB HisP HlyB
 
Figure 1-3. Structures of nucleotide binding domain of ABC transporters. 
(A) Structure of HisP monomer (Hung et al., 1998). The arm I contains the Walker A and Walker B motifs. Arm 
II contains mainly α-helices. α-helices are shown in orange and β-sheets in green. The location of conserved 
motifs are indicated by different colors: red (Walker A), blue (Walker B), cyan (C-loop). The bound ATP is in 
ball and stick representation. (B) Crystal structure of the HlyB-NBD H622A dimer with bound ATP/Mg
2+ 
(Zaitseva et al., 2005). ATP in stick representation and Mg
2+ (green spheres) are sandwiched at the interface of 
the two HlyB-NBD monomers (shown in light tan and light yellow). N- and C-termini of the individual 
monomers are labeled. Conserved motifs are colored red (Walker A), brown (Q-loop), bleu (C-loop or ABC 
signature motif), magenta (Walker B), black (D-loop), and green (H-loop) and labeled accordingly. 
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  The structures of the ATP-bound state of isolated NBDs and the NBDs of Sav1866 are 
very similar in structure and, indeed, show two ATP molecules (or non-hydrolysable 
analogues) sandwiched between the NBDs (Smith et al., 2002; Zaitseva et al., 2005; Dawson 
and Locher, 2006). Unlike the ATP-bound state, the nucleotide-free state seems to impose 
less stringent constraints on the NBDs. Common to the nucleotide-free structures is a 
substantial separation of the key motifs, leaving a gap that was also observed in the isolated 
NBD dimer (MalK subunits) from the maltose transporter (Chen et al., 2003). Due to the high 
conservation of the NBDs of ABC transporters it is very likely that the mechanism of 
hydrolysis is similar in all ABC proteins. The catalytic cycle for ATP hydrolysis shown in 
Figure 1-4 represents a ‘dual-mode’ mechanism and is divided into distinct steps that involve 
different conserved sequence motifs as key players, acting to coordinate intramolecular 
movements (Zaitseva et al., 2006).  
(i)  In the first step ATP binding induces NBDs dimerization; 
(ii)  In the next step a rigid-body movement of the helical domain, employing the Q- and 
  Pro-loop as hinges, occurs; 
(iii)  These conformational changes are transmitted to the TMDs and result in a 
  rearrangement of the membrane helices. The dimer is formed, and this results in full 
  displacement of the substrate binding site to the periplasmic site. For exporters, the 
  substrate is now released, and for importers this results in opening of the binding 
  protein, and binding of the substrate to the binding site in the TMDs. 
(iv)  Hydrolysis of ATP destabilizes the dimer interface, and leads to dissociation of the 
  dimer and TMDs rearrangement. This results in return of the transporter to its resting 
 state. 
  For the importers the substrate is now transported to the other side of the membrane. 
Depending on the stability of the dimer after hydrolysis of the first ATP, the dimer can either 
dissociate immediately, or a second ATP molecule needs to be hydrolyzed to completely 
destabilize the dimer (van der Does and Tampé, 2004). In this model, one can assign distinct 
functions to the conserved motifs of NBDs: the Walker A and B motifs, as well as the ABC 
signature, the catalytic glutamate and H-loops are required for ATP binding and hydrolysis, 
whereas the Pro-, Q- and D-loops act as hinges and are likely central to NBD-NBD and NBD-
TMD communication (Zaitseva et al., 2006).  Chapter 1    Introduction 
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Figure 1-4. Catalytic cycle of the nucleotide binding domain (NBD) of Haemolysin B exporter (HlyB). 
The crystal structures of the monomeric nucleotide-free (Schmitt et al., 2003), ADP-bound and the dimeric ATP-
bound NBD are shown (PDB Accession Numbers: 1MT0, 2FF7 and 1XEF). The conserved motifs Walker A 
(red), Walker B (orange), C-loop (yellow), Q-loop (magenta), D-loop (black), and H-loop (olive) are illustrated. 
ATP and ADP are shown as stick model (Zaitseva et al., 2005). 
 
1.2.4  Translocation pathways for diverse substrates: architectures of transmembrane 
domains 
 
Unlike the NBDs, the membrane-spanning TMDs are highly diverse with respect to 
their primary sequences. This diversity likely reflects that of the substrate transported by the 
different ABC proteins. The determined crystal structures have revealed three unrelated 
transmembrane domain folds (Sav1866, ModBC, and those of BtuCD and HI1470/71, which 
are similar) (Dawson et al., 2007). 
ABC exporters contain a conserved core of 12 transmembrane helices (TM). 
Additional TM helices are found in several human homologues but are likely facilitating 
regulatory functions. For example, the human ABC transporter associated with antigen 
processing (TAP) has additional, N-terminal TM helices that are essential for the interaction 
with tapasin (Koch et al., 2004). The crystal structure of Sav1866 is the first to reveal the 
conserved core structure of an ABC exporter (Dawson and Locher, 2006). The TM-helices 
extend beyond the membrane boundary and protrude far into the cytoplasm (Figure 1-2). 
Sav1866 exhibits a pronounced outward-facing conformation, with two wings, each 
consisting of six TM helices, which diverge towards the external side of the membrane. Each 
wing consists of TM1-TM2 from one TMD and TM3-TM6 from the other, which is in part a Chapter 1    Introduction 
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consequence of the substantial twisting of the TMDs, a feature observed in ABC exporters 
only (Dawson et al., 2007). The transmembrane segments are connected by long cellular and 
short extracellular loops (CLs and ECLs, respectively). The CLs extend the helical secondary 
structure beyond the lipid bilayer and protrude approximately 25 Å into the cytoplasm 
(Dawson and Locher, 2006). The TM helices of Sav1866 are arranged around a large, central 
cavity that is shielded from the cytoplasm but open to the extracellular space and to the outer 
leaflet of the lipid bilayer. The surface of this cavity is mostly hydrophilic and reflects a 
putative translocation pathway of the substrate. 
In contrast to ABC exporters, the TMDs of ABC importers have many sizes and 
shapes. They feature a total of 10-20 TM helices, indicating a higher degree of structural 
diversity than the TMDs of exporters. For example, molybdate transporters of mesophilic 
organisms have 10 TM helices, whereas their counterparts from hyperthermophiles have 12 
(Self et al., 2001; Hollenstein et al., 2007). The CLs of ABC importers are short with the 
NBDs close to the inner leaflet of the membrane, whereas the CLs of Sav1866 are much 
longer (Figure 1-2). 
 
1.2.5  The translocation cycle: the ATP-switch model 
 
The ATP-switch model involves repeated communication, in both directions, between 
the NBDs and TMDs (Abele and Tampé, 2004; Higgins and Linton, 2004; van der Does and 
Tampé, 2004). In the first step, ligand and nucleotide bind to the transporter independently 
from each other (van Endert et al., 1994; Tomazin et al., 1996). Ligand binding allows a 
putative NBD dimerization in the presence of ATP. In step 2, NBD dimerization induces a 
large conformational change in the TMDs sufficient to translocate the ligand (Hung et al., 
1998; Smith et al., 2002; Chen et al., 2003; Janas et al., 2003). In this closed conformation, 
the bound nucleotides are sandwiched between the Walker A motifs (P-loops) and the 
LSGGQ motifs (C-signature), as depicted in the crystal structure of Sav1866 (Dawson and 
Locher, 2006). Compared to the nucleotide-free state of the import protein ModBC, ATP 
binding to the NBDs of Sav1866 causes the coupling helices approaching one another by 10-
15 Å (Hollenstein et al., 2007). This presumably triggers the flipping of the transmembrane 
helices from the inward-facing to the outward-facing conformation. In this state, importers 
may now accept substrates from their cognate binding proteins, whereas exporters probably 
release their substrate that has previously entered the translocation pore (Figure 1-5). If the 
substrate binding affinity is changed in this state, is controversially discussed. According to Chapter 1    Introduction 
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functional data of LmrA of Lactococcuis lactis, the substrate-binding affinity is drastically 
decreased (van Veen et al., 2000). In case of human TAP however, no changes in affinity 
were observed in the trapped transition state (Chen et al., 2003b). Controverse results were 
obtained for P-glycoprotein (Ramachandra et al., 1998; Qu et al., 2003; Russell and Sharom, 
2006). In step 3, ATP hydrolysis initiates NBD dissociation (Smith et al., 2002; Zaitseva et 
al., 2005). In the last step, Pi and ADP are released to complete the transport cycle and restore 
the protein to a high-affinity state for ligand (Smith et al., 2002; Zaitseva et al., 2006). 
The ATP-switch model is the product of biochemical data interpreted in light of recent 
advances in structure determination of several ABC transporters. The model is divided into 
four steps (Figure 1-5), or four conformational changes; the first associated with the binding 
of ligand, then three that make use of the free energy available from protein-ATP and protein-
protein interactions associated with ATP binding, ATP hydrolysis, and ADP·Pi release. 
 
 
 
Figure 1-5. Model of the ATP-switch mechanism of ABC transporters. 
Ligand binding to a high-affinity pocket formed by the TMDs induces a conformational change in the NBDs. 
Two molecules of ATP bind to the NBDs. The energy released by the formation of the closed NBD dimer causes 
conformational change in the TMDs. ATP hydrolysis triggers dissociation of the closed NBD dimer resulting in 
further conformational changes in the TMDs. Finally, phosphate and ADP release restores the transporter to the 
open NBD dimer conformation ready for the subsequent cycle (Abele and Tampé, 2004; Linton, 2007). 
 
1.2.6  Coupling helices: an architecturally conserved motif transmits conformational 
changes 
 
Based on the biochemical and structural data of ABC proteins a putative model of 
transmission interface has been proposed. According to this model, binding and hydrolysis of 
ATP induce conformational changes in the NBDs that are transmitted to the TMDs via non-
covalent interactions (Dawson et al., 2007). The TMD-NBD interface therefore serves as a 
putative ‘transmission interface’ that couples the changes at the NBDs to distinct 
conformations of the TMDs. The crystal structures of ABC transporters reveal that in the Chapter 1    Introduction 
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NBDs, predominantly residues around the Q-loops contribute to the transmission interface. 
However, the TMDs of these transporters, despite their unrelated architectures, all feature 
strikingly similar short α-helices located in cytoplasmic loops between transmembrane 
segments. These helices show several contacts to the NBDs, and therefore they have been 
labeled ‘coupling helices’ (CH), which highlights their probable function (Dawson and 
Locher, 2006). 
In the bacterial exporter Sav1866 the TMDs contribute to this interface mainly through 
the cellular loops CL1 and CL2. Both CLs contain short helices oriented roughly parallel to 
the membrane plane and providing the bulk of the contacts (Figure 1-6) (Dawson and Locher, 
2006). These coupling helices can putatively modulate mechanistically crucial conformational 
changes. The CLs of Sav1866 reach across and contact both NBDs of the opposite subunit, 
therefore they are domain-swapped, a characteristic observed also in various enzymes (Liu 
and Eisenberg, 2002; Dawson and Locher, 2006). Domain swapping is not apparent in 
bacterial ABC importers. In contrast, the TMDs of the ABC importer BtuCD contact only one 
NBD, resulting in a large gap at the centre of the four protein domains (Locher et al., 2002). 
However, there are also similarities with ABC importers. On the part of the NBDs, the contact 
surface with the TMD is primarly lined with residues around the Q-loop (Schneider and 
Hunke, 1998), as was also observed in BtuCD (Locher et al., 2002). One prominent exception 
include the conserved residue Glu-473, which interacts with both CLs and is part of a 
previously unrecognized, short sequence motif (TEVGERG) that appears conserved in ABC 
export proteins only (Dawson and Locher, 2006). This newly identified sequence (called X-
loop) functions in coupling the CLs. Because the X-loops precede the ABC signature motifs, 
they probably respond to ATP binding and hydrolysis and may transmit conformational 
changes to the CLs. 
 
 Chapter 1    Introduction 
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Figure 1-6. The putative TMD-NBD transmission interface. 
Close-up view of Sav1866 (PDB Accession Number: 2HYD). The homodimeric protein has the subunits 
coloured green and blue, as ribbon representation. The coupling helices (CHs) of the green subunit are coloured 
red, the Q-loop of both subunits is coloured in magenta, and the X-loop of the blue subunit is shown in yellow. 
Bound ADP (brown) is in stick-model representation (Dawson and Locher, 2006). 
 
1.3  Transporter associated with antigen processing 
 
The first indication of peptide transporters was discovered from the studies of various 
mutant cell lines deficient in cell surface expression of MHC class I molecules, even though 
the expression levels of MHC class I heavy chain and β2m are normal (DeMars et al., 1985). 
The genes responsible for these defective phenotypes are tap1 and tap2 located in the MHC 
class II locus of human chromosome 6 (Trowsdale et al., 1991). Transfection of these cell 
lines with cDNA of TAP1 and TAP2 could restore cell surfaces expression of the MHC class 
I molecules (Powis et al., 1991; Spies and DeMars, 1991; Attaya et al., 1992; Spies et al., 
1992). Heterologous expression of TAP1 and TAP2 in insect cells and yeast showed a 
functional peptide translocation in the absence of factors of the adaptive immune system 
(Meyer et al., 1994; Urlinger et al., 1997). 
 
1.3.1  Structural organization of TAP 
 
The most recent annotation of the human genome sequence revealed 48 genes for 
ABC proteins, which were grouped into seven subclasses, from ABCA to ABCG (see: 
http//nutrigene.4t.com/humanabc.htm; Holland et al., 2003). The transporter associated with 
antigen processing (TAP) belongs to the subfamily B of ATP-binding cassette (ABC) 
transporters and is a central component in the major histocompatibility complex (MHC) class 
I dependent antigen presentation pathway. TAP translocates peptides derived mainly from Chapter 1    Introduction 
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proteasomal degradation from the cytosol into the lumen of the endoplasmic reticulum (ER), 
where these peptides are loaded onto MHC class I molecules (Figure 1-1). The transport of 
substrates across membrane is driven by ATP hydrolysis (Higgins, 1992; Schmitt and Tampé, 
2002; Davidson and Chen, 2004). Stable peptide-MHC complexes traffic to the cell surface to 
present their antigenic cargo to CD8
+-cytotoxic T-lymphocytes. The recognition of viral or 
tumor antigens leads to an efficient elimination of the infected or malignant cell. 
TAP1 was proposed to contain 808 aa in the initial reports (Trowsdale et al., 1990). 
Human TAP forms a heterodimer consisting of TAP1 (748 aa) and TAP2 (686 aa) (Kelly et 
al., 1992). Both subunits are essential and sufficient for peptide transport (Powis et al., 1991; 
Spies and DeMars, 1991; Meyer et al., 1994). TAP is localized in the ER and cis-Golgi (Kelly 
et al., 1992; Kleijmeer et al., 1992), although neither an ER-targeting sequence nor an ER-
retention signal has been identified. Each subunit contains a transmembrane domain (TMD), 
followed by a cytosolic nucleotide binding domain (NBD) (Figure 1-7). The TMDs comprise 
the peptide binding pocket and the translocation pathway for the substrate. On the basis of 
sequence alignments with other ABC transporters of the subfamily B in combination with 
hydrophobicity plots, 10 and 9 TMs have been predicted for human TAP1 and TAP2, 
respectively (Tampé et al., 1997; Lankat-Buttgereit and Tampé, 1999). Recently, the 
topological organization of transmembrane segments of TAP1 within a functional transport 
complex has been elucidated for the first time. Based on these results, it has been concluded 
that the transporter core is formed by 6 + 6 TMs, which is common for most ABC transporters 
(Schrodt et al., 2006). In addition to the 6 + 6 TM core, TAP1 and TAP2 comprise an extra 
N-terminal domain that is essential for assembly of the peptide-loading complex mediated by 
the adapter protein tapasin (Koch et al., 2004). Importantly, TAP1 and TAP2 lacking the first 
predicted four and three transmembrane helices, respectively, are targeted to the ER 
membrane and assemble into a fully functional heterodimeric transport complex, 
demonstrating that the extra N-terminal domains of both subunits are not required for peptide 
binding and transport (Koch et al., 2004; Koch et al., 2005). Topological investigations of 
these unique N-terminal domains of TAP1 and TAP2 revealed that the N-terminus of both 
subunits is located in the cytosol (Schrodt et al., 2006; Baldauf et al., manuscript in 
preparation). Because the N-terminus and the C-terminal nucleotide binding domain are both 
located in the cytosol, it can be suggested that TAP1 and TAP2 have an even number of 
transmembrane helices. 
The peptide-binding site of human TAP is contributed by the transmembrane domains 
of both subunits (Androlewicz et al., 1993; Androlewicz et al., 1994). Mapped by photo-Chapter 1    Introduction 
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crosslinking experiments, the cytosolic loops between TM4 and TM5 and a C-terminal stretch 
of approximately 15 amino acids after TM6 are shown to be involved in peptide binding 
(Nijenhuis and Hämmerling, 1996; Nijenhuis et al., 1996). Deletion of some of these amino 
acids in the TAP1 region resulted in loss of peptide transport (Ritz et al., 2001). The NBDs 
containing the highly conserved Walker A/B motifs and the C-loop (ABC signature) energise 
peptide transport by ATP binding and hydrolysis. The NBD sequences of TAP1 and TAP2 
show a variation of the canonical C-loop sequence. TAP2 shows a degenerative C-loop 
sequence (LAAGQ). TAP chimera with exchanged C-loops (LSGGQ) preserved transport 
activity as wild type, whereas the TAP complexes with two degenerative LAAGQ motifs had 
the lowest transport rate. These mutational studies demonstrate that the ABC signature motifs 
control the ATPase activity as well as the peptide transport of TAP (Chen et al., 2004).  
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Figure 1-7. Schematic model of the TAP complex. 
TAP forms a heterodimer composed of TAP1 and TAP2. Each subunit comprises an N-terminal transmembrane 
domain (red) and a C-terminal cytosolic NBD (blue, as ribbon representation). The transmembrane domain can 
be subdivided into a six helices containing core-domain (blue), which forms the peptide binding pocket and the 
translocation pore across the membrane, and an NH2-terminal extension of four helices for TAP1 and TAP2, 
respectively. The CL1 and CL2 of both subunits are illustrated in magenta and brown, respectively. The NBDs 
in the cytosol are depicted in the ribbon diagram and show an ATP (green) bound dimer from MJ0796 (PDB 
Accession Number: 1L2T). The figure was modeled by using PyMOL (www.pymol.org). 
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1.3.2  Peptide specificity and transport of TAP  
 
A prerequisite for peptide transport is peptide binding to TAP. This step is ATP 
independent (Androlewicz and Cresswell, 1994; van Endert et al., 1994). In contrast, peptide 
transport strictly requires ATP hydrolysis (Neefjes et al., 1993). Derived from the topological 
model of TAP (Figure 1-7), the peptide binding regions include the cytosolic loops between 
TM-helix 4 and 5 as well as an extension of 15 amino acids following TM-helix 6 in TAP1 as 
well as in TAP2 (Nijenhuis and Hämmerling, 1996). Peptides with 8-16 residues were found 
to be optimal for binding to TAP (van Endert et al., 1994). Interestingly, peptides which are 
sterically restricted by long and bulky side chains or even labeled with large fluorophores are 
bound and even transported by TAP (Uebel et al., 1995; Gromme et al., 1997; Neumann and 
Tampé, 1999). 
  In addition to the peptide size, also the amino acid sequence determines the efficiency 
of translocation by TAP. To resolve the recognition principle and the substrate-binding motif 
in a systematic approach, complex peptide libraries were applied (Uebel et al., 1997). In this 
method, the affinity of a randomized peptide mixture with one residue in common was 
compared with a totally randomized peptide library. Systematically, the influence of each 
amino acid on the affinity for TAP could be determined unbiased on the sequence context of 
the peptide. Besides free N- and C-termini, the first three N-terminal amino residues and the 
C-terminal amino acid are important for TAP recognition. At the C-terminus, human TAP 
favors peptides with hydrophobic or basic amino acids (Figure 1-8A). Strikingly, this is also a 
preferred anchor residue for MHC class I binding. Notably, upon stimulation by INF-γ, 
immunoproteasomes preferentially generate peptides with hydrophobic and basic C-terminal 
residues. The knowledge that the C-terminal peptide specificity of immunoproteasome, MHC 
class I and TAP are identical (Figure 1-8B), suggests a coevolution between the cleavage 
selectivity of the immunoproteasome and the binding specificity of TAP and MHC class I 
(Abele and Tampé, 2004). Remarkably, the T-cell receptors mainly contact the residues of 
antigenic peptides apart from the anchor residues where TAP shows the lowest specificity 
(Garboczi et al., 1996; Garcia et al., 1996). Peptides which are longer than 8-11 amino acids, 
will be N-terminal degraded by the ER-aminopeptidases ERAP1/2 (Serwold et al., 2002). The 
sequence in between both ends of the peptides presented to the T cell receptor are highly 
promiscuous with respect to TAP and MCH I binding. This ensures that a limited set of 
peptide transporter and MHC I molecules can offer a maximal peptide diversity, protecting 
the organism against pathogens (Abele and Tampé, 2004). In conclusion, TAP binds peptides Chapter 1    Introduction 
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through the two termini and transports peptides with maximal sequence diversity of the center 
residues for T-cell recognition (Figure 1-8B). 
Peptide binding is composed of a fast, diffusion-controlled peptide association, 
followed by a slow structural rearrangement, which includes ~25% of the residues of TAP as 
shown by kinetic and thermodynamic studies (Neumann and Tampé, 1999; Neumann et al., 
2002). An essential question in the ABC proteins family is how the allosteric interaction 
between substrate binding, ATP hydrolysis and substrate translocation implies a crosstalk 
between the NBDs and substrate binding pocket? By developing an enrichment and 
reconstitution protocol for TAP, it was possible to restore the function in proteoliposomes and 
to examine the specific ATPase activity (Gorbulev et al., 2001). Nucleotide hydrolysis was 
found to be strictly dependent on binding of peptides and on crosstalk with the peptide-
binding and the translocation sites. The strict correlation between peptide binding and 
stimulation of ATP hydrolysis may be a strategy to avoid ‘wasting’ ATP without transport of 
peptides (Lankat-Buttgereit and Tampé, 2003). A further indication of the tight coupling 
between ATP hydrolysis and peptide transport is the observation that sterically restricted 
peptides, which cannot be transported by TAP, do not induce ATP hydrolysis. Maximal 
ATPase activity of TAP was found to be independent of substrate affinity, because peptides 
with different Kd values for the transporter exhibited the same Vmax values (Gorbulev et al., 
2001). The two NBDs of the functional TAP complex can both interact with ATP, even if 
TAP1 or TAP2 are expressed separately (Müller et al., 1994; Wang et al., 1994). However, 
alone, the NBDs are unable to hydrolyze ATP. Thus, communication between the NBDs and 
TMDs, leading to a conformational change of the NBDs by peptide binding to TAP, seems to 
be a requirement to activate ATPase function. Furthermore, TAP function is dependent on the 
presence of both NBDs since disruption of one NBD leads to loss of transport (Chen et al., 
1996). Chapter 1    Introduction 
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Figure 1-8. Peptide specificity of human TAP. 
(A) TAP selectivity is illustrated for positions of the peptide. Favored (upper) and disfavored residues (lower) 
are given at the individual positions as elucidated using combinatorial peptide libraries. (B) Model of the 
peptide-binding pocket including residues utilized for MHC I binding and T-cell recognition (Abele and Tampé, 
1999). 
 
1.3.3 Functional  nonequivalence  of  the two motor domains of TAP 
 
  By functional reconstitution of TAP, it has been demonstrated that peptide binding is 
tightly coupled to ATP hydrolysis (Gorbulev et al., 2001). The contribution of both subunits 
in ATP hydrolysis was shown by nucleotide trapping and photo-cross-linking experiments 
(Chen et al., 2004). The ATPase activity of both subunits was stimulated in the presence of 
peptide in the same way, suggesting an equal contribution of both NBDs for peptide transport. Chapter 1    Introduction 
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However, based on mutational studies, the non-equivalence of both subunits was derived. 
Chimeric TAP complexes with two identical NBDs showed a drastically reduced transport 
activity whereas TAP with exchanged NBDs was fully active (Arora et al., 2001; Daumke 
and Knittler, 2001). Furthermore, loss of transport was observed after mutation of the 
conserved lysine in the Walker A motif of TAP2 (ATP-binding site II), whereas the same 
exchange in TAP1 (ATP-binding site I) resulted in an only slightly decreased transport 
activity (Karttunen et al., 2001; Lapinski et al., 2001; Saveanu et al., 2001). Site I is defined 
as the ATP-binding pocket composed of residues of the Walker A and B motifs of TAP1 and 
the C-loop of TAP2. Therefore, site II seems to be the canonical ATP-binding site, whereas 
site I is degenerate, also reflected by sequence comparison. In TAP1, the highly conserved 
glutamate (‘catalytic base’) and the histidine of the H-loop are replaced by aspartate and 
glutamine, respectively. Furthermore, the C-loop in TAP2, which contacts the γ-phosphate of 
ATP bound to site I, is degenerate to LAAGQ compared to the canonical signature motif 
LSGGQ. It is assumed that the highly conserved serin regulate the ATPase activity as shown 
for other ABC transporters (Hoof et al., 1994; Browne et al., 1996). TAP chimeras with two 
canonical C-loops showed highest transport rate compared to chimeras with two degenerate 
C-loops showing lowest transport rate, demonstrating that the ABC signature motifs control 
peptide transport efficiency (Chen et al., 2004). Markedly, mutations of the leucine or glycine 
in TAP1 (LSGGQ) fully abolished peptide transport, whereas equivalent mutations in TAP2 
still showed residual transport activity (Chen et al., 2004). In summary, the functional 
asymmetry of both TAP subunits suggests an sequential catalytic site model for ATP 
hydrolysis where NBD2 (site II) first hydrolyzes ATP due to the canonical ABC transporter 
sequences before ATP hydrolysis and phosphate release occurs at NBD1, the degenerate site 
(van der Does and Tampé, 2004). 
 
1.4  Objective 
 
Peptide binding induces a large conformational change comprising 25% of all TAP 
residues, which could be the trigger for ATP hydrolysis and subsequently peptide transport 
(Neumann et al., 2002). Remarkably, peptides with very bulky side-chains, which bind to 
TAP but are not transported, do not induce ATP hydrolysis (Gorbulev et al., 2001). Thus, a 
key question regarding the mechanism of TAP is what senses the quality of incoming peptides 
and transmits it to the motor domain? Regarding the mechanism of TAP and how the TMD-
NBD crosstalk during the catalytic cycle, the following questions were addressed: Chapter 1    Introduction 
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1.  Which role plays CL1 (TAP1) in the substrate sensing and signal transmission? 
 
2.  How is the molecular architecture of CL1 organized? 
 
3.  How is the spatiotemporal communication coordinated between distinct events in 
the TMDs and NBDs? 
 
To address these questions three strategies were applied. One strategy comprised the 
establishment of a TAP-cleavage assay by modifying the peptide epitope by a small chemical 
protease. Based on this, final evidence of a peptide sensor and transducer region was 
supposed to be provided by a cysteine-scanning approach and thiol-specific cross-linking. A 
second strategy involved the cysteine accessibility using fluorescence labeling. Furthermore, 
fluorescence labeling kinetics provided evidence of a direct correlation between covalent 
modification of CL1 and TMD-NBD signaling. Finally, the inter-domain communication and 
a dynamic transmission interface between TMD-NBD were found by using a cysteine cross-
linking approach combined with functional assays. Based on these results, the CLs have 
different functions in substrate recognition, signaling and transport binding. Chapter 2    Materials 
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2. Materials 
 
2.1 Chemicals 
 
Table 2-1. Chemical list. 
 
Chemicals                                                                                      Company 
 
Aluminium chloride (AlCl3)      Sigma-Aldrich 
Acrylamide  30%  (w/v)          National  Diagnostics 
Adenosine-5’-diphosphate (ADP)         Fluka Chemie 
Adenosine-5’-triphosphate  (ATP)        Fluka  Chemie 
AEBSF  hydrochloride            Merck 
Agarose                       BioWhittaker 
AmpLigase           Epicentre 
Ampicillin           PAA  laboratories 
Ammonium  peroxydisulfate  (APS)     Roth 
Aprotinin           Merck 
Apyrase          Sigma-Aldrich 
5-Bromo-3-indolyl-D-galactoside (bluo-gal)       Sigma-Aldrich 
1,8-bis-Maleimidotriethylene glycol [BM(PEO)3]     Pierce 
10x Bacteriophage T4 polynucleotide kinase buffer    Fermentas 
Bacteriophage T4 polynucleotide kinase       Fermentas 
Bacto  agar           Roth      
BaculoGold Transfection Kit            BD Bioscience Pharmingen 
BCA-Kit           Pierce 
Benzamidine  hydrochloride         Calbiochem 
BODIPY  maleimide  (BM)      Invitrogen 
Bovine serum albumin (BSA)           Sigma-Aldrich 
Bromphenol  blue          Roth 
Calf intestine alkine phosphatase (CIAP)       Fermentas 
Calcium chloride (CaCl2)       R o t h  
Chloramine  T           Riedel-de  Haen 
Concanavalin  A  sepharose         Sigma-Aldrich 
Coumarin  maleimide  (CM)      Invitrogen 
Copper sulfate (CuSO4)      F l u k a  
Digitonin           Calbiochem 
Dimethylsulfoxide  (DMSO)         Fluka 
N,N-Dimethylformamide (DMF)        Fluka 
Dinucleotide-5’-triphosphate  (dNTP)        Fermentas Chapter 2    Materials 
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Disodium hydrogen phosphate (Na2HPO4)    Roth 
1,4-dithiothreitol  (DTT)        Roth 
Dowex 1 x 8 anion exchange           Sigma-Aldrich 
Dynabeads
®  M-280          Dynal  Biotech 
Enhanced ChemiLuminescence System (ECL)       Amersham Pharmacia 
1,2-Ethanediyl-bis-methanethiosulfonate (MTS-2-MTS)    Toronto Chemicals 
Ethylendiamine-tetraacetic acid (EDTA)      Roth 
N-Ethylmaleimide  (NEM)      Fluka 
Fetal  calf  serum  (FCS)       Sigma-Aldrich 
FluoroStar  fluorometer       BMG  Labtechnologies 
Tetradecylphosphocholine  (FC-14)     Anatrace 
Fungizone        Invitrogen    
G l y c e r o l         R o t h  
G l u c o s e        R o t h  
N-(2-Hydroxyethyl)-piperazine-N’-2-ethansulfonic acid   Roth 
trans-4-Hydroxycinnamic acid (p-Coumaric acid)    Sigma-Aldrich 
Igepal  (NP-40)        Sigma-Aldrich 
Iodoacetamidofluorescein  (IAF)    Invitrogen 
Isopropyl-β-D-thiogalactopyranoside (IPTG)      BTS-BioTech Trade & Service 
K-acetate        Roth 
Kanamycin  (Km)       PAA  Laboratories 
Potassium  chlorid  (KCl)     Roth 
Leupeptin        Merck 
10x  Ligation  buffer       Fermentas 
β-mercaptoethanol (β- M E )       R o t h  
M e t h a n o l         R o t h  
Methyl-α-D-mannopyranoside      Sigma-Aldrich 
Mangnesium chloride (MgCl2)       R o t h  
Micro BCA protein assay reagent kit        Pierce 
Manganese chloride (MnCl2)       R o t h  
3-(N-morpholino)propanesulfonic acid (MOPS)     Roth 
MultiScreen plates with glass fibre filter,       Millipore 
pore size 1.0 µm 
MN  Mini  kit        Macherey-Nagel 
Sodium  chloride  (NaCl)     Roth 
Sodium  hydroxide  (NaOH)      Roth 
Neutral  red        Invitrogen Chapter 2    Materials 
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Ni-NTA  beads        Qiagen 
Nucleospin  plasmid  kit       Macherey-Nagel 
Oligos         MWG  Biotech 
PCR buffer (10x, with 20 mM MgCl2)     Fermentas 
PCR  Purification  Kit       Qiagen 
Penicillin/Streptomycin  (100x)      PAA  Laboratories 
Pepstatin  A        Merck 
1,5-Pentanediyl-bis-methanethiosulfonate (MTS-5-MTS)  Toronto Chemicals 
Pfu  DNA  Polymerase       Fermentas 
1,10-Phenanthroline       Sigma-Aldrich 
Phenylmethanesulfonyl fluoride (PMSF)      Fluka 
Pluronic  F-69  (10%)       Invitrogen 
Polyethylenimine  cellulose  plates     Merck 
Polyethylimine  (PEI)       Roth 
Potassium dihydrogen phosphate (KH2PO4)    Roth 
PVDF  membrane       Schleicher-Schuell  Bioscience 
QIAquick  gel  extraction  kit      Qiagen 
QIAquick spin PCR purification kit        Qiagen 
Rubidium  chloride  (RbCl)      Roth 
Restriction  enzymes       Fermentas 
RNase  A        Macherey-Nagel 
Saponin       Sigma-Aldrich 
SF900II  medium       Invitrogen 
Skim  milk  powder       Roth 
Sodium azide (NaN3)        R o t h  
Sodium disulfite (Na2S2O5)       M e r c k  
Sodium  dodecyl  sulfate  (SDS)      Roth 
Sodium  fluoride  (NaF)       Fluka 
Sodium iodide (Na
125I)       Amersham  Pharmacia 
Sodium  luminol      Roth 
T4  DNA  ligase        Fermentas 
10x  Y+  Tango  buffer       Fermentas 
10x Taq  PCR  buffer       Fermentas 
Taq  polymerase        Invitrogen 
Tetracycline        PAA  Laboratories 
N,N,N`,N`-Tetramethylethylendiamine (TEMED)    Sigma-Aldrich 
Transfection buffers A and B          BD Bioscience Chapter 2    Materials 
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Tris-acetate        Roth 
T r i t o n   X - 1 0 0         R o t h  
Tryptone        Roth 
Yeast  extract        Roth 
 
2.2 Peptides 
 
Table 2-2. Peptides used in this work. 
 
Peptides Sequence  Notes 
C4F  RRYC(Ψ)KSTEL (Ψ) cysteine labeled with 
iodoacetamidofluorescein 
 
R9LQK 
 
R9LQK radioactive 
RRYQKSTEL 
 
RRY(
125I)QKSTEL 
 
 
(
125I) tyrosine labeled with 
radioactive Na
125I 
 
R9NST 
 
RRYQNSTEL 
 
 
2.3 Antibodies 
 
Table 2-3. Antibodies used in this study. 
 
Antibodies Protein  Type  Recognition  site 
148.3  TAP1 monoclonal  CYWAMVQAPADAPE 
1P1  TAP1 polyclonal  GRLTDWILQDGSA 
1P2  TAP1 polyclonal  ETEFFQQNQTGNIMSR 
1P3  TAP1 polyclonal  TVRSFANEEGEAQKFR 
1P4  TAP1 polyclonal  SEKIFEYLDRTPR 
435.3  TAP2 monoclonal  DVSFAYP 
2P1  TAP2 polyclonal  RVIDILGGDFD 
2P2  TAP2 polyclonal  RIREQLFSSLL 
2P3  TAP2 polyclonal  EAVGGLQTVRSFGAEE 
2P4  TAP2 polyclonal  VGAAEKVFSYMDRQPN 
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2.4 Vector  maps 
 
2.4.1   pGEM-3Z 
 
Figure 2-1. pGEM-3Z vector promoter and multiple cloning region sequence. 
   
       
 
Figure 2-2. pGEM-3Z_TAP1_Cys-less vector circle map and sequence reference points. 
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Figure 2-3. DNA sequence of TAP1_Cys-less (start 26, end 2338). 
 
   1  gggcgaattc gagctcggta cccggggatc catggcttcc tccagatccc ctgctcctag   
  61  aggctccaga tctctgcctg gcgcttccct ggcttggctg ggcaccgtcc tgctgctgct   
 121  ggctgactgg gtcctgctga gaaccgctct gcctagaatc ttctccctgc tggtccctac   
 181  cgccctgcct ctgctgagag tctgggctgt cggcctgtcc agatgggctg tcctgtggct   
 241  gggtgcttcc ggagtcctga gagctaccgt cggctccaag tccgaaaacg ctggcgctca   
 301  gggctggctg gctgctctga agcctctggc cgctgctctg ggcctggcct tgccaggtct   
 361  ggctctgttc agagaactga tctcctgggg cgctcccggg tccgctgact ccaccagact   
 421  gctgcactgg ggctcccatc caaccgcttt cgtcgtctcc tacgctgctg ccctgcctgc   
 481  tgccgccctg tggcacaagc tgggttccct gtgggtccca ggcggtcagg gcggctccgg   
 541  caaccctgtg agaagactgc tgggctccct gggttccgaa accagaagac tgtccctgtt   
 601  cctggtcctg gtcgtcctgt cctctctggg cgaaatggct atccctttct tcaccggcag   
 661  actgaccgac tggattctgc aggatggctc cgctgacacc ttcacgcgta acttaaccct   
 721  gatgtccatc ctgaccatcg cttccgctgt cctggaattc gtcggcgacg gcatctacaa   
 781  caacaccatg ggccacgtcc actcccacct gcagggcgaa gtcttcggtg ccgtcctgag   
 841  acaggaaacc gaattcttcc agcagaacca gaccggcaac atcatgtcca gagtcaccga   
 901  agatacgtcc accctgtctg actccctgtc cgaaaacctg tccctgttcc tgtggtacct   
 961  ggtcagaggc ctggccctgc tgggcatcat gctgtggggc tccgtctccc tgactatggt   
1021  gaccctgatc accctgcctc tgctgttcct gctgcctaag aaggtcggca agtggtacca   
1081  gctgctggaa gtccaggtca gagaatccct ggctaagtcc tcccaggtcg ctatcgaagc   
1141  cttaagtgct atgcctaccg tcagatcctt cgctaacgaa gaaggcgaag ctcagaagtt   
1201  cagagaaaag ctgcaggaaa tcaagaccct gaaccagaag gaagctgtcg cttacgctgt   
1261  caactcctgg accacctcca tctccggcat gctgctgaaa gtcggtatcc tgtacatcgg   
1321  cggccaactg gtgacctccg gcgctgtgag ctctggcaac ctggtcacct tcgtcctgta   
1381  ccagatgcag ttcacccagg ccgtcgaagt cctgctgtcc atctacccta gagtccagaa   
1441  ggctgtcggc tcctccgaaa agatcttcga atacctggac agaaccccta gatccccacc   
1501  tagtggcctg ctgacccctc tgcatctgga aggactggtc cagttccagg acgtctcctt   
1561  cgcttaccct aacagacctg acgtgctggt cctgcagggt ctgaccttca ccctgagacc   
1621  tggcgaagtc accgcactgg tcggccctaa cggctccggc aagtccaccg tcgctgctct   
1681  gctgcagaac ctgtaccagc ctaccggcgg ccagctgctg ctggacggca agcctctgcc   
1741  tcagtacgaa cacagatacc tgcacagaca ggtcgctgct gtcggccagg aacctcaggt   
1801  cttcggcaga tctctgcagg aaaacatcgc ttacggcctg acccagaagc ctaccatgga   
1861  agaaatcacc gccgccgctg tcaagtccgg ggcccactcc ttcatctccg gcctgcctca   
1921  gggctacgac accgaagtag acgaagctgg ctctcagctg tccggcggcc agagacaggc   
1981  tgtcgctctg gctagagccc tgatcagaaa gccttccgtc ctgatcctgg acgacgctac   
2041  ctccgctctg gacgctaact cccagctgca agtcgaacaa ctgctgtacg aatcccctga   
2101  aagatactcc agatccgtcc tgctgatcac ccagcacctg tccctggtcg aacaggctga   
2161  ccacatcctg ttcctggaag gtggcgctat cagagaaggc ggcacccacc agcagctgat   
2221  ggaaaagaag ggctcctact gggctatggt ccaggctcct gctgacgctc ctgaactggt   
2281  ccctagaggc tccggtggac atcaccatca ccatcaccat caccatcact gaaagcttga   
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2.4.2   pPCR-Script 
 
Figure 2-4. pPCR-Script vector promoter and multiple cloning site region (sequence shown 598-826). 
 
 
 
Figure 2-5. pPCR-Script_TAP2_C213 vector circle map and sequence reference points. 
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Figure 2-6. DNA sequence of TAP2_C213 (start 674, end 2839). 
 
 661  gccccccctc gagatgagac tgcctgacct gagaccctgg acctctctgc tgctggtcga   
 721  cgctgctctg ctgtggctgc tgcaaggtcc actgggtacc ctgctgccac aaggtctgcc   
 781  tggtctgtgg ctggaaggca ccctgagact gggcggcctg tggggcctgc tgaagctgag   
 841  gggcctgctg ggcttcgtcg gcactctgct gttgcctctg tccctggcta cccctctgac   
 901  cgtctccctg agggctctgg tcgctggcgc ttccagggct cctcctgcta gagtcgcctc   
 961  tgctccttgg tcttggctgt tggtcggcta cggcgctgct ggcctgtcct ggtccctgtg   
1021  ggctgtcctg tcccctcctg gcgctcagga aaaggaacaa gatcaggtca acaacaaggt   
1081  cctgatgtgg cgtctgctta agctgtccag acctgacctg cctctgctgg tcgctgcttt   
1141  cttcttcctg gtcctggccg tcctgggtga aaccctgatc ccacactact ccggcagagt   
1201  catcgacatc ctgggcggcg acttcgaccc tcacgctttc gcttccgcta tcttcttcat   
1261  ggccctgttc tccttcggtt cttccctgtc cgctggtgcc agaggcggtt gtttcaccta   
1321  caccatgtcc agaatcaacc tgagaatcag agaacaactg ttttcctccc tgctgagaca   
1381  ggacctgggc ttcttccagg aaaccaagac cggcgaactg aactccagac tgtcctccga   
1441  caccaccctg atgtccaact ggctgccttt aaacgctaac gtcctgctga gatccctggt   
1501  caaggtcgtc ggcctgtacg gttttatgct gtctatctcc cctagactga ccctgctgtc   
1561  cctgctgcac atgcctttca ccatcgctgc tgaaaaggtc tacaacacca gacaccagga   
1621  agtcttaaga gaaatccagg acgctgtcgc tagagctggc caggtcgtca gagaagctgt   
1681  cggcggcctg caaaccgtca gatccttcgg cgctgaagaa cacgaagtct ccagatacaa   
1741  ggaagctctg gaacagtcca gacagctgta ctggagaaga gacctggaaa gagccctgta   
1801  cctgctggtc agaagagtcc tgcacctggg agtccagatg ctgatgctgt ccgtcggtct   
1861  gcaacagatg caggacggcg agctcacaca gggctccctg ctgtccttca tgatctacca   
1921  ggaatctgtc ggctcctacg tccagaccct ggtctacatc tacggcgaca tgctgtccaa   
1981  cgtcggtgcc gccgagaagg ttttctccta catggacaga cagcctaacc tgccttcccc   
2041  tggcaccctg gctcctacca ccctgcaagg agtcgtcaag ttccaggacg tctctttcgc   
2101  ttaccctaac agacctgata ggcctgtcct gaagggcctg accttcaccc tgagacctgg   
2161  cgaagtcacc gctctggtcg gccctaacgg ttctggcaag tccaccgtcg ctgctctgct   
2221  gcagaacctg taccagccta ccggcggcca ggtcctgctg gacgaaaagc ctatctccca   
2281  gtacgaacac cactacctgc actcccaggt cgtctccgtc ggccaggaac ctgtcctgtt   
2341  ctccggctcc gtcagaaaca acatcgctta cggcctgcag tcctccgaag acgacaaggt   
2401  catggctgct gctcaggctg ctcacgctga cgacttcatc caggaaatgg aacacggcat   
2461  ctacaccgat gtcggcgaaa agggctccca actggctgct ggtcagaagc agagactggc   
2521  tatcgctagg gctctggtca gagatccgcg ggtcctgatc ctggacgaag ctacctccgc   
2581  tctggacgtg cagtccgaac aggctctgca ggactggaac tccagaggcg acagaaccgt   
2641  cctggtcatc gctcacagac tgcagaccgt ccagagagcc caccagatcc tggtcctgca   
2701  agaaggcaag ctgcagaagc tggctcagct gcaagagggc caggacctgt actccagact   
2761  ggtccagcag agactgatgg acctggtccc tagaggctcc ggtggatctg cttggagaca   
2821  tccacagttc ggtggttgaa  
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2.4.3   pFastBac1 
 
Figure 2-7. pFastBac1 vector promoter and multiple cloning site region (sequence shown 3901-4400). 
 
 
     
 
Figure 2-8. pFastBac1 vector circle map and sequence reference points.                                 
    
 
 Chapter 3    Methods 
 
 
32
3. Methods 
 
3.1 Molecular  cloning 
 
3.1.1  E. coli culture 
 
  E. coli DH5α cells were grown in LB-medium (10 g trypton, 5 g yeast extract, 10 g 
NaCl per liter) at 37°C. If not indicated, 100 µg/ml ampicillin (final concentration) was 
added after autoclaving. E. coli DH10Bac was grown in LB-medium containing 50 µg/ml 
kanamycin and 10 µg/ml tetracycline.    
 
3.1.2 Preparation  of  E. coli DH5α competent cells  
 
Transformation buffer 1 (TFB-1)  Transformation buffer 2 (TFB-2)   
30 mM K-acetate    10 mM MOPS      
100  mM  RbCl    10  mM  RbCl     
50 mM MnCl2    75  mM  CaCl2    
10 mM CaCl2    15  %  glycerol   
15%  glycerol   pH  6.8 
pH 5.8       
 
  The following protocol was used to prepare batches of competent bacteria that yield 
5 x 10
6 to 2 x 10
7 transformed colonies/µg of supercoiled plasmid DNA. This efficiency of 
transformation is high enough to allow all routine cloning in plasmids to be performed with 
ease. Competent cells made by this procedure are preserved at -80°C, although there may be 
some deterioration in the efficiency of transformation during prolonged storage.   
•  Inoculate 5 ml of LB medium without ampicillin with 100 µl of E. coli DH5α cells. 
•  Incubate the culture overnight at 37°C. 
•  Inoculate 100 ml of LB medium with 5 ml from the previous overnight culture. 
•  Incubate the culture for 2-3 h until the OD600 = 0.3 – 0.5 at 37°C. 
•  Transfer the culture to ice, and keep it for 10 min on ice. 
•  Centrifugate the cells for 10 min at 2,000 x g, 4°C. 
•  Resuspend gently the pellets in 15 ml ice cold TFB-1 buffer. 
•  Incubate the cell suspension for 1 h at 4°C. 
•  Centrifugate the cell suspension for 10 min at 3,000 x g, 4°C. 
•  Resuspend gently the pellet in 4 ml of TFB-2 buffer. 
•  Split the competent cells in 100 µl aliquots and freeze them in liquid nitrogen. Chapter 3    Methods 
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•  Store the cells at -80°C. 
 
3.1.3 Preparation  of  E. coli DH10Bac competent cells  
 
  In order to prepare E. coli DH10Bac competent cells, the same procedure was 
applied as indicated at 3.1.2, except for LB-medium containing 50 µg/ml kanamycin and 10 
µg/ml tetracyclin. 
 
3.1.4  Transformation of Rb-competent E. coli cells 
 
•  Transfer an aliquot of competent cells (100 µl) to an ice bath, and allow it to thaw on 
ice. 
•  Add DNA (not more than 1 µg in a volume of 10 µl). Mix by gently swirling. 
•  The cells are incubated on ice for 30 min. 
•  Transfer the cells to 42°C for 90s. 
•  Allow the cells to recover for 1-2 min at 4°C. 
•  Add 500 µl of LB medium without antibiotic. 
•  Incubate the culture for 45 min at 37°C; the cells may be gently agitated (50 
cycles/min or less in a rotary shaker). 
•  Transfer 100 µl of transformed competent cells onto agar LB plate containing the 
appropriate antibiotic (e.g. 100 µg/ml ampicillin). 
•  The rest of the cells (500 µl) are centrifuged at 20,000 x g for 30s at 25°C. 
Resuspend the cell pellet in 100 µl of LB medium without antibiotic. 
•  Transfer the cell suspension onto agar plate containing the appropriate antibiotic 
(e.g. 100 µg/ml ampicillin). 
 
3.1.5 DNA  isolation 
 
  To obtain highly purified plasmids for sequencing and restriction analysis, DNA was 
isolated by MN Mini kit (MACHEREY-NAGEL GmbH & Co. KG, Germany). 
 
3.1.6 Oligonucleotide-directed  mutagenesis (Ligase Chain Reaction) 
 
  Oligonucleotide-directed mutagenesis is used to introduce point mutations in a 
particular gene. 
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3.1.6.1 Primer phosphorylation 
 
•  Phosphorylation of oligonucleotide primers with bacteriophage T4 polynucleotide 
kinase. 
  Synthetic oligonucleotide  200 pmoles 
  10x bacteriophage T4 polynucleotide kinase buffer (Fermentas)  2 µl 
  10 mM ATP (Fermentas)  2 µl 
  bacteriophage T4 polynucleotide kinase (Fermentas)  4 units 
 H 2O  to 20 µl  
•  Incubate the reaction for 30 min at 37°C and then inactivate the polynucleotide 
kinase for 10 min at 70°C. 
 
3.1.6.2 Ligase chain reaction (LCR) 
 
•  Anneal the phosphorylated mutagenic oligonucleotide primer to the double stranded 
plasmid DNA containing the target sequence. 
  Double-stranded template DNA (~200 ng)  0.5 pmoles 
  Phosphorylated mutagenic oligonucleotide  20 pmoles 
  10x PCR buffer (+20 mM MgSO4) (Fermentas)  10 µl 
  2 mM dNTP (Fermentas)  10 µl 
  100 mM NAD (Fermentas)  1 µl 
  Pfu DNA polymerase (Fermentas)  2.5 units 
  AmpLigase (Epicentre)  5 units 
 H 2O  to 100 µl 
•  Perform the following LCR-program: 
   95°C   3  min 
   95°C   1  min 
    60°C*   1 min    30x (typical 2 min pro 1 kbp template) 
   65°C   10  min  30s   
   65°C   10  min 
   4°C   pause 
  * annealing temperature is primer dependent, and should not exceed 65°C 
 
3.1.6.2.1 PCR purification 
 
  The LCR-product is purified using the PCR Purification Kit (Qiagen). 
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3.1.6.2.2 Selection of mutants with DpnI 
 
  The products of the amplification reaction are treated with the restriction enzyme 
DpnI, which specifically cleaves fully methylated G
Me6ATC sequences, but it will not digest 
DNA synthetized during the course of the LCR (Sambrook and Russell, 2001). 
  10x Y+ Tango buffer (Fermentas)  2 µl 
  Purified LCR product  19 µl 
  DpnI (Fermentas) 20  units 
 H 2O  to 23 µl 
Incubate the reaction for 6 – 24 h at 37°C and then inactivate the restriction enzyme by 
heating for 20 min at 80°C. 
 
3.1.6.2.3 Transformation of amplified product 
 
In a sterile microfuge tube mix: 
  Restriction digest  10 µl 
  E.coli DH5α competent cells   100 µl 
then perform the standard transformation into E.coli DH5α competent cells (see 3.1.4). 
 
3.1.7  Directional cloning into plasmid vectors 
 
  Directional cloning requires that the plasmid vector is cleaved
 with two restriction 
enzymes that generate incompatible termini
 and that the fragment of DNA to be cloned 
carries termini that
 are compatible with those of the doubly cleaved vector (Sambrook and 
Russel, 2001).
  The present protocol describes the cloning procedure, as example, when 
termini are produced by restriction endonucleases BamHI and HindIII. 
 
3.1.7.1 Target DNA restriction, isolation and purification 
 
Tris-acetate EDTA buffer (TAE)    
40 mM Tris-acetate       
1  mM  EDTA    
pH 8.3    
1.  In a sterile microfuge tube mix: 
  - target DNA (2 – 4 µg)  3 µl 
 -  BamHI (Fermentas)   20 units 
 -  HindIII (Fermentas)  20 units   
 -  10x Y+ Tango buffer (Fermentas) 4  µl 
 -  H2O 40  µl Chapter 3    Methods 
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2.  Incubate the reaction for 2 h at 37°C. 
3.  Run electrophoresis on 0.8% agarose in TAE buffer and visualize under UV light. 
4.  Excise the target band from the gel. 
5.  Purify the target DNA using the QIAquick Gel Extraction Kit (Qiagen), elute the 
DNA in 30 µl elution buffer (Qiagen) and visualize an aliquot on 0.8% agarose gel 
electrophoresis. 
 
3.1.7.2 Vector DNA isolation and purification 
 
1.  In a sterile microfuge tube mix: 
  - vector DNA (2 – 4 µg)  5 µl 
 -  BamHI (Fermentas)  20 units 
 -  HindIII (Fermentas) 20  units 
 -  10x Y+ Tango buffer (Fermentas) 4  µl 
 -  H2O   40 µl 
2.  Incubate the reaction for 2 h at 37°C. 
3.  Run electrophoresis on 0.8% agarose in TAE buffer and visualize under UV light. 
4.  Excise the band from the gel, which represents the vector DNA. 
5. Purify the vector DNA using the QIAquick Gel Extraction Kit (Qiagen), and 
visualize it on 0.8% agarose gel electrophoresis. 
 
3.1.7.3 Ligation 
 
1.  In a sterile microfuge tube mix: 
  - 10x Ligation buffer (Fermentas)   1.5 µl 
  - T4 DNA ligase (Fermentas)  7.5 units 
  - target DNA  1 µl 
  - vector DNA  6 µl 
  - molar ratio between target : vector   1:6 
 -  H2O  ad to 15 µl 
2.  Incubate the reaction mixture overnight at 16°C or for 4 h at 20°C. 
3.  Inactivate the DNA ligase by incubating the reaction mixture for 20 min at 70°C. 
4.  Transform competent E. coli DH5α cells with ligation reaction. 
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3.1.8 Plasmid  construction  for  generation of baculovirus 
 
  Point mutations were generated by ligase chain reaction using various mutagenic 
primers (Tables 3-1; 3-2) and the plasmids pGEM3Z_TAP1_cys-less and pPCR-
Script_TAP2_C213 as templates (Figures 2-1 to 2-6). To validate the introduced mutations, 
the tap1 and tap2 genes were sequenced using sequencing primers (Tables 3-3; 3-4). 
 
3.1.8.1  Generation of single cysteine mutants of the coupling helix 1 (TAP1) 
 
  When plasmid pGEM3Z_TAP1_cys-less was used for generation of baculovirus, the 
tap1 gene containing the desired mutation was excised with the restriction enzymes BamHI 
and HindIII (Fermentas), and purified using the QIAquick Gel Extraction Kit (Qiagen). 
Subsequently, pFastBac1_TAP1_cys-less was digested with BamHI and HindIII and the 
linearized vector was purified. After ligation, the following mutants (TAP1) were obtained: 
Q277C, G282C, N283C, I284C, M285C, S286C, R287C, and V288C. 
Alternatively, a fragment of tap1 gene (437 bp) containing the desired mutation was 
excised with the restriction enzymes BspTI and MluI (Fermentas) and purified. 
Subsequently, the pFastBac1_TAP1_cys-less was digested with BspTI and MluI and the 
linearized vector was purified. After ligation, the following mutations were generated: 
T273C, E274C, F275C, Q278C, and N279C.   
 
3.1.8.2  Generation of single cysteine mutants of the coupling helix 2 (TAP1) 
 
  A similar approach has been used, as described above with one modification. In this 
case the fragment of the tap1 gene (322 bp) and pFastBac1_TAP1_cys-less were treated 
with the restriction enzymes SphI and StuI (Fermentas). After ligation, the following 
mutations were confirmed by sequencing: I368C, E369C, A370C, P375C, T376C, V377C, 
R378C, S379C, F380C, A381C, and N382C. 
 
3.1.8.3  Generation of single cysteine mutant of the X-loop (TAP1) 
 
  A similar approach has been used, as described above with one modification. A 
fragment of the tap1 gene (866 bp) containing the mutation E638C was excised with the 
restriction enzymes Bsp119I and HindIII (Fermentas) and purified. Subsequently, the 
pFastBac1_TAP1_cys-less was digested with Bsp119I and HindIII and the linearized vector 
was purified. After ligation, the introduced mutation was confirmed by sequencing 
(pFastBac1_TAP1_E638C). 
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3.1.8.4  Generation of single cysteine mutants of the X-loop (TAP2) 
 
  From previous studies in our group (unpublished data), it has been shown that 
Cys213 (TAP2) was essential in preserving the TAP function. Therefore, for generation of 
single cysteine mutants of X-loop (TAP2) the plasmid pPCR-Script_TAP2_C213 was used 
as template for LCR. Afterwards, a 500 bp fragment of the tap2 gene containing the desired 
mutation was excised with the restriction enzymes AjiI and AatII (Fermentas) and purified.  
pFastBac1_TAP2_C213 was linearized with AjiI and AatII and purified. After ligation the 
following single cysteine mutations were confirmed by sequencing: E602C, E602R, E602D, 
and E602A.  
 
Table 3-1. Primer sequences used for LCR. Single cysteines were introduced into the cysteine-less TAP1 
and single cysteine TAP2 (C213) coding sequence by site-directed mutagenesis, employing the mutagenic 
oligonucleotides (in each case the cysteine codon is in bold underlined). 
 
 Primer  Sequence 
  TAP1 T273C  CGT CCT GAG ACA GGA ATG CGA ATT CTT CCA   
  TAP1 E274C  GAC AGG AAA CCT GCT TCT TCC AGC AGA AC   
  TAP1 F275C  AAC CGA ATT CTG CCA GCA GAA CCA GAC  
  TAP1 Q277C  CCG AAT TCT TCC AGT GCA ACC AGA CCG GC 
  TAP1 Q278C  GAA TTC TTC CAG TGC AAC CAG ACC GGC AAC AT  
  TAP1 N279C  TTC TTC CAG CAG TGC CAG ACC GGC AAC AT 
  TAP1 G282C  GCA GAA CCA GAC CTG CAA CAT CAT GTC C 
  TAP1 N283C  CAG AAC CAG ACC GGC TGC ATC ATG TCC AGA G 
  TAP1 I284C  GAC CGG CAA CTG CAT GTC CAG AG 
  TAP1 M285C  GAC CGG CAA CAT CTG CTC CAG AGT CAC CGA AG 
  TAP1 S286C  GGC AAC ATC ATG TGT AGA GTC ACC GAA GA 
  TAP1 R287C  GCA ACA TCA TGT CCT GCG TCA CCG AAG ATA C 
   TAP1 V288C  CGG CAA CAT CAT GTC CAG ATG CAC CGA AGA TAC G 
  TAP1 I368C  CCC AGG TCG CTT GCG AAG CCT TAA GTG   
  TAP1 E369C  CAG GTC GCT ATC TGC GCC TTA AGT GCT A 
  TAP1 A370C  GGT CGC TAT CGA ATG CTT AAG TGC TAT GCC   
  TAP1 P375C  GCC TTA AGT GCT ATG TGT ACC GTC AGA TCC 
  TAP1 T376C  GTG CTA TGC CTT GCG TCA GAT CCT TC 
  TAP1 V377C  TGC TAT GCC TAC CTG CAG ATC CTT CGC TAA 
  TAP1 R378C  TAT GCC TAC CGT CTG CTC CTT CGC TAA C 
  TAP1 S379C  CCT ACC GTC AGA TGC TTC GCT AAC GAA GA Chapter 3    Methods 
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  TAP1 F380C  TAC CGT CAG ATC CTG CGC TAA CGA AGA AG  
  TAP1 A381C  CAG ATC CTT CTG TAA CGA AGA AGG CGA AGC TC 
  TAP1 N382C  AGA TCC TTC GCT TGC GAA GAA GGC GAA GCT C 
  TAP1 E638C                 GAC ACC GAA GTA GAC TGT GCT GGC TCT CA 
  TAP1 R659C  GAC CCC TGA TCT GTA AGC CTT CCG TCC TG 
  TAP2 L3C  CTC GAG ATG AGA TGT CCT GAC CTG AGA 
  TAP2 T43C  TCT GTG GCT GGA AGG CTG CCT GAG ACT G                           
 
Table 3-2. Primer sequences used for LCR (E602, TAP2). The highly conserved E602 of X-loop (TAP2) 
has been mutated to C, R, A and D using the plasmid pPCR-Script_TAP2_ C213 as template, employing the 
mutagenic nucleotides (in each case the mutated codon is in bold underlined). 
 
 Primer  Sequence 
TAP2  E602C  TAC ACC GAT GTC GGC TGC AAG GGC TCC CAA CTG
TAP2 E602R  CCG ATG TCG GCA GAA AGG GCT CCC AAC T 
TAP2 E602A  TAC ACC GAT GTC GGC GCT AAG GGC TCC CAA CT  
TAP2 E602D  CCG ATG TCG GCG ATA AGG GCT CCC AAC T 
 
Table 3-3. Primers used for TAP1 sequencing. 
 
 Primer  Sequence 
  TAP1 Seq 0F  GTG CTG CAA GGC GAT TAA GT 
   TAP1 Seq 3F  CTG CTC TGG GCC TGG CC 
  TAP1 Seq 4F  GGG TTC CGA AAC CAG AAG AC 
  TAP1 Seq 5F  GTC AGA GGC CTG GCC CTG 
  TAP1 Seq 6F  TGC TAT GCC TAC CGT CAGAT 
  TAP1 Seq 8F  CAA GCC TCT GCC TCA GTA CG 
  TAP1 Seq 9F  GAC CTG GCG AAG TCA CC 
  TAP1 Seq 6R  AGC AGG CCA CTA GGT GG 
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Table 3-4. Primers used for TAP2 sequencing. 
 
 Primer  Sequence 
  TAP2 Seq 2F  GTA AAA CGA CGG GCA GTG AG 
  TAP2 Seq 9F  GAC CTG GCG AAG TCA CC 
   TAP2 Seq 2R  AGC AGG AGG AGC CCT GG 
  TAP2 Seq 12R  ACA AGC TTT CAA CCA CCG 
 
 
3.1.9 Transposition  in  DH10Bac 
 
SOC Medium        LB Medium (Luria-Bertani) 
Tryptone    20 g    Tryptone   10 g 
Yeast extract    5 g    Yeast extract  5 g 
NaCl    0.5 g    NaCl  10 g 
KCl    0.186 g    Bacto agar  15 g 
MgCl2   10  mM    H2O  to 1000 ml 
Glucose   20  mM 
H2O   to 1000 ml     
  
  100 µl of competent DH10Bac cells were thawed on ice. 6 µl (20 ng) of pFastBac1 
from miniprep was added to the cells and the mixture was incubated for 30 min on ice. 
Then, the cells were heat-schocked for 45s at 42°C and immediately transferred to 4°C for 2 
min. Then 900 µl of SOC medium was added and cells were subsequently incubated at 
37°C for 4 h. Cells were then spinned down and diluted serially with SOC medium to 10
-1, 
10
-2 and 10
-3. 100 µl mixture of each dilution was plated onto LB agar plates containing 50 
µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracyclin, 100 µg/ml Bluo-gal and 40 
µg/ml IPTG. Insertions of the mini-Tn7 into the mini-attTn7 attachment site on the bacmid 
disrupt the expression of the LacZα peptide, so colonies containing the recombinant bacmid 
are white in a background of blue colonies that harbor the unaltered bacmid. Plates were 
incubated at 37°C for 48 h for development of blue-white colonies. The white colonies were 
selected for amplification to isolate the recombinant bacmids for transfection of insect cells. 
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3.1.9.1  Isolation of recombinant bacmid DNA (according to Invitrogen) 
 
Solution-1-bacmid buffer    Solution-2-bacmid buffer 
15 mM Tris-HCl (pH 8.0)    0.2 N NaOH     
10 mM EDTA      1% (w/v) SDS  
100 µg/ml RNase A (Macherey-Nagel) 
 
LB Medium       K-acetate buffer 
Tryptone   10 g  3 M K-acetate 
Yeast extract  5 g  pH 5.5 
NaCl   10  g 
H2O   1000  ml 
pH 7.0 
 
•  Inoculate a single, isolated bacterial colony in 2 ml of LB medium containing 50 
µg/ml kanamycin, 7 µg/ml gentamicin, and 10 µg/ml tetracyclin. The culture is 
grown at 37°C overnight. 
•  Centrifuge 1.5 ml of bacterial culture for 1 min, at 14,000 x g, 4°C. 
•  Resuspend the cell pellet in 0.3 ml of Solution-1-bacmid buffer. 
•  Add 0.3 ml of Solution-2-bacmid buffer and mix gently. Incubate at room 
temperature for 5 min. 
•  Add slowly 0.3 ml of 3M K-acetate. Mix gently during addition. Incubate the 
sample on ice for 10 min. 
•  Centrifuge for 10 min at 14,000 x g. 
•  Mix the supernatant with 0.8 ml isopropanol. Invert the tube several times to mix 
and incubate on ice for 10 min. 
•  Centrifuge the sample for 15 min at 14,000 x g at room temperature. 
•  Add to the pellet 0.5 ml 70% ethanol. Invert the tube several times to wash the 
pellet.  
•  Centrifuge for 5 min at 14,000 x g at room temperature. 
•  Air dry the pellet for 5-10 min at room temperature. 
•  Dissolve the DNA pellet in 40 µl of 1 x AE buffer (Qiagen). 
•  Store the DNA at +4°C. 
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3.1.9.2  Analyzing recombinant bacmid DNA by PCR (according to Invitrogen) 
 
  In order to verify the presence of the gene of interest in the recombinant bacmid by 
PCR, the M13 forward and M13 reverse primers (Table 3-5) together with Taq polymerase 
(Invitrogen) were used. The bacmid containts M13 forward and M13 reverse priming sites 
flanking the mini-attTn7 site within the lacZα-complementation region to facilitate PCR 
analysis. 
 
Table 3-5. Primers used for analyzing recombinant bacmid DNA by PCR. 
 
 Primer  Sequence 
  M13 forward  GTT TTC CCA GTC ACG AC 
  M13 reverse  CAG GAA ACA GCT ATG AC 
 
a)  For each sample, set up the following PCR reaction (50 µl): 
  Recombinant bacmid DNA (100 ng)  1 µl  
  10x Taq PCR buffer (Fermentas)  5 µl 
  10 mM dNTP (Fermentas)  1 µl 
 50  mM  MgCl2  1.5 µl  
  PCR primers (1.25 µl each 10 µM stock)  2.5 µl 
 H 2O 38.5  µl 
  Taq polymerase (5 units/µl) (Invitrogen)  2.5 units 
 
b)  For amplification the following cycling parameters were used: 
  
Step Time  Temperature  Cycles 
Initial denaturation  5 min  95°C  1 
Denaturation 1  min  95°C 
Annealing 1  min  52°C 
Extension 5  min  72°C 
 
30 
Final extension  10 min  72°C  1 
 
c)  Remove 10 µl from the reaction and analyze by agarose gel electrophoresis (0.8%). 
 
3.2 Cell  Culture 
 
3.2.1  Monolayer culture of Sf9 insect cells  
 
  Spodoptera frugiperda (Sf9) monolayer culture was grown in SF900 II medium 
(Invitrogen) supplemented with 50 units/ml penicillin, 0.05 mg/ml streptomycin, 0.2% 
pluronic acid, 0.5 µg/ml fungizone and 5% fetal calf serum. Before passage, medium and 
floating cells from a confluent monolayer were discarded by aspiration. 10 ml of Chapter 3    Methods 
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supplemented SF900 II medium was added to 75 cm
2 flask. Cells were then detached from 
the surface by tapping the flask. 2.5 ml of cells were diluted into a new flask in 10 ml 
medium and incubated at 27°C.    
 
3.2.2  Shaker culture of Sf9 insect cells  
 
  The culture flask was incubated at 27°C in less than 1/4 of the total flask volume 
until it reaches a cell density of 2 x 10
6 cells/ml. Then cells were diluted to 0.4 x 10
6 
cells/ml with supplemented SF900 II medium and placed on a rotary shaker (60 rpm).  
 
3.2.3  Transfection of Sf9 insect cells  
 
  2 x 10
6 Sf9 insect cells were seeded onto a 60 mm tissue plate. Initially cell density 
should be 50-70% confluent. Cells were incubated at 27°C for 1 h to allow them to attach 
firmly onto the plate. Then the culture medium was removed and 1 ml of transfection buffer 
A (BD Bioscience) was added to the plate. All areas of the plate should be covered by this 
buffer. 5 µg of bacmid DNA from mini-prep was mixed with 1 ml transfection buffer B 
(BD Bioscience). Subsequently the mixture was added to the plate drop by drop. After 
every two or three drops, the plate should be gently rotated to facilitate the mixing of buffer 
B with buffer A. Following incubation of the plate at 27°C for 4 h, the transfection solution 
was removed and 3 ml of  fresh SF900 II medium (Invitrogen) was added. The plate was 
incubated at 27°C for 5-7 days before the recombinant virus (P1 stock) can be harvested.  
 
3.2.4 Virus  amplification 
 
  3 ml of P1 virus stock harvested from transfection generally have a titre of 1 x 10
7 
pfu/ml. Viruses were amplified two times before going for infection of cells in large scale. 
10 ml P2 virus stock was obtained by infecting 1.2 x 10
6 cells of monolayer in 75 cm
2 flask 
for 5 days with 1 ml P1 stock; after that, 25 ml of P3 can be harvested from infection of 3 x 
10
7 cells with 3 ml in 175 cm
2 flask for 5 days. For large scale virus amplification, 6 x 10
8 
cells in 500 ml were infected with 10 ml P3 stock; after 6-8 days the virus is harvested and 
stored at 4°C. Typically, 98% cells should be dead as determined by trypan blue staining. 
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3.2.5  Co-transfection of Sf9 insect cells with TAP1/TAP2 viruses  
 
  Phosphate-buffered saline (PBS)  
 137  mM  NaCl 
 2.7  mM  KCl 
 10  mM  Na2HPO4 
 2  mM  KH2PO4 
 H 2O 1000 ml 
 pH  7.4 
 
  100 ml of Sf9 insect cells were grown at 27°C in a Erlenmeyer flask to a density of 
1.8 x 10
6 cells/ml. 5 ml of virus P4 stock (TAP1) and 10 ml of virus P4 stock (TAP2) were 
added and the culture was incubated for 48 h. Typically, 30% cells are dead at this time 
point. Subsequently the cells were harvested by centrifugation at 200 x g for 5 min. Cell 
pellets were washed with 20 ml PBS buffer once and were frozen at -20°C. 
 
3.2.6  Determination of virus titer by plaque assay   
 
  Neutral red/PBS solution 
  1 vol 0.4% Neutral red (Invitrogen) 
  19 vol PBS 
  
  Sf9 cells (1 x 10
6 cells) were seeded into 35 mm petri dishes and incubated at room 
temperature for 2 h. Virus stock was serially diluted from 10
-1, 10
-2, to 10
-7. After removal 
of the medium from the culture, 100 µl of virus dilution was added, then the mixture was 
incubated at room temperature for 1h with gently agitation every 15 min. During incubation, 
the agarose solution was prepared by mixing 8 ml medium with 4 ml 3% low melting 
agarose (plus 120 µl X-gal 25 mg/ml in DMF). After this, the viral solution was removed 
and 2 ml of 1% agarose solution (40°C) was added onto each dish. When the agarose 
solidified, 1 ml of medium was overlaid on it. The dishes were kept at 27°C for 3-4 days 
and then stained with 1 ml Neutral Red/PBS solution. After incubation at 27°C in the dark 
for 2h, the liquid was removed. Incubation of inverted dishes overnight resulted in several 
white plaques in dark red background. Each plaque is generated by infection of Sf9 cells 
with an individual baculovirus particle, therefore the total amount of the virus can be 
determined. 
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3.3  General biochemical methods  
 
3.3.1 SDS-PAGE   
 
Sample buffer  Running buffer 
150 mM Tris (pH 6.8)  25 mM Tris 
6 % (w/v) SDS  192 mM glycine 
30 % (v/v) glycerol  0.1% (w/v) SDS 
0.3 % (w/v) bromophenol blue  pH 8.3 
300 mM DTT 
 
Stacking gel buffer      Separating gel buffer 
500 mM Tris      1500 mM Tris 
0.4% (w/v) SDS      0.4% (w/v) SDS  
pH 6.8      pH 8.8 
   
 
  The acrylamide solution consists of 30% acrylamide and 0.8% N,N’-
methylenebisacrylamide. Stock aliquots of 10% ammonium peroxydisulfate (APS) are 
prepared in H2O and stored at -20°C. Before electrophoresis the proteins were denatured in 
sample buffer. Membrane proteins were incubated for 20 min at 65°C. The SDS 
electrophoresis was performed at 150 V for 1-1.5 h in running buffer for electrophoresis. 
 
Table 3-6. Composition of stacking and running gel according to Laemmli (Laemmli, 1970) for 8 gels. 
 
  Stacking gel 
5% 
Separating gel 
7.5% 
 
10% 
 
12% 
Acrylamide  6.8 ml  18 ml  24 ml  29 ml 
Stacking gel buffer  5 ml  -  -  - 
Running gel buffer  -  18 ml  18 ml  18 ml 
H2O  28 ml  36 ml  30 ml  25 ml 
APS  320 µl  470 µl  470 µl  470 µl 
TEMED  32 µl  40 µl  40 µl  40 µl 
 
 
3.3.2 Immunoblotting   
 
Transfer  buffer    Blocking  buffer 
25 mM Tris-HCl      10 mM Tris-HCl pH 8.0 
192  mM  glycine    150  mM  NaCl 
20% methanol (v/v)      0.1% (v/v) Triton X-100 
pH 8.2      7% (w/v) skim milk powder 
    0.1%  (w/v)  NaN3   
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Tris-buffered saline with triton (TBS-T)  Electrochemiluminescence buffer 1 (ECL-1) 
10 mM Tris-HCl      2.5 mM Sodium luminol 
150 mM NaCl      0.4 mM Coumaric acid 
0.1% (v/v) Triton X-100    100 mM Tris-HCl (pH 8.5) 
pH 8.0  
 
Electrochemiluminescence buffer 2 (ECL-2) 
100 mM Tris-HCl (pH 8.5) 
0.019% (v/v) H2O2 
 
  To transfer proteins from the gel onto nitrocellulose, a blotting sandwich was 
prepared with the following layers: 1) filter paper soaked in transfer buffer, 2) gel, 3) 
membrane soaked in transfer buffer (in the case of PVDF membrane, it should be soaked in 
methanol for 1 min previously), 4) filter paper soaked in transfer buffer. The sandwich was 
set onto a semidry blotting apparatus (Bio-Rad Laboratories GmbH, Germany) with the 
nitrocellulose/PVDF membrane facing the anode. The electroblotting was performed at 
constant current (100 mA per mini gel) for 90 min. For immunodetection, the membrane 
was blocked with blocking buffer for at least 30 min at room temperature or overnight at 
4°C. The membrane was incubated at room temperature for 1 h with the primary antibody 
diluted in TBS-T buffer (1:20 dilution). After 3 times washing with TBS-T for 10 min, the 
membrane was incubated with horseradish peroxidase conjugated second antibody 
(1:30,000 dilution) for 1 h. Subsequently, the membrane was washed again 3 times and 
incubated with 10 ml ECL-1 buffer for 1 min, followed by 10 ml ECL-2 buffer for 1 min. 
The chemiluminescent signal was detected by a LumiImager (ROCHE). 
 
3.4  Biochemical assays for TAP  
 
3.4.1  Preparation of crude membranes 
  
Phosphate buffered saline (PBS)   Tris buffer 
137  mM  NaCl    10  mM  Tris-HCl 
2.7  mM  KCl   pH  7.5   
10 mM Na2HPO4 
2 mM KH2PO4 
pH 7.4   
 
Protease inhibitors mix 
50 µg/ml AEBSF hydrochloride 
1 µg/ml aprotinin Chapter 3    Methods 
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10 µg/ml leupeptin 
5 µg/ml pepstatin A 
150 µg/ml benzamidin 
    
  200 ml of Sf9 insect cells (1.8 x 10
6 cells/ml) were co-transfected with baculoviruses 
encoding for tap1 and tap2 genes at MOI (multiplicity of infection) of 5. After 48 h, the 
cells were harvested by centrifugation at 2,600 x g for 10 min, at 4°C and washed once with 
PBS containing 15% (v/v) glycerol plus 1 mM DTT. The pellets were frozen at -20°C for 1 
h, followed by thawing on ice. Sf9 pellets were resuspended in 20 ml of Tris buffer and 1% 
protease inhibitors plus 1 mM DTT. After incubation on ice for 30 min, cells were then 
homogenized by a glass douncer and centrifuged at 200 x g for 4 min followed by 700 x g 
for 8 min at 4°C. The resulting supernatant was centrifuged at 154,000 x g in a Ti70 rotor 
for 30 min at 4°C. The pellet was resuspended in 4 ml PBS pH 7.4 plus 1 mM DTT, and 
aliquots were frozen in liquid nitrogen and stored at -80°C. Typically aliquots of 100 µl had 
a protein concentration of 5 mg/ml. 
 
3.4.2  Peptide labeling with Na
125I 
  RRY(
125I)QKSTEL – radioactive labeled peptide 
  1 mg/ml chloramine T 
  0.17 mg/ml sodium disulfite (Na2S2O5) 
  10% (v/v) bovine serum albumin (BSA) 
  Dowex 1x8 anion exchange  
  PBS buffer, pH 7.0 
  
    The chloramine T method, a chemical oxidation, covalently couples iodine to 
tyrosine residue (Hunter and Greenwood, 1964). The reaction was started by adding to 50 µl 
of  88 µM peptide, 10 µl Na
125I (100 µCi), and 10 µl chloramine T (1 mg/ml in PBS 7.0). 
After 5 min incubation at room temperature, the reaction was stopped by addition of 120 µl 
Na2S2O5. Free iodine was removed by anion exchange chromatography using Dowex 1 x 8 
material. Initially, Dowex (10 mg) was equilibrated in PBS buffer containing 0.2% dialyzed 
BSA and was washed 3 times with PBS buffer without BSA. The dowex suspension (250 
µl) was added to the reaction mix, vortexed and incubated for 5 min at room temperature. 
The suspension was applied to an empty spin column and centrifuged for 30 sec at 500 x g. 
The flow-through contained the radiolabeled peptide in a concentration of 10 µM. 
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3.4.3  Peptide binding assay  
 
3.4.3.1 Peptide binding assay (Centrifugation assay) 
 
PBS buffer  Binding buffer 
137 mM NaCl  PBS buffer      
2.7 mM KCl  5 mM MgCl2 
8.1 mM Na2HPO4  pH 7.0 
1.8 mM KH2PO4 
pH 7.0 
 
Lysis buffer      RRYC(F)KSTEL (C4F) peptide     
PBS buffer      RRYQKSTEL      (R9LQK) peptide 
1% (w/v) SDS       
pH 7.0  
 
  Crude membranes (100 µg total protein) were mixed with 500 nM 
iodoacetamidofluorescein labeled peptide (C4F) in binding buffer (total volume 150 µl). To 
determine unspecific binding control sample contained 400-fold excess of unlabeled peptide 
(R9LQK, 200 µM). After 15 min of incubation on ice, the crude membranes were washed 
twice with 400 µl binding buffer and centrifuged at 20,000 x g for 8 min. Afterwards, the 
pellets were resuspended in 300 µl of lysis buffer to solubilize the crude membranes as well 
as the peptides, and 250 µl lysate solution was added to the filter plate. Filter plate was 
incubated at room temperature for 15 min. Subsequently, the fluorescence emission of the 
solution was measured in the multi-well plate at 520 nm with the excitation wavelength at 
470 nm using FluoroStar fluorometer (BMG Labtechnologies, GmbH, Germany). The C4F 
peptide was diluted in lysis buffer to a series of defined concentration (0, 10, 20, 40, 80 and 
100 nM), which were used as standard.  
 
3.4.3.2 Peptide binding assay (Filter assay) 
 
Binding buffer             RRY(
125I)QKSTEL- radioactive labeled peptide 
PBS  buffer     
5 mM MgCl2    
pH 7.4  
 
  The filter assay was performed using a multiple filtration manifold (Multiscreen 
Assay System, Millipore) that is capable of handling 96 samples in parallel. The binding 
reaction took place in multi-well plates in which crude membranes (40 µg total protein) Chapter 3    Methods 
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were mixed with radioactive labeled peptide R9LQK at indicated concentration in binding 
buffer in a final volume of 50 µl. After incubation on ice for 15 min, the mixture was 
transferred onto a multiscreen filter (MultiScreen Plates with glass fibre filter, pore size 1.0 
µm, Millipore), which was preincubated with 100 µl 0.3% polyethylimine. Unbound 
peptide was removed by washing with 100 µl ice-cold binding buffer twice. The filters were 
air-dried, and radioactivity was quantified by γ-counting. The amount of bound peptides 
were corrected for unspecific binding, which was determined in the presence of 400-fold 
molar excess of unlabeled peptide R9LQK. To determine the peptide dissociation constant, 
the data were fitted with Langmuir (1:1) binding equation: 
                                         
B =
×
Bmax
C
Kd + C
(Eq. 1)
 
where B represents the bound peptide, Bmax – maximal amount of bound peptide, C -
concentration of peptide, and Kd – dissociation constant. 
 
3.4.4 TAP  concentration 
 
Binding  buffer    RRY(
125I)QKSTEL- radioactive labeled peptide 
PBS buffer 
5 mM MgCl2 
pH 7.4 
 
  The amount of TAP in crude membranes was considered to be equal to their active 
peptide-binding sites under saturation condition assuming one peptide-binding site per TAP 
complex. The crude membranes (15 µg protein) were incubated  with 1 µM radiolabeled 
RRY(
125I)QKSTEL on ice for 15 min in 50 µl binding buffer. The mixture was loaded on 
the filter plates, which were then washed with binding buffer two times (details see 3.4.3.2). 
Afterwards, the radioactivity of filter plates was directly measured. In parallel, the 
radioactivity of 1 µl peptide (cpm/µl) was measured and the specific radioactivity of this 
peptide (cpm/mol) can be calculated. After counting the retained radioactivity of the filter 
plates, the total amount of the peptides (peptide-binding sites) was determined. 
 
3.4.5 Protein  concentration 
 
Micro BCA Protein Assay Reagent Kit (Pierce) 
Bovine serum albumin (BSA, Sigma-Aldrich) 
FluoroStar fluorometer (BMG Labtechnologies) 
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  The bicinchoninic acid assay (BCA) combines the reduction of Cu
2+ to Cu
1+ by 
protein in an alkaline medium with the highly sensitive and selective colorimetric detection 
of the cuprous cation (Cu
1+) by bicinchoninic acid. In the first step the chelation of copper 
with protein in an alkaline environment induces a blue colored complex. In the second step, 
BCA, a highly sensitive and selective colorimetric detection reagent reacts with the cuprous 
cation (Cu
1+) and forms a colored complex, whose absorbtion is measured at 594 nm. In this 
respect, 150 µl of sample or standard protein (BSA) is mixed with 150 µl BCA reagent in a 
96 multiwell-plate and incubated for 60 min at 37°C. A calibration curve is generated using 
serial dilutions with BSA, and this is used to determine the protein concentration of the 
sample of interest. 
 
3.4.6  Peptide transport  
 
3.4.6.1 Peptide transport (semi-permeabilized cells) 
 
Transport lysis buffer       Binding buffer 
50 mM Tris-HCl         PBS buffer 
150  mM  NaCl      5  mM  MgCl2  
5  mM  KCl      pH  7.4 
1 mM CaCl2 
1 mM MnCl2 
1% (v/v) Igepal (Sigma) 
pH 7.4 
     
  To probe the TAP function, insect cells (2.5 x 10
6) were semipermeabilized with 
0.05% saponin (Sigma) for 1 min at 25°C in 200 µl of binding buffer. After washing, the 
cells were resuspended in a volume of 100 µl of binding buffer containing ATP (10 mM). 
The transport reaction was initiated by adding 0.50 µM fluorescent peptide 
RRYQNSTC(Ψ)L (Ψ indicates iodoacetamidofluorescein coupled via a cysteine residue) 
for 3 min at 32°C and terminated with 1 ml ice cold binding buffer supplemented with 10 
mM EDTA. After centrifugation, the cells were solubilized in 1 ml transport lysis buffer for 
60 min on ice. N-core glycosylated and thus transported peptides were recovered with 60 µl 
concanavalin A (ConA)-Sepharose beads (Sigma-Aldrich) overnight at 4°C. After three 
times washing with 500 µl transport lysis buffer, the glycosylated  peptides were eluted with 
300 µl methyl-α-D-mannopyranoside (200 mM, Sigma) and quantified with a fluorescence 
plate reader (λex/em = 485/520 nm; Polarstar Galaxy, BMG Labtech). Background transport 
activity was measured in the presence of apyrase (1 unit, Sigma-Aldrich). Chapter 3    Methods 
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3.4.6.2 Peptide transport (crude membranes) 
 
  The peptide transport assay has been investigated using either radioactive labeled 
peptide [RRY(
125I)QNSTEL, where 
125I is covalently coupled to tyrosine residue] or 
iodoacetamidofluorescein labeled peptide (RRYQNSTC(Ψ)L, where Ψ indicates 
iodoacetamidofluorescein coupled via a cysteine residue. In the first case, the crude 
membranes (150 µg total protein) where incubated with 3 mM ATP in 50 µl binding buffer 
on ice for 1 min. The transport starts by adding 1 µM radioactive labeled peptide and 
incubating the reaction mixture for 3 min at 32°C. The reaction was stopped by adding 1 ml 
of ice-cold binding buffer supplemented with 10 mM EDTA. After centrifugation, the 
pellets were solubilized in 500 µl of transport lysis buffer by incubation for 30 min on ice. 
The insoluble material was removed by centrifugation, and the supernatant was incubated 
with 60 µl concanavalin A (ConA)-Sepharose (50%, w/v, Sigma-Aldrich) for 1h. After 
three washing steps with 500 µl transport lysis buffer, the radioactivity associated with 
ConA-Sepharose was quantified by γ-counting.  
 
3.4.7 Immunoprecipitation 
 
IP-lysis  buffer    IP-wash  buffer 
20 mM Tris-HCl       20 mM Tris-HCl 
150  mM  NaCl    150  mM  NaCl 
5 mM MgCl2   2  mM  EDTA 
1% (w/v) Digitonin      0.1% (w/v) Digitonin 
pH  7.5    pH  7.5 
  
  The TAP complex was immunoprecipitated as a complex using Dynabeads
®M-280 
Sheep anti-Mouse IgG magnetic beads (Dynal Biotech) bound with TAP2 antibody 435.3. 
Initially, 150 µl magnetic beads were washed three times with 1 ml IP-lysis buffer 
containing 0.1% (w/v) BSA. Subsequently, 1 ml of hybridoma supernatant (monoclonal 
antibody mAb. 435.3) was added and incubated for 2h at 4°C. After three washing steps 
with 1 ml IP-lysis buffer (0.1% BSA), the beads were equilibrated with 600 µl IP-lysis 
buffer containing 0.1% (w/v) digitonin. 
  TAP was solubilized in 1 ml IP-lysis buffer for 60 min at 4°C. After centrifugation 
for 45 min at 20,000 x g at 4°C, the solubilized membranes were added to the equilibrated 
magnetic beads and incubated for 2h at 4°C. After three washing steps with 1 ml IP-wash 
buffer, the beads were resuspended in SDS-sample buffer, and an aliquot was loaded on Chapter 3    Methods 
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10% SDS-PAGE. Precipitation of TAP1 and TAP2 was confirmed by immunoblotting with 
TAP1-(mAb 148.3) and TAP2-(mAb 435.3) antibodies, respectively. 
 
3.4.8 AlFx-trapping of the TAP complex 
 
Trapping  buffer     
PBS buffer        
5  mM  ATP     
3 mM MgCl2    
2.5 mM AlCl3     
250  mM  NaF    
pH 7.4 
 
  TAP-containing membranes (500 µg total protein) were pre-incubated with 1 µM 
RRYQKSTEL in 500 µl trapping buffer for 25 min at 27°C. Afterwards, membranes were 
washed in ice-cold trapping buffer, collected by centrifugation at 20,000 x g for 8 min at 
4°C and resuspended in 100 µl PBS buffer supplemented with 3 mM MgCl2 for oxidative 
cross-linking, peptide transport or peptide binding. 
 
3.4.9  Cysteine accessibility using fluorescence labeling  
 
Hepes  buffer    IP-lysis  buffer     
50 mM Hepes       20 mM Tris-HCl   
145  mM  NaCl    145  mM  NaCl     
1  mM  KCl    5  mM  MgCl2    
pH 7.5      1% (w/v) Digitonin     
    pH  7.5 
     
 TAP-containing  crude  membranes (500 µg total protein) were labeled with 50 µM of 
the thiol-specific probes 5-iodoacetamidofluorescein (5-IAF), BODIPY maleimide (BM) or 
coumarin maleimide (CM) (Invitrogen) for 3 min at 4°C in 100 µl HEPES buffer. The 
labeling reaction was stopped with β-mercaptoethanol (80 mM) and the membranes were 
washed once with 500 µl ice cold HEPES buffer and pelleted by centrifugation for 8 min, at 
20,000 x g. After labeling, the TAP complex was solubilized with digitonin (1%) in 1 ml of 
IP-lysis buffer and purified via immunoprecipitation using Dynabeads M280-Sheep anti-
mouse IgG (Dynal Biotech) coupled with TAP2-(mAb 435.3) antibody. Purification of 
TAP1 and TAP2 was confirmed by immunoblotting with TAP1-(mAb 148.3) and TAP2-
(mAb 435.3) antibodies, respectively. Fluorescence labeling was monitored by in-gel 
fluorescence using the Lumi-Imager F1
TM (Roche Applied Science). Images of the gel were Chapter 3    Methods 
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quantified using densitometric analysis (Lumi-Imager Software). Cys-less TAP was used as 
a negative control in the labeling reaction. 
 
3.4.10  Kinetics of fluorescence labeling 
 
Hepes  buffer       
50 mM Hepes        
145  mM  NaCl     
1  mM  KCl     
pH  7.0     
 
  TAP-containing crude membranes (60 µg total protein) were incubated with 3 mM 
ATP or ADP for 10 min at 4°C or 1 unit apyrase for 1 min at 32°C in 100 µl Hepes buffer. 
Afterwards, the membranes were labeled with BM (50 µM) at 4°C. The reaction was 
stopped with β-mercaptoethanol (80 mM) at different time points (1-30 min), then SDS-
sample buffer (containing 300 mM DTT) was added, and the samples were loaded on SDS-
PAGE (10%). For the 100% labeling, the sample was labeled with BM (50 µM) for 30 min 
at 4°C, then denaturated in SDS (2%) for 10 min at room temperature, and additionally 
labeled with BM (100 µM) for 5 min. Fluorescence labeling was monitored by in-gel 
fluorescence (see 3.4.9). Fluorescence intensity of the TAP1 bands (normalized to TAP1 
immunoblot signal) was expressed as a percentage of the denatured sample and plotted as a 
function of labeling time. The profiles were fitted using non-linear regression of the 
exponential association curve, 
L =
×
Lmax (1 – e-kt) (Eq. 2) 
where L is the percent labeled, Lmax is the maximum percent labeled, t is time (min), and k is 
the observed rate constant for labeling. 
 
3.4.11  Influence of fluorescence labeling on the function of TAP 
 
Hepes  buffer       
50 mM Hepes      
145  mM  NaCl     
1  mM  KCl     
pH  7.0     
 
  TAP-containing crude membranes (500 µg total protein) were labeled with 50 µM 
BM for 10 min at 4°C in 100 µl Hepes buffer in the presence of 10 mM MgATP. The 
reaction was stopped with β-mercaptoethanol (80 mM) and subsequently the peptide Chapter 3    Methods 
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binding and ATP-dependent peptide transport were investigated. The non-labeled probe 
(100% activity) has been treated identical as described above except that the sample was 
incubated with 50 µM DMSO instead of BM. 
 
3.4.12  Cysteine cross-linking of single cysteine mutants (radioactive) 
 
Phosphate buffer saline (PBS)   
137  mM  NaCl     
2.7  mM  KCl    
10 mM Na2HPO4 
2 mM KH2PO4 
pH 7.4   
 
  TAP-containing membranes (500 µg total protein) were incubated with 1.25 µM of 
radiolabeled peptide RRY(
125I)QKCTEL in 200 µl PBS for 15 min at 4°C. Experiments 
were performed in the presence or absence of competitor peptide (250 µM RRYQKSTEL). 
Chemical cross-linking was initiated by adding of BM[PEO]3 (200 µM final). After 
incubation for 45 min at 4°C, the reaction was quenched with DTT (5 mM). Membranes 
were washed with 1 ml PBS buffer and collected by centrifugation at 20,000 x g for 8 min 
at 4°C. TAP was solubilized in 100 µl  PBS buffer containing 35 mM Foscholine-14 
(Anatrace) for 20 min at 4°C. Insoluble material was removed by centrifugation at 100,000 
x g for 30 min at 4°C. The supernatant (100 µl) was incubated with 100 µl Ni-NTA beads 
(Qiagen) for 45 min at 4°C. For oxidative cross-linking, TAP-containing membranes and 
radiolabeled RRY(
125I)QKCTEL were incubated with CuPhe (1 mM CuSO4/4 mM 1,10-
phenanthroline) for  5 min at 4°C under the same conditions as  described above. The 
reaction was stopped by  addition of N-ethylmaleimide (10 mM) and  purified as stated 
above. TAP was analyzed by SDS-PAGE (10%) and cross-linked products were detected by 
autoradiography with a Phosphorimager 445i (Molecular Dynamics). 
 
3.4.13  Cysteine cross-linking of double cysteine mutants 
 
100 mM CuSO4     
100 mM 1,10-phenanthroline       
100 mM 1,2-Ethanediyl bismethanethiosulfonate (MTS-2-MTS) 
100 mM 1,2-Pentanediyl bismethanethiosulfonate (MTS-5-MTS) 
 
  TAP-containing membranes (500 µg total protein) were washed once with 1 ml PBS 
buffer  and collected by centrifugation at 20,000 x g for 8 min at 4°C. Afterwards, the Chapter 3    Methods 
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  TAP-containing membranes (500 µg total protein) were washed once with 1 ml PBS 
buffer  and collected by centrifugation at 20,000 x g for 8 min at 4°C. Afterwards, the 
oxidative cross-linking was initiated with copper phenanthroline (1 mM CuSO4/4 mM 1,10-
phenanthroline) in 100 µl of PBS buffer (pH 7.0) for 1 min at 4°C. The reaction was 
stopped by addition of 10 mM N-ethylmaleimide. Membranes were washed with 500 µl 
PBS buffer containing 10 mM EDTA and collected by centrifugation at 20,000 x g for 8 
min at 4 °C. Membranes were resuspended in SDS-sample buffer containing 10 mM NEM 
and were analyzed by non-reducing SDS-PAGE (6%) and immunoblotting with TAP1-
(mAb. 148.3) and TAP2-(mAb. 435.3) monoclonal antibodies. To reduce the disulfide 
bonds after cross-linking, 100 mM DTT were added in the sample buffer before 
electrophoresis. 
 
3.4.14  Influence of cross-linking on the function of TAP 
 
TAP-containing membranes (500 µg total protein) were washed once with 1 ml PBS 
buffer (pH 7.0) and collected by centrifugation at 20,000 x g for 8 min at 4°C. Afterwards, 
the oxidative cross-linking was initiated with or without CuPhen (1 mM CuSO4/4 mM 1,10 
phenanthroline) for 1 min at 4°C in 100 µl PBS buffer. Then, the membranes were 
incubated with or without 100 mM β-mercaptoethanol for 5 min at 4°C, washed twice with 
1 ml PBS containing 10 mM EDTA, and the peptide binding (see 3.4.3.2) and peptide 
transport (see 3.4.6.2) were performed. 
 
3.5 Molecular  modeling 
 
3.5.1  Homology modeling of the core TAP transport complex  
The homology modeling of the core TAP transport complex has been performed by 
Megan L. O’Mara, W. F. Drew Bennett and D. Peter Tieleman (Department of Biological 
Sciences, University of Calgary, Canada). Each TAP1 and TAP2 half-transporter was 
modeled on the corresponding subunit of the ADP-bound S. aureus Sav1866 homodimer 
(2HYD.pdb) (Dawson and Locher, 2006). Although the Sav1866 structure was crystallized 
with ADP, the tight NBD dimer conformation and outwards-facing configuration of the 
TMDs is believed to represent the ATP-bound state. The Sav1866 conformation allowed us 
to develop a homology model of heterodimeric TAP complex in the ATP-bound state. We Chapter 3    Methods 
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aligned the amino acid sequence of human TAP1 and TAP2 with that of Sav1866 using 
ClustalW2 (Thompson et al., 1994). Secondary structure predictions (Rost et al., 2003) and 
experimental data on the membrane topology (Schrodt et al., 2006) for the TAP1 and TAP2 
TMHs corresponded to the Sav1866 based alignment. The alignment for TAP1 and TAP2, 
respectively, against Sav1866 was 27% and 28%, although this varies markedly between the 
TMDs and NBDs. The absolute sequence identity between TAP1 and Sav1866 is 20% for 
the TMDs and 37% for the NBDs. For the alignment between TAP2 and Sav1866, the 
sequence identity is 22% for the TMDs and 34% for the NBDs. When sequence similarity is 
taken into account, these percentages become 61% and 56% for the TMDs, and 69% and 
63% for the NBDs of TAP1 and TAP2, respectively. TAP1(173-741) and TAP2(141-686) 
were modeled separately using MODELLER v9.3 (Sali and Blundell, 1993). The TAP1 and 
TAP2 models were dimerized to reproduce the Sav1866 subunit interface and refined to 
remove steric clashes (Guex and Peitsch, 1997). The models were inserted into a 1-
palmitoyl-2-oleoyl-phosphatidyl ethanolamine (POPE) lipid bilayer and the system was 
solvated. Position restraints on the protein backbone conformation were relaxed over a 40-
ns period using the GROMACS 3.2.1 simulation package to give an energy minimized 
TAP1/2 heterodimer. Additional MD simulations were not performed, as short timescale 
simulations have been shown to increase the backbone disorder of homology models. 
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4. Results 
 
4.1  Role of the CL1 mutants (TAP1) in the substrate sensing and signal 
 transmission   
 
4.1.1  The CL1 is an important region of the TMD-NBD interface 
 
  As shown in earlier studies with purified and reconstituted TAP, the allosteric 
interaction between peptide binding, ATP hydrolysis and peptide translocation involves a 
dialogue between the NBDs and the substrate binding site in the TMDs (Gorbulev et al., 
2001). However, how this downstream mechanism functions at molecular level remains 
unknown. Based on the X-ray structures of ABC transporters, cytoplasmic loops in TMDs 
display the interface with the NBDs (Locher et al., 2002; Dawson and Locher, 2006). In 
biochemical studies, the EAA motif in a cytoplasmic loop of the TMD, which is part of the L-
loop found in BtuCD, and the Q-loop in the NBD were identified to be important for signal 
transduction between the TMDs and NBDs in ABC importers (Mourez et al., 1997; Hunke et 
al., 2000). The main contacts between the membrane spanning domain BtuC and the ABC-
cassette BtuD are formed by the L-loop of BtuC and the Q-loop of BtuD of the vitamin B12 
transporter (Locher et al., 2002). The L-loop consists of two short helical stretches named L1 
and L2 interrupted by a glycine residue. By sequence comparasion, this L-loop sequence, can 
be found in cytoplasmic loops of nearby all ABC transporters. Interesting the position of the 
L-loop is variable, depending on the ABC transporter.  
The cytosolic loops of ABC exporters and importers are verry different. For example, in 
contrast to the ABC import proteins, the ABC exporters like MsbA and Sav1866 show an 
enlarged TMD-NBD interface comprising the large cytosolic loops CL1 and CL2 of the TMD 
and different regions in the NBD (Dawson and Locher, 2006). In order to define residues of 
the transmission interface in TAP, a 3D homology model of the core TAP complex based on 
the x-ray structure of Sav1866 has been constructed (Dawson and Locher, 2006; Figure 4-
1A). The homology modeling of the core TAP transport complex has been performed by 
Megan L. O’Mara, W. F. Drew Bennett and D. Peter Tieleman (Department of Biological 
Sciences, University of Calgary, Canada). The final TAP model had a backbone root-mean-
square deviation (RMSD) of 3.08 Å from the Sav1866 structure. The quality of the TAP1/2 
model was assessed using WHATIF on local factors such as backbone conformations, bond 
lengths, side chain planarity, and overall packing quality and found to be of comparable 
quality to Sav1866. However, some caveats must be applied when using WHATIF for 
analysis of transmembrane proteins (O’Mara and Tieleman, 2007). Therefore, an additional Chapter 4    Results 
  58
analysis of the Ramachandran plot using SPDBV (Guex and Peitsch, 1997) was used as an 
extra structural analysis method. The Ramachandran plot showed 99% of all TAP1/2 residues 
fell within favourable regions, increasing our confidence in the backbone geometry. The 
cytosolic loops of TAP and Sav1866 are of similar length and clearly distinct from the short 
cytosolic loops of ABC importers (Figure 4-1A).    The constructed model is in full 
agreement with a number of experimental data, including the membrane topology, structure 
and function of a core transport complex, peptide-binding regions, and the sensor loop 
(Nijenhuis and Hämmerling, 1996; Koch et al., 2004; Schrodt et al., 2006; Herget et al., 
2007). The NBDs are close together with distances reflecting the ATP-bound state and the 
TMDs opened to the ER-luminal site, reflecting an outward-facing conformation. The 
cytosolic loops are composed of TMH-extended helices, which are connected by short 
coupling helices (CHs) in parallel orientation to the membrane plane (Figure 4-1A). 
Importantly, the X-loop of TAP occupies a central position, in which the conserved glutamate 
is surrounded by residues of CL1 and 2 of the opposite subunit (Figure 4-1A). The X-loop is 
localized in the α-helical domain of the NBD close to the C-loop, suggesting a role in 
transmitting conformational changes generated by ATP binding and hydrolysis. The sequence 
conservation of CL1 and 2 including the coupling helix 1, the identified peptide sensor and 
coupling helix 2, as well as the X-loop are illustrated in Figure 4-1B.  
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TAP1     272 E T E F F Q Q NQT G N I M S R V
TAP2     238 D L G F F Q E T K T G E L N S R L
Sav1866  108 S A R F Y A N N Q V G Q V I S R V
coupling helix 1 peptide sensor
TAP1     368 I E A L S A M P T V R S F A N E 
TAP2     333 R E A V G G L Q T V R S F G A E
Sav1866  204 H E R V Q G I S V V K S F A I E
coupling helix 2
TAP1     634 T E V D E A G
TAP2     598 T D V G E K G
TAPL     634 T E T G E K G
MDR1     522 T L V G E R G
MDR1    1167 T K V G D K G
MsbA     472 T I I G E N G   
Sav1866  469 T E V G E R G 
X-loop
 
Figure 4-1. The TMD-NBD interface of the TAP complex. (A) 3D homology model of the core TAP complex 
composed of TAP1 (green) and TAP2 (cyan) based on the x-ray structure of Sav1866 (2HYD.pdb) (26). The 
homology modeling of the core TAP transport complex has been performed by Megan L. O’Mara, W. F. Drew 
Bennett and D. Peter Tieleman (Department of Biological Sciences, University of Calgary, Canada). The TMHs 
of the extra N-domain (TMD0) are indicated by cylinders. CL1 and CL2 are extensions between TMH2 and 3, 
and TMH4 and 5, respectively. The region of CL1 and CL2 in TAP1 investigated by cysteine scanning and 
cross-linking is colored in orange, the X-loop of TAP2 in yellow, respectively. The conserved glutamate (E602) 
in the X-loop and residues in CL1 and CL2 (Q277 and A381) are highlighted in red using a stick representation. 
A zoom-in of the transmission interface illustrates the close interaction of coupling helix 1 and 2 and the X-loop 
of TAP2. The extensions of the TMHs are indicated by numbers. (B) Multiple alignments of the transmission 
interface of different ABC exporters (Swiss-Prot accession numbers: Q03518/9, human TAP1/2 (ABCB2/3); 
Q9NP78, human TAPL (ABCB9); P08183, human MDL1 (ABCB1); P63359, S. typhimurium MsbA; Q99T13, 
S. aureus Sav1866) using ClustalW2 (http://www.clustalW.org). The coupling helix 1 and 2, the peptide sensor, 
and the X-loop are presented. Residues with high conservation are shaded dark grey and bold. The conserved 
glutamate of X-loop is labeled in red. 
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4.1.2  Expression of single cysteine CL1 mutants of TAP1 
 
  In order to investigate the contribution of the CL1 in the intramolecular crosstalk 
between TMD and NBD of TAP, cysteines were introduced in cys-less TAP construct. 
Recently, cysteine-less human TAP subunits were created, replacing all 19 cysteines in TAP1 
and TAP2. Cysteine-less TAP1 and TAP2 are fully functional in respect of intracellular 
peptide transport and MHC class I antigen presentation (Heintke et al., 2003). Based on the 
structure of BtuCD, where residues located in the L2 helix make contacts with the NBD, we 
have mutagenized all residues of the L2 helix of cysteine-less TAP1 to cysteine. Furthermore, 
the Q277 and the highly conserved G282 were replaced by cysteine. In our studies, all CL1 
(TAP1) mutants were combined with a wild type counterpart (TAP2), which resulted in the 
following mutants: TAP1-Q277C/TAP2-wt, G282C/wt, N283C/wt, I284C/wt, M285C/wt, 
S286C/wt, R287C/wt, V288C/wt. All TAP1 and TAP2 constructs were cloned individually 
into one baculovirus, and co-expressed in Sf9 insect cells under the control of the polyhedrin 
promoter, respectively. Two days after infection (with an multiplicity of infection of 5), cells 
were harvested and crude membranes were prepared. As revealed by immunoblotting, all 
TAP1 mutants were expressed in crude membranes at comparable level to TAP C-less/wt 
(Figure 4-2). 
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Figure 4-2. Expression of single cysteine CL1 mutants (TAP1).  
Immunoblotting of crude membranes from Sf9 insect cells co-transfected with baculoviruses encoding TAP1 
mutants and TAP2wt. The anti-TAP1 (148.3) and anti-TAP2 (435.3) monoclonal antibodies were used to detect 
TAP1 and TAP2 protein expression, respectively (Herget et al., 2007). 
 
 
 
 
 
 Chapter 4    Results 
  61
4.1.3  Peptide binding of CL1 mutants 
 
  In order to investigate if the CL1 mutants are functionally active, we have examined 
first peptide binding at 4°C. Crude membranes containing TAP variants were incubated with 
increasing concentrations of radiolabeled R9LQK peptide. As shown in Figure 4-3, the data 
were fitted by the Langmuir (1:1) binding equation and the peptide dissociation constants Kd 
as well as the maximal peptide-binding capacity Bmax were determined. All the constants are 
summarized in Table 4-1.  The Bmax values of each mutant show only 2 fold difference, 
indicating similar expression. The Kd values of all CL1 mutants are quite similar with TAP C-
less/wt, demonstrating that the substitution of the CL1 residues with cysteines does not alter 
the peptide-binding affinity. 
 
Table 4-1. Summary of peptide binding constants of single cysteine CL1 mutants (TAP1). 
CL1 mutants 
(TAP1) 
Kd 
(µM) 
Bmax 
(cpm/1000) 
C-less/2wt  0.57 ± 0.17  40.41 ± 4.13 
Q277C/2wt  0.61 ± 0.24  59.62 ± 8.12 
G282C/2wt  0.77 ± 0.17  73.93 ± 7.36 
N283C/2wt  1.31 ± 0.52  132.33 ± 22.81 
I284C/2wt  0.58 ± 0.19  54.55 ± 8.59 
M285C/2wt  0.51 ± 0.17  79.91 ± 12.34 
S286C/2wt  1.04 ± 0.66  43.22 ± 12.63 
R287C/2wt  1.67 ± 0.13  53.76 ± 2.51 
V288C/2wt  0.57 ± 0.29  52.54 ± 13.16 Chapter 4    Results 
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Figure 4-3. Peptide binding of CL1 mutants (TAP1). 
Crude membranes (35 µg protein) of CL1 mutants were incubated with increasing concentrations of radiolabeled 
peptide R9LQK (15 min, 4°C). Free peptides were removed by washing and membrane-associated peptides were 
determined by γ-counting. Amount of specifically bound peptides is plotted against the peptide concentration 
and fitted by a Langmuir (1:1) binding equation. The peptide affinities and Bmax values are summarized in table 
4-1. Data resemble the mean of triplicate measurements. The error bars indicate the deviation of triplicate 
measurements. 
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4.1.4  Peptide transport of CL1 mutants  
 
  We next investigated the peptide transport activity of the CL1 mutants in whole cells 
using fluorescent peptide RRYQNSTC
(F)L. As shown in Figure 4-4, mutations of the most 
conserved residues within the sensor loop (Gly-282, Ile-284, and Arg-287) strongly decreased 
peptide transport. In these mutants, the coupling between peptide binding and transport is 
disrupted, indicating that this sensor site serves as a checkpoint in controlling downstream 
events. 
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Figure 4-4. Peptide transport of single-cysteine CL1 mutants (TAP1). 
ATP-dependent peptide transport of single cysteine TAP1 mutants was analyzed in semipermeabilized insect 
cells. The assay was performed with fluorescein-labeled peptide (0.50 µM, RRYQNSTC
(F)L) for 3 min at 32°C 
in the presence and absence of Mg-ATP (10 mM). N-core-glycosylated and therefore transported peptides were 
bound to ConA-beads and quantified by fluorescence detection after elution with methyl-α-D-mannopyranoside. 
The relative ATP-dependent transport efficiencies of the single-cysteine TAP constructs are plotted in 
comparision to that of TAP1 Cys-less/TAP2wt. The error bars indicate the deviation of three independent 
experiments (Herget et al., 2007). 
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4.1.5  The sensor loop is in contact with the bound peptide  
 
  Recently, the peptide contact site was identified by mass spectrometry (Herget et al., 
2007). This contact site is located in the cytosolic loop 1 (CL1) between TM2 and TM3 of 
TAP1, and shares some degree of homology with CL1 of the bacterial multidrug exporter 
Sav1866 and the L-loop of the bacterial vitamin B12 importer. Based on the x-ray structure of 
these proteins these loops form the major contact between the transmembrane domain and the 
Q-loop as well as the α-helical subdomain of the nucleotide-binding domain as derived from 
distance measurements. To proof the direct contact of the sensor region with the bound 
peptide, a cross-linking approach was established with TAP1 mutants and radioactive labeled 
peptide RRYQKCTEL (C6-peptide), each containing a single cysteine. After binding of 
radio-labeled peptide to TAP, membranes were incubated with the thiol-specific cross-linker 
BM[PEO]3. Cross-linking products were analyzed by SDS-PAGE and autoradiography. As 
shown in Figure 4-5A, specific cross-linking was detected only if a single cysteine (V288C) 
was placed at the peptide contact site identified by mass spectrometry. Background labeling 
was observed in the presence of an excess of the epitope, demonstrating the specificity of the 
cross-linking. No cross-linking was monitored for cysteine-less TAP1. TAP1 mutants with 
single cysteines placed in the NBD (R659C) did not show specific cross-linking (Figure 4-
5A). To prove the direct contact of the sensor region with the bound peptide, also oxidative 
cross-linking of single cysteine TAP and peptides with copper phenanthroline was performed, 
which induces disulfide formation only if two cysteines are in very close proximity (Wu and 
Kaback, 1996). A 200-fold excess of non-labeled peptide, RRYQKSTEL, was used as 
competitor. As negative control, the construct TAP1 C-less/TAP2 wt was used in the cross-
linking experiments. After quenching of free cysteines with NEM, cross-linking products 
were analyzed by non-reducing SDS-PAGE and autoradiography. Notably, the bound C6-
peptide was cross-linked to the TAP1 contact site identified by mass spectrometry, including 
position 288 (Figure 4-5B). The cysteine-less and TAP1-R659C mutant did not show a 
specific cross-linking. In addition, the TAP1 mutants I284C, M285C ans S286C are cross-
linked to a very small extend in the nucleotide free state (Figure 4-6A). Interestingly, in the 
ATP bound state the bound C6-peptide was cross-linked to the position 288. In addition, the 
TAP1 mutants I284C and S286C are cross-linked to a very small extend, but the mutant 
M285C is not cross-linked, suggesting a state dependent rearrangement of the sensor interface 
in TAP1 (Figure 4-6B). All other residues within the peptide sensor site are not in contact Chapter 4    Results 
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with the bound peptide. Importantly, the crosslinking observed is TAP1 specific, since the 
TAP1 C-less/TAP2 wt shows no crosslinking with the bound C6-peptide. 
 
V288C
- +
R659C
- +
C-less
- +
82
kDa
autoradiography
TAP1
α TAP1 (148.3)
competitor
A
V288C
- +
R659C
- +
C-less
- + competitor
autoradiography
82
kDa
α TAP1 (148.3)
TAP1
B
 
Figure 4-5. Bound peptides are in direct contact with the cytosolic loop 1 of TAP1. 
(A) Site-specific thiol cross-linking with BM[PEO]3. TAP-containing membranes (0.5 mg of total protein; TAP1 
(single cysteine or cysteine-less) combined with TAP2 wt were preincubated with radio-labeled C6-peptide (1.25 
µM) in the absence or presence of the peptide RRYQKSTEL (250 µM). Cross-linking was induced by adding 
0.2 mM of BM[PEO]3. After purification of TAP via metal affinity beads, cross-linked products were analyzed 
by reducing SDS-PAGE and autoradiography. (B) Oxidative cysteine cross-linking with copper phenanthroline. 
Experiments were performed as described in (A), except that membranes were incubated with copper 
phenanthroline (1mM) and SDS-PAGE was performed under non-reducing conditions. Equal amounts of TAP in 
each experiment were confirmed by immunoblotting (Herget et al., 2007). 
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Figure 4-6. The C-terminal part of the CL1 is in contact with the bound peptide. 
TAP-containing membranes (0.5 mg of total protein) were incubated with either 2 units apyrase (A) or 3 mM 
ATP (B). Afterward, radiolabeled C6-peptide (1.25 µM) was added in the absence or presence of the competitor 
peptide RRYQKSTEL (250 µM). Cross-linking was induced by adding copper phenanthroline (1 mM). After 
metal affinity capture of TAP, cross-linked products were analyzed by non-reducing SDS-PAGE (10%) and 
autoradiography. Equal amounts of TAP in each experiment were confirmed by immunoblotting (Herget et al., 
2007).  
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4.1.6  The peptide sensor interface is restructured in the transition state of the ATPase 
domains  
 
  Peptide transport by TAP is a multistep process composed of peptide binding, 
interdomain signal transmission, ATP binding/hydrolysis and peptide translocation. To 
elucidate structural changes in the peptide sensor and transmission interface, we examined the 
peptide-TAP1 contact site at various stages of the ATP hydrolysis cycle. We focused on the 
single cysteine mutant TAP1 (V288C)/TAP2 (wt), since this construct showed the strongest 
cross-linking with the bound C6-peptide in the ATP-bound and nucleotide free states (Figure 
4-6A, B). To fix each single state, we performed this experiment at 4°C where ATP 
hydrolysis is absent. Apart from an ATP-bound, ADP-bound, and nucleotide-free state, a 
catalytic transition state can be arrested by aluminium fluoride (AlFx). AlFx is a potent 
ATPase inhibitor, which replaces the γ-phosphate of ATP and traps ADP stably in the ATP 
binding pocket of TAP (Chen et al., 2003) and also other ATPases like P-glycoprotein 
(Sankaran  et al., 1997) or F1-type ATPases (Lunardi et al., 1988). Derived from x-ray 
structures of myosin, this ADP-trapped state mimics the pentacovalent phosphorus transition 
state of ATP hydrolysis (Fisher et al., 1995). In this state, peptide transport but not peptide 
binding by TAP is inhibited (Figure 4-7A and B). As shown in Figure 4-7C, cysteine cross-
linking of the single cysteine peptides to residue 288 of TAP1 was observed in the presence of 
ADP or ATP. In addition, in the presence of the non-hydrolyzable ATP-analogues ATPγS and 
AMP-PNP, which do not energize peptide transport (Meyer et al., 1994), peptide cross-
linking occurred. Disulfide formation was most efficient in the absence of nucleotides. 
Strikingly, if the TAP complex was arrested in the translocation incompetent ADP•AlFx state, 
no specific peptide contact to the peptide sensor site was observed. These results demonstrate 
a structural reorganization of the peptide sensor and transmission interface and an inter-
domain cross-talk of the TMD and NBD during ATP hydrolysis. 
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Figure 4-7. The peptide sensor loop is remodelled during the ATP hydrolysis cycle. 
TAP-containing membranes were preincubated with 1 µM RRYQKSTEL and 5 mM ATP in the presence or 
absence of 2.5 mM AlFx for 25 min at 27°C. Afterwards, membranes were washed once. (A) Peptide binding 
affinity. Pre-treated TAP1(V288C)/TAP2(wt) (25 µg of total protein) was incubated with increasing 
concentrations of radiolabeled RRYQKCTEL (plus 1 mM dithiothreitol) for 15 min at 4°C. The amount of 
specifically bound peptide was plotted against peptide concentration and fitted by a Langmuir (1:1) isotherm. (B) 
Peptide transport. Pre-treated TAP1(V288C)/TAP2(wt) (150 µg of total protein) was incubated with 1 µM of 
RRYQNSTC
(F)L (fluorescein-labeled cysteine) in the presence of 5 mM ATP or ADP for 3 min at 32°C. 
Transported and glycosylated peptides were purified and detected by fluorescence emission (λex/em =485/520). 
ATP-specific transport of trapped (ADP•AlFx) and non-trapped (ATP) TAP is depicted. The data and errors were 
derived from triplicate measurements. (C) Oxidative cross-linking. TAP1(V288C)/TAP2(wt) (500 µg of total 
protein) was trapped in the ADP•AlF4
- transition state as described above or incubated with either 3 mM ATP, 3 
mM ADP, 3 mM AMP-PNP, 3 mM ATPγS, or apyrase (2 units). Afterwards, radiolabeled C6-peptide (1.25 µM) 
was added in the absence or presence of the competitor peptide RRYQKSTEL (250 µM). Cross-linking was 
induced by adding copper phenanthroline (1 mM). After metal affinity purification of TAP, cross-linked 
products were analyzed by non-reducing SDS-PAGE and autoradiography. TAP amount was quantified by 
immunoblotting. The cross-linking intensities (quantified by ImageQuaNTsoftware) were normalized to TAP 
amounts, and relative specific cross-linking was related to cross-linking in the presence of apyrase as depicted in 
the lower panel (Herget et al., 2007). 
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4.2  Architecture of CL1 revealed by fluorescence labeling 
 
4.2.1  Cysteine accessibility using fluorescence labeling  
 
  In the previous chapter, I have characterized biochemically the residues of CL1 
(TAP1) in respect of protein expression, peptide binding and substrate translocation. Single 
cysteine mutations in CL1 region have no effect on peptide binding, but in peptide transport, 
thereby demonstrating their importance in the translocation process.  
  To characterize the molecular architecture of CL1, a convenient and minimally 
perturbing approach was used, which combined cysteine substitution in the CL1 region and 
determination of accessibility to thiol specific compounds with different properties. 
Therefore, the single cysteine CL1 mutants (TAP1) were co-expressed with TAP2 cysteine 
less, and the fluorescence labeling has been performed in crude membranes. The thiol specific 
probes used in this study were: iodoacetamidofluorescein (5-IAF, hydrophilic, negative 
charged at pH 7.5), coumarin-maleimide (CM, hydrophobic), and BODIPY-maleimide (BM, 
amphiphilic). The TAP1/TAP2 cysteine less isoform was used as a control for non-specific 
probe interaction. Similar investigations using cysteine-scanning mutagenesis combined with 
fluorescence labeling to elucidate the topography of key domains of membrane proteins were 
applied for P-glycoprotein (Rothnie et al., 2004; Storm et al., 2008).  
  In order to optimize the labeling reaction, we have tested 5-IAF and determined the 
effect of time, fluorophore concentration and temperature on the fluorescence labeling in the 
crude membranes. After labeling, the reaction has been quenched with β-mercaptoethanol and 
the membranes were solubilized with digitonin (1%) and purified by immunoprecipitation 
with α-TAP2 antibody (mAb 435.3). Figure 4-8 summarizes the results obtained for in-gel 
fluorescence measurements and corresponding TAP1 and TAP2 specific immunoblots of C-
less (TAP1)/C-less (TAP2), C-less/wt, and Q277C/C-less. Notably, the isoform C-less/wt, 
which contains 10 cysteines showed the highest fluorescence after 5 min of labeling at 4°C. 
Interestingly, the cysteine at position 277 (Q277C) was already labeled after 1 min at 50 µM 
5-IAF. Minor differences of labeling efficiency after 3 or 5 min were observed. The reaction 
is site-specific, because C-less TAP shows no labeling (Figure 4-8A). Increasing the 5-IAF 
concentrations (50 – 200 µM) does not induces a higher labeling efficiency (Figure 4-8B). 
The optimal temperature for 5-IAF labeling was 4°C, because at this temperature TAP 
degradation is reduced, thereby facilitating a better labeling efficiency (Figure 4-8C). At 
higher temperatures TAP is degraded, as observed from the TAP1 and TAP2 specific 
immunoblots. Taken together, the optimal fluorescence labeling in crude membranes occured Chapter 4    Results 
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at 50 µM 5-IAF, 4°C, for 3 min. These labeling conditions were used for all fluorophores 
tested in the present work. 
13 5
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Figure 4-8. Optimization of fluorescence labeling of single-cysteine CL1 mutants. 
(A) Influence of time on fluorescence labeling. TAP-containing membranes (0.5 mg of total protein) were 
labeled with 50 µM thiol-specific probe 5-IAF for 1-5 min at 4°C. (B) Influence of fluorophore concentration. 
TAP-containing membranes (0.5 mg of total protein) were labeled with 50-200 µM 5-IAF for 3 min at 4°C. (C) 
Influence of temperature on fluorescence labeling. TAP-containing membranes (0.5 mg of total protein) were 
labeled with 50 µM 5-IAF for 4 min at 4 - 37°C. The labeling reaction was stopped with β-mercaptoethanol (80 
mM). After labeling, the TAP complex was solubilized with digitonin (1%) and purified via 
immunoprecipitation using Dynabeads M280-Sheep anti mouse IgG coupled with α-TAP2 (435.3) antibody. Co-
purification of TAP1 and TAP2 was confirmed by immunoblotting with α-TAP1 and α-TAP2 antibodies, 
respectively. Cysteine-less TAP was used as negative control in the labeling reaction. The difference in mobility 
observed for C-less/wt (fluorescence gel and TAP2 immunoblot) are attributed to the absence of histidine tag 
(His-tag) on this construct, whereas C-less TAP2 had a 10 His-tag on C-terminus.   
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To determine the topography of CL1, cysteine accessibilities with dyes of different 
hydrophilic characteristics were studied under the established conditions. To normalize the 
labeling efficiency to TAP amount, the ratio between fluorescence labeling and TAP1 
immunoblot signal has been determined. Importantly, the absolute fluorescence between the 
thiol-specific probes is not comparabile, because of their different physicochemical 
properties. The hydrophilic probe 5-IAF labeled with high degree two mutants (Q277C and 
N283C), and with reduced efficiency three other constructs (G282C, I284C, and V288C; 
Figure 4-9B). Interestingly, 3 mutants (M285C, S286C, and R287C) were not labeled with 5-
IAF. The reaction is cysteine specific, because cys-less TAP shows no labeling. Equal 
amounts of TAP1 and TAP2 were detected after immunoprecipitation (Figure 4-9B). The 
amphiphilic probe BM labeled all of the CL1 mutants, however, with different efficiencies. 
The highest labeling was observed for three mutants (G282C, N283C, and I284C), whereas a 
reduced efficiency was detected for five other constructs (Q277C, M285C, S286C, R287C, 
and V288C; Figure 4-9C). The hydrophobic probe CM labeled the single cysteine CL1 
mutants in a similar fashion compared with the BM probe. Again, the highest degree of 
labeling was observed for three constructs (G282C, N283C, and I284C; Figure 4-9D). 
Interestingly, labeling of the Q277C construct had a low efficiency.  
  The results are summarized in the Table 4-2, which provides a qualitative assessment 
of the relative accessibility of the residues to covalent modification. The results are presented 
as (i) complete labeling during the reaction period (denoted +++), (ii) incomplete, but 
significantly different from the cysteine-less protein (denoted as + or ++ to enable easier 
identification of alterations in accessibility), or (iii) unlabeled during the reaction (denoted -). 
Two striking features are evident from an examination of the data presented in the Table 4-2, 
namely a good accessibility of the N-terminal residues (Q277C, G282C, N283C, and I284C) 
for the different fluorescent probes used, whereas the rest of the mutants were less accessible. 
A second observation is that the C-terminal region of CL1 (M285C, S286C, R287C, and 
V288C) is accessible for hydrophobic probe (CM), partially labeled by the amphiphilic probe 
(BM) and poorly labeled by the hydrophilic probe (5-IAF), demonstrating that these amino 
acid side chains are in a more hydrophobic environment. 
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Figure 4-9. Labeling of the single-cysteine CL1 mutants. 
(A) Structures of iodoacetamidofluorescein (5-IAF), BODIPY-maleimide (BM), and coumarin-maleimide (CM). 
TAP-containing membranes (0.5 mg of total protein) were labeled with 50 µM thiol-specific probes 5-IAF (B), 
BM (C), and CM (D) for 3 min at 4°C. The labeling reaction was stopped with β-mercaptoethanol (80 mM). 
After labeling, the TAP complex was solubilized with digitonin (1%) and purified via immunoprecipitation using 
Dynabeads M280-Sheep anti mouse IgG coupled with α-TAP2 antibody. Co-purification of TAP1 and TAP2 
was confirmed by immunoblotting with α-TAP1 and α-TAP2 antibodies, respectively. Cysteine-less TAP was 
used as negative control in the labeling reaction. 
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Table 4-2. Summary of relative accessibilities of CL1 mutants. 
The accessibility of each introduced cysteine residue was determined using 5-IAF, BM or CM, and the ratio 
between fluorescence labeling and TAP1 immunoblot signal as shown in Fig. 4-9 was quantified. Labeling with 
a ratio higher than 1.5 was denoted as (+++), whilst incomplete labeling was denoted with either (++) or (+) to 
enable clear illustration of changes in accessibility. No significant labeling of an isoform with a particular probe 
is denoted (-). The absolute fluorescence between the thiol-specific probes is not comparabile, because of their 
different physicochemical properties. 
 
CL1 mutant (TAP1)  5-IAF  BM  CM 
Q277C +++  +  - 
G282C ++  +++  ++ 
N283C +++  +++  +++ 
I284C + +++  +++ 
M285C -  +  ++ 
S286C -  +  ++ 
R287C -  +  + 
V288C ++  ++  ++ 
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Figure 4-10. TAP labeling efficiency. 
TAP containing crude membranes (0.5 mg total protein) were labeled with 50 µM thiol-specific probes 5-IAF 
(white), BM (grey), and CM (black) as described in Figure 4-9. The ratio between fluorescence labeling and 
TAP1 immunoblot signal as shown in Figure 4-9 was quantified. 
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4.2.2  Fluorescence labeling kinetics  
 
  From the fluorescence accessibility studies the amphiphatic character of CL1 (TAP1) 
residues can be suggested. An important question is whether this loop undergoes an 
conformational change during the transport cycle. In the previous studies (Chapter 4.1) using 
a crosslinking approach, residues located in CL1 region which are essential for tight coupling 
of peptide binding and transport were identified. In order to characterize conformational 
changes of CL1 during the transport cycle, I investigated the kinetics of fluorescence labeling 
with BM in different states of TAP, such as ATP-, ADP-bound or nucleotide free 
conformation. The different conformations of TAP were induced by addition/depletion of 
nucleotides. BM has been the fluorescent probe used in this investigation because it could 
label all of the CL1 mutants (Figure 4-9). TAP containing membranes were incubated with 3 
mM Mg-ATP, Mg-ADP or 1 unit apyrase. Afterwards, the membranes were labeled with 50 
µM BM at 4°C, and the reaction was stopped with 80 mM β-mercaptoethanol at different time 
points (1-30 min). The protein samples were separated by SDS-PAGE (10%) and the TAP-
associated fluorescence has been quantified using in-gel fluorescence imaging and normalized 
by TAP1 amount observed from immunoblotting. To determine 100% labeling, crude 
membranes containing TAP were solubilized with 2% SDS and then incubated with 150 µM 
BM for 30 min. Taking a pseudo first order kinetics into account, with a large excess of BM, 
the data were fitted by a monoexponential equation (see Chapter 3.4.10, equation. 2). Figure 
4-11 shows a representative example for the efficiency of labeling Q277C and G282C with 
BM in different conformations. For Q277C mutant, the highest efficiency of labeling occurred 
in the ATP bound state (60%), and in the nucleotide free state the efficiency decreased to 
50%. Similar labeling efficiencies were observed for G282C construct, for example in the 
ADP and nucleotide free state. These values were 62% and 60% respectively, whereas in the 
ATP bound state the efficiency decreased to 54% (Figure 4-11). Higher labeling efficiencies 
where observed for N283C and I284C mutants. The labeling of N283C with BM in the ADP 
bound state reached ~ 100%, whereas in the ATP bound conformation the efficiency 
decreased to 60%. Interestingly, the I284C mutant reached 95% labeling even after 1 min 
incubation in the nucleotide free state, whereas in the ATP/ADP bound conformations the 
labeling efficiency reached 95% after 30 min incubation (Figure 4-12). Similar high labeling 
efficiencies were observed for M285C and S286C mutants (Figure 4-13). The M285C, for 
example, shows a maximum level of labeling (95%) in the nucleotide free state, and a 
decreased efficiency (80%) in the ADP bound conformation. The highest labeling efficiency 
for S286C was observed in the nucleotide-free conformation (58%), whereas in the ATP Chapter 4    Results 
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bound state the efficiency decreased to 40% (Figure 4-13). The labeling of R287C and V288C 
with BM in the ADP bound state reached a significant level (90% and 120% respectively), 
whereas in the ATP bound conformation the efficiencies decreased to 60% (R287C) and 58% 
(V288C) (Figure 4-14).  
A complete graphical representation including the rate constants for BM labeling in 
different conformational states in shown in Figure 4-15 and Table 4-3. Taken together, the 
kinetics of fluorescence labeling suggest that the CL1 undergoes nucleotide binding-
dependent conformational changes. For example, in the nucleotide free state the I284C mutant 
is labeled very fast, by reacting very rapidly with the fluorescent probe BM (Figure 4-12). In 
contrast, in the ATP bound and post-hydrolytic states the rate constant is 100- and 36-fold 
reduced, respectively. Interestingly, the maximal labeling values are similar for all three 
conformational states investigated. V288C displayed a significant reduction of the maximal 
labeling values following the attachement of BM in the ATP bound state (Table 4-3). 
Regarding the kinetics of fluorescence labeling in different conformational states, we can 
classify the CL1 mutants in four groups: 
(i) residues which have a slow kinetic of labeling for all conditions tested (N283C, 
R287C and V288C); 
(ii) residues which have higher rate constants for BM labeling in the absence of 
nucleotide than in the ATP bound state (I284C, M285C and S286C); 
(iii) mutants with higher rate constants in the ATP bound state than in the nucleotide 
free state (G282C); 
(iv) mutants with higher rate constants in the nucleotide free/ADP bound state than in 
the ATP bound conformation (Q277C). 
Alternatively, we can classify the CL1 mutants in respect of the maximal labeling values 
obtained in different conformations: 
  (i) mutants which have a higher maximal labeling in the ATP bound conformation 
 (Q277C); 
  (ii) residues which have a higher maximal labeling in the ADP bound state (N283C, 
 R287C  and  V288C); 
  (iii) mutants with a higher maximal labeling in the nucleotide free state (G282C); 
  (iv) residues with similar maximal labeling in all of the conformational states 
 investigated  (I284C, M285C and S286C). 
 Chapter 4    Results 
  76
  The knowledge that in the presence/absence of nucleotides significant values of the 
labeling rate constant (kon) are observed, suggests that the nucleotide bound/free state of the 
NBD induces a conformational change of the CL1 during the transport cycle. 
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Figure 4-11. Labeling kinetics of the TAP1-single cystein mutants Q277C and G282C. 
TAP containing crude membranes (0.5 mg total protein) were labeled with 50 µM BM in the presence of ATP, 
ADP and apyrase (nucleotide free). The reaction was stopped with β-mercaptoethanol at different time points (1 
– 30 min). Aliquotes were applied to SDS-PAGE (10%). BM labeling was monitored by in-gel fluorescence 
imaging. Fluorescence intensity of TAP1 bands (normalized to TAP1 immunoblot signal) was expressed as 
percentage of the SDS-denaturated TAP labeled with BM and plotted as a function of labeling time. The profiles 
were fitted using non-linear regression of the exponential association curve, L = Lmax x (1-e
-kt), where L is the 
percent labeled, Lmax is the maximum percent labeled, t is time and k is the observed rate constant for labeling. 
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Figure 4-12. Labeling kinetics of the TAP1-single cystein mutants N283C and I284C. 
TAP containing crude membranes (0.5 mg total protein) were labeled with 50 µM BM in the presence of ATP, 
ADP and apyrase (nucleotide free). The reaction was stopped with β-mercaptoethanol at different time points (1 
– 30 min). Aliquotes were applied to SDS-PAGE (10%). BM labeling was monitored by in-gel fluorescence 
imaging. Fluorescence intensity of TAP1 bands (normalized to TAP1 immunoblot signal) was expressed as 
percentage of the SDS-denaturated TAP labeled with BM and plotted as a function of labeling time. The profiles 
were fitted using non-linear regression of the exponential association curve, L = Lmax x (1-e
-kt), where L is the 
percent labeled, Lmax is the maximum percent labeled, t is time and k is the observed rate constant for labeling. 
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Figure 4-13. Labeling kinetics of the TAP1-single cystein mutants M285C and S286C. 
TAP containing crude membranes (0.5 mg total protein) were labeled with 50 µM BM in the presence of ATP, 
ADP and apyrase (nucleotide free). The reaction was stopped with β-mercaptoethanol at different time points (1 
– 30 min). Aliquotes were applied to SDS-PAGE (10%). BM labeling was monitored by in-gel fluorescence 
imaging. Fluorescence intensity of TAP1 bands (normalized to TAP1 immunoblot signal) was expressed as 
percentage of the SDS-denaturated TAP labeled with BM and plotted as a function of labeling time. The profiles 
were fitted using non-linear regression of the exponential association curve, L = Lmax x (1-e
-kt), where L is the 
percent labeled, Lmax is the maximum percent labeled, t is time and k is the observed rate constant for labeling. 
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Figure 4-14. Labeling kinetics of the TAP1-single cystein mutants R287C and V288C. 
TAP containing crude membranes (0.5 mg total protein) were labeled with 50 µM BM in the presence of ATP, 
ADP and apyrase (nucleotide free). The reaction was stopped with β-mercaptoethanol at different time points (1 
– 30 min). Aliquotes were applied to SDS-PAGE (10%). BM labeling was monitored by in-gel fluorescence 
imaging. Fluorescence intensity of TAP1 bands (normalized to TAP1 immunoblot signal) was expressed as 
percentage of the SDS-denaturated TAP labeled with BM and plotted as a function of labeling time. The profiles 
were fitted using non-linear regression of the exponential association curve, L = Lmax x (1-e
-kt), where L is the 
percent labeled, Lmax is the maximum percent labeled, t is time and k is the observed rate constant for labeling. 
 
 
 
 
 
 
 
 Chapter 4    Results 
  80
             
Q277C G282C N283C I284C M285C S286C R287C V288C
Nucleotide free
ATP
ADP
10-1
100
101
102
k
o
n
(
m
i
n
-
1
)
 
Figure 4-15. Rate constants for BM labeling. 
TAP containing membranes (0.5 mg total protein) were labeled with 50 µM BM in the presence of ATP (red), 
ADP (green) and apyrase (nucleotide free; black) as described above (Figures 4-11 to 4-14). For each single 
cysteine mutant the rate constant has been determined by a monoexponential function. 
 
Table 4-3. Rate constants (kon) and efficiency of maximal labeling in different conformational states. 
 
CL1 
mutants 
Nucleotide free  ATP  ADP 
 
 
kon 
 (min
-1) 
Maximal 
labeling (%) 
kon 
 (min
-1) 
Maximal 
labeling (%) 
kon 
 (min
-1) 
Maximal 
labeling (%) 
Q277C 
 
4.84 ± 2.95  41 ± 2.48  1.81 ± 0.59  51 ± 3.91  4.57 ± 1.08  45 ± 1.16 
G282C 
 
0.15 ±0.05  65 ± 9.50  1.03 ± 0.52  40 ± 5.41  0.83 ± 0.58  45 ± 7.61 
N283C 
 
0.41 ± 0.11  71 ± 4.72  0.57 ± 0.21  64 ± 5.02  0.44 ± 0.14  79 ± 6.03 
I284C 
 
25.56 ± 1.13  88 ± 3.05  0.21 ± 0.06  93 ± 9.21  0.69 ± 0.21  84 ± 5.19 
M285C 
 
2.18 ± 2.22  74 ± 7.71  0.26 ± 0.10  76 ± 8.51  0.58 ± 0.22  73 ± 5.80 
S286C 
 
2.01 ± 2.39  37 ± 5.01  0.17 ± 0.07  38 ± 5.90  0.65 ± 0.36  39 ± 4.29 
R287C 
 
0.15 ± 0.04  81 ± 7.64  0.13 ± 0.06  61 ± 9.78  0.10 ± 0.03  96 ± 9.24 
V288C 
 
0.42 ± 0.15  90 ± 8.52  0.77 ± 0.27  60 ± 4.09  0.39 ± 0.04  118 ± 3.46 
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4.2.3  Modification of the CL1 influences the TMD-NBD signaling  
 
  We have seen that residues in the CL1 (TAP1) undergo conformational changes 
during the transport cycle. In the next phase of investigation the functional consequences of 
perturbing the CL1 topography were assessed. Topographical perturbation was achieved 
through covalent attachement of BM to the introduced cysteines. BM was chosen since it 
labels each of the chosen residues. Functional characterization of the covalently modified 
isoforms was determined by measuring the peptide binding and transport. For this reason we 
chose five CL1 single cysteine TAP1 mutants which were functional in respect of peptide 
binding and transport, namely Q277C/C-less, N283C/C-less, M285C/C-less, S286C/C-less, 
and V288C/C-less. Additional controls for labeling included C-less/C-less and F265C/C-less. 
The labeling efficiency of these mutants showed values between 36% (M285C) and 66% 
(N283C) (Table 4-4), which are smaller than the maximal labeling values measured in 
different conformational states. The maximal labeling values were estimated for a labeling 
period of 30 min, whereas for studying the effects of fluorescence labeling on TAP function, 
the labeling period was 10 min only. The peptide binding and transport of the mutant isoforms 
in the presence or absence of covalent modification by BM are shown in the Figure 4-16. 
Importantly, for all mutants tested there was no measurable effect of BM labeling on the 
peptide binding (Figure 4-16B). This suggests that the initial peptide binding is not adversely 
disrupted by labeling with BM. However, the peptide transport decreased after BM labeling. 
We identified two single cysteine mutants (N283C, and V288C) that exhibit 33% and 47% 
decrease in transport activity after BM labeling, respectively (Figure 4-16C). A particular 
interesting situation is observed for the single cysteine mutant V288C/C-less. Labeling 
efficiency of this mutant was 51% and the peptide binding after BM labeling was not 
influenced. However, a significant decrease of 47% of transport activity was observed after 
BM labeling. This suggests that fluorescence labeling of V288C disrupts completely the ATP-
dependent peptide transport. Val-288, together with Ile-284 and Arg-287 are essential in 
sensing the bound peptide and interdomain signal transmission (Herget et al., 2007). 
  Overall, the covalent attachment of BM to cysteine residues along the CL1 of TAP1 
generated a number of specific effects on peptide transport. The main manifestations were a 
reduction in the degree of peptide transport after BM labeling. The observation that the 
covalent modification has no effect on peptide binding, but on the ATP dependent peptide 
transport, suggests that modifications of the CL1 residues influenced the TMD-NBD 
signaling.  
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Figure 4-16. The effects of fluorescence labeling with BODIPY-maleimide on TAP function. 
TAP containing membranes (0.5 mg total protein) were incubated with (+) or without (-) 50 µM BM in the 
presence of 10 mM Mg-ATP. After 10 min at 4°C the reaction was stopped with β-mercaptoethanol. Aliquotes 
were taken for immunoblot analysis and in-gel fluorescence measurements (A), as well as peptide binding (B) 
and ATP-dependent peptide transport (C), as described in Methods (Chapter 3). For peptide binding, TAP-
containing membranes (35 µg of total protein) were incubated with 1 µM radiolabeled RRY(
125I)QKSTEL at 
4°C for 15 min and the radioactivity was quantified by γ-counting. Specific peptide binding of the not-labeled 
construct (-BM) was normalized to 100%. For peptide transport, crude membranes (150 µg of total protein) were 
incubated with radiolabeled (1 µM RRY(
125I)QNSTEL) for 3 min at 32°C in the presence or absence of ATP (10 
mM). N-core glycosylated and therefore transported peptides were bound to ConA-beads and the radioactivity 
associated with ConA-Sepharose was quantified by γ-counting. Specific peptide transport of the not-labeled 
construct (-BM) was normalized to 100%. C-less TAP has been used as negative control of labeling. In order to 
obtain 100% labeling, the mutant F265C/C-less was labeled with 50 µM BM for 30 min at 4°C, then denaturated 
in 2% (w/v) SDS for 10 min and additionally labeled with 100 µM BM for 5 min at 4°C. BM labeling was 
monitored by in-gel fluorescence imaging using the LumiImager software (Roche) and normalized for the TAP1 
amount quantified by immunoblot detection. The error bars indicate the deviation of three independent 
experiments. 
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Table 4-4 The effects of fluorescence labeling with BODIPY-maleimide on TAP function. 
Labeling efficiencies, peptide binding and transport activity (%) were determined from the in-gel fluorescence 
measurements and immunoblot detection (Figure 4-16). 
 
CL1 mutant  Labeling efficiency (%)  Binding activity (%)  Transport activity (%) 
Q277C  64  82 ± 11  80 ± 21 
N283C  66  91 ± 9  67 ± 11 
M285C  36  97 ± 13  96 ± 11 
S286C  45  95 ± 9  82 ± 17 
V288C  51  94 ± 13  53 ± 9 
 
 
4.3  Transmission interface in ABC proteins 
 
4.3.1  The role of the X-loop in the transmission interface of ABC proteins  
 
  ATP binding and hydrolysis in the nucleotide binding domain of an ABC transporter 
generates conformational changes, which are transmitted to the transmembrane domains 
through non-covalent interactions at the shared interface (Dawson and Locher, 2006). Based 
on the x-ray structures of ABC transporters, cytoplasmic loops in the TMDs display the 
interface with the NBDs (Locher et al., 2002; Dawson and Locher, 2006). In biochemical 
studies, the EAA motif in a cytoplasmic loop of the TMD, which is part of the L-loop found 
in BtuCD, and the Q-loop in the NBD were identified to be important for signal transduction 
between TMDs and NBDs in ABC importers (Mourez et al., 1997; Hunke et al., 2000). In 
contrast to the ABC import proteins, the ABC exporters like MsbA and Sav1866 show an 
enlarged TMD-NBD interface comprising the large cytosolic loops CL1 and CL2 of the TMD 
and different regions in the NBD (Reyes et al., 2006; Dawson and Locher, 2006). Unique for 
the ABC exporter is the interaction between CL2 in the TMD and the newly identified X-loop 
of the NBD. Strikingly, most of these interactions are between the TMD of one subunit and 
the NBD of the second one. 
  To probe the relevance of the recently identified X-loop in the peptide transporter 
TAP, I substituted the highly conserved glutamate of the X-loop of TAP2 by different amino 
acids and analyzed its impact on function. By detailed cysteine scanning combined with 
biochemical experiments, the physical contact between the X-loop and residues within CL1 
and CL2 of an ABC exporter has been investigated. In addition, I identified residues in TAP1, 
which decouple peptide binding and transport. Trapping TAP by disulfide formation between 
residues in the TMD and the X-loop induced conformations incapable in peptide binding or 
transport demonstrating the relevance of structural rearrangements in the domain interface 
during the transport cycle. Chapter 4    Results 
  84
4.3.2  Rational design for the communication between the transmembrane and 
nucleotide binding domain 
 
  During a transport cycle of ABC transporters, there is an intensive communication 
between the transmembrane and nucleotide binding domains. It is assumed that the binding of 
substrate is transmitted to the nucleotide binding domains, which subsequently induce 
conformational changes generated by NBD closure and ATP hydrolysis, allowing substrate 
translocation. The transmission interface is formed by coupling helices in the intracellular 
loops of the transmembrane domains and loop regions of the nucleotide binding domains 
(Locher et al., 2002; Dawson and Locher, 2006). Based on the structure of the ABC exporter 
Sav1866 and in contrast to the x-ray structures of the importers, the coupling helices of one 
subunit interact not only with the own but also with the opposite nucleotide binding domain. 
The coupling helices are short α-helical stretches, which connect the long transmembrane 
helices and are the most far distant part of the transmembrane domain. Besides the Q-loop of 
the NBD, the ABC exporter specific X-loop is part of this interdomain network. To identify 
the interaction site in TAP, a 3D homology model of the core TAP complex based on the x-
ray structure of Sav1866 has been constructed (Dawson and Locher, 2006). The CLs of TAP 
and Sav1866 are of similar length and are clearly distinct from the short intracellular loops of 
ABC importers. The constructed model is in agreement with experimental data concerning 
membrane topology, peptide binding pocket and peptide sensor. The NBDs are tightly 
engaged with distances reflecting the ATP bound state and the transmembrane domain opened 
to the ER luminal site. The X-loops of TAP1 and TAP2 occupy a central position where the 
conserved glutamates are surrounded by residues of the coupling helices 1 and 2 of the 
opposite subunits demonstrating the domain swapping. The X-loop is localized in the α-
helical domain of the NBD close by the C-loop suggesting a possible role in transmitting 
conformational changes generated by ATP binding and hydrolysis. Interestingly, the X-loop 
of TAP2 shows higher sequence conservation in comparation to TAP1 (Figure 4-1). The 
function of the X-loop in coupling peptide binding to peptide transport was investigated. To 
elucidate the functional relevance of the interdomain cross-talk, I performed a cysteine scan 
of residues in CL1 and CL2 of cysteine-less TAP1 involved in interdomain contacts or 
identified to be crucial for signal transduction of peptide binding and transport (Herget et al., 
2007). By cysteine cross-linking the domain swapping was tested. 
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4.3.3  Function of the X-loop in coupling peptide binding to peptide transport 
 
  Based on the peptide sensor identified in CL1 next to coupling helix 1 of TAP1 
(Herget et al., 2007), we focused on the interaction and inter-domain communication with the 
X-loop of TAP2. The conserved glutamate (E602) was substituted by cysteine, arginine, 
aspartate, and alanine in a TAP2 variant containing a single cysteine (C213), important for the 
substrate selection (C. Baldauf, S. Schrodt, J. Koch, and R. Tampé, unpublished results). The 
X-loop mutants were co-expressed with Cys-less TAP1. Importantly, the X-loop mutations 
did not affect peptide binding (Figure 4-17B). The slight differences observed are caused by 
slide variations in the expression level due to co-infection. These results also demonstrate that 
the X-loop mutations do not interfere with membrane insertion and heterodimer assembly, 
which is required for peptide binding. Remarkably, all X-loop mutations showed a reduced 
transport activity, with 50% transport activity for E602C and 20% for E602D or E602A 
(Figure 4-17C). Complete disruption of peptide transport was observed for the E602R mutant. 
Thus, the conserved glutamate in the X-loop has a key function in the translocation event, but 
not in solute binding. 
 
4.3.4  Functional important residues in the TMD (TAP1) - NBD (TAP2) interface 
 
  To decipher the transmission interface between the TMD-NBD in the TAP complex, 
we introduced single cysteines substitution in CL1 and CL2 of cysteine-less TAP1. The 
positions were identified by homology modeling to be in close contact with the NBDs or to be 
involved in interdomain signal transduction (Herget et al., 2007). All 24 single cysteine TAP1 
variants were co-expressed with the TAP2_E602C construct. All TAP mutants showed 
similar expression (Figure 4-18). Peptide binding of CL1 mutants was not strongly influenced 
(Figure 4-18A). Minor effects correlate nicely with slight differences in TAP expression. 
However, all cysteine substitutions in coupling helix 1 besides Q277C interfered with peptide 
transport (Figure 4-18A). In addition, mutation of G282, I284 and R287 in the peptide sensor 
decreased transport activity. Surprisingly, in CL2, part of the peptide binding pocket 
(Nijenhuis et al., 1996; Ritz et al., 2001), only the mutation of R378C decreased significantly 
peptide binding, which is also reflected in diminished transport (Figure 4-18B). Furthermore, 
the cysteine substitution of P375 showed a prominent effect on peptide transport, whereas 
peptide binding is not disturbed (Figure 4-18B). In conclusion, mutations in CL1 do not 
interfere with peptide binding but have a strong effect on transport. Therefore, CL1 seems to 
be the transmission interface between TMDs and NBDs. CL2 is part of the peptide binding Chapter 4    Results 
  86
pocket also reflected in the disruption of peptide binding by cysteine substitution of R378. 
However, this loop has only minor effects in signaling since only the cysteine mutation of 
P375 disturbs coupling between peptide binding and transport. 
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Figure 4-17. Functional importance of the conserved glutamate of the X-loop of TAP2. 
(A) Expression of X-loop mutants. Crude membranes from Sf9 insect cells (20 µg protein/lane) were analyzed 
by SDS-PAGE (10%) followed by immunoblotting against TAP1 (mAb 148.3, α-TAP1) and TAP2 (mAb 435.3, 
α-TAP2). (B) Peptide binding of X-loop mutants. TAP-containing membranes (35 µg of total protein) were 
incubated with 1 µM radiolabeled RRYQKSTEL at 4°C for 15 min. Specific peptide binding to TAP1_C-
less/TAP2_C213_E602 was normalized to 100%. (C) Peptide transport of X-loop mutants. Crude membranes 
(150 µg of total protein) were incubated with fluorescein-labeled peptide (1 µM, RRYQNSTC
(F)L) for 5 min at 
32°C in the presence or absence of ATP (3 mM). N-core-glycosylated and therefore transported peptides were 
bound to ConA-beads and quantified by fluorescence detection after elution with methyl-α-D-mannopyranoside. 
ATP-specific transport of TAP1_C-less/TAP2_C213_E602 was normalized to 100%. The experiments were 
performed in triplicate. Error bars show the standard deviation. Chapter 4    Results 
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Figure 4-18. CL1 and CL2 of TAP1 have different functions. 
Single cysteine TAP1 mutants of CL1 (A) or CL2 (B) in complex with TAP2_E602C were analyzed for peptide 
binding (open bars) and transport (filled bars). For peptide binding, TAP-containing membranes (35 µg of total 
protein) were incubated with 1 µM radiolabeled RRYQKSTEL at 4°C for 15 min. Specific peptide binding to 
TAP1_C-less/TAP2_E602 was normalized to 100%. For peptide transport crude membranes (150 µg of total 
protein) were incubated with fluorescein-labeled peptide (1 µM RRYQNSTC
(F)L) for 5 min at 32°C in the 
presence or absence of ATP (3 mM). N-core-glycosylated and therefore transported peptides were bound to 
ConA-beads and quantified by fluorescence detection after elution with methyl-α-D-mannopyranoside. ATP-
specific transport of TAP1_C-less/TAP2_E602C was normalized to 100%. The experiments were performed in 
triplicate. Error bars show the standard deviation. Equal amounts of TAP were confirmed by immunoblotting.  
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4.3.5  Establishing disulfide formation 
 
  To investigate the domain swapping, the spatial proximity between residues in the CLs 
of TAP1 and the X-loop of TAP2 was analyzed by oxidative cysteine cross-linking. To enable 
disulfide formation even in hydrophobic environment, copper phenanthroline (CuPhen) was 
used as catalyst. The cross-linking conditions were established with crude membranes 
containing combinations of TAP1_I368C / TAP2_E602C and TAP1_I381C / TAP2_E602C. 
Both TAP1 mutations are located in CL2 and do neither influence peptide binding nor 
transport. Cross-linking was performed at 4°C to minimize thermal denaturation of TAP and 
to decrease structural fluctuations within the TAP complex. The reaction time was restricted 
to 1 min, in which on one hand to reach maximal disulfide formation but on the other hand 
with minimal site reactions (oxidation of thiols to sulfite). After incubation with CuPhen, 
reaction was stopped by complexing copper by EDTA. After oxidative crosslinking, disulfide 
formation was inhibited by blocking free sulfhydryl groups by N-ethylmaleimide. 
Subsequently, samples were separated by SDS-PAGE and analyzed by immunoblotting using 
monoclonal antibodies against human TAP1 and TAP2. In addition to monomeric TAP1 and 
TAP2 (75 kDa), also higher molecular weight species of TAP1 and TAP2 were observed 
under oxidizing conditions (Figure 4-19A, B). Immunoblotts probed with anti-TAP1 antibody 
showed high molecular weight bands with a molecular weight of 174 kDa and 162 kDa, 
whereas stained with anti-TAP2 antibody bands at 162 kDa and 150 kDa occurred. Notably, 
all three high molecular weight bands were visible if immunoblotts stained with both 
antibodies simultaneously. Remarkably, single expressed TAP1 or TAP2 cysteine containing 
subunits showed bands at 174 kDa and 150 kDa, respectively, indicating the formation of 
homodimeric complexes, reported also previously (Antoniou et al., 2002). In conclusion, the 
upper band resembles TAP1 homodimers (174 kDa), the middle of the three bands indicate 
TAP1/2 heterodimers (162 kDa), whereas the lower band reflects TAP2 cross-linked 
homodimers (150 kDa). Interestingly, for TAP1 constructs with a single cysteine in CL1 a 
cross-linked homodimeric TAP1 species was only observed for single expressed TAP1 but 
not in combination with TAP2 probably reflecting the different expression levels. The cross-
linking is cysteine specific since cysteine-less constructs of TAP show no higher molecular 
weight bands. In addition, disulfide bond formation is CuPhen dependent and reversible by 
reducing with DTT (Figure 4-19A). Cross-link efficiency could not be enhanced by increasing 
concentrations of CuPhen or elongation of the reaction time most probably due to 
unproductive sulfhydryl oxidation either to sulfinic or sulfonic acid (Careaga and Falke, 
1992). Chapter 4    Results 
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  Since the TAP2 construct used for cysteine cross-linking studies contained in addition 
to the cysteine in the X-loop also the functional important cysteine at position 213, the 
contribution of this region in subunit contacts was analyzed. Therefore, TAP2 variants with 
single natural occurring cysteines, all located in transmembrane helix two of the TAP2 core 
complex, were expressed in combination with cysteine-less TAP1 or with TAP1_A381C. All 
of these cysteines are shielded or spatially separated since none of these cysteines are capable 
to form covalently linked neither homodimeric nor heterodimeric complexes (Figure 4-19C). 
In contrast, the TAP2 variant containing C213 and E602C form homodimeric as well as 
heterodimeric cross-linked complexes. In conclusion, we have evolved conditions, under 
which TAP subunits can be specifically cross-linked by cysteines located in the CLs of TAP1 
and the X-loop of TAP2. Chapter 4    Results 
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Figure 4-19. Oxidative cross-linking between TAP1 and TAP2. 
Crude membranes containing different TAP1 and TAP2 constructs (500 µg of total protein) were incubated in 
the presence or absence of copper phenanthroline (1 mM Cu
2+) for 1 min at 4°C. Oxidative cross-linking was 
terminated by NEM and EDTA, 10 mM each. Samples (20 µg of total protein per lane) were subjected to non-
reducing SDS-PAGE (6%) followed by immunoblotting against TAP1 (mAb 148.3, α-TAP1) and TAP2 (mAb 
435.3, α-TAP2). The positions of the cross-linked TAP1/TAP2 (highlighted in bold), homodimeric (TAP1)2 and 
(TAP2)2 and monomeric TAP1 and TAP2 are indicated. (A) Disulfide formation under oxidative conditions. 
Copper phenanthroline dependent intermolecular disulfide formation was tested with 
TAP1_I368C/TAP2_E602C. To show reversibility of disulfide cross-linking, 100 mM DTT were added in the 
sample buffer. (B) Identification of TAP oligomers. To assign the high molecular weight bands to hetero- and 
homooligomeric TAP complexes, crude membranes containing TAP1_A381C, TAP2_E602C or both subunits 
were cross-linked and analyzed by immunoblotting. (C) C213 of TAP2 is not involved in disulfide formation. 
Crude membranes of different TAP variants were cross-linked and immunoblotted. 
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Figure 4-19. continued 
 
 
4.3.6  Domain swapping within the TAP complex 
 
  To investigate the spatial proximity of the CLs of TAP1 and the X-loop of TAP2 and 
therefore proof the domain swapping, we performed oxidative cross-linking with all described 
mutants. Interestingly, all cysteine mutants in CL1 of TAP1 are in physical contact with the 
X-loop (Figure 4-20). However, gradual differences exist. Strongest cross-linking was 
observed for residues covering the C-terminal half of the coupling helix 1 and the N-terminal 
half of the peptide sensor. Cross-linking of residues within CL2 with the X-loop are less 
efficient. Pronounced interaction was detected only for residues 380 and 381 (Figure 4-21). 
Similar cross-linking for all mutants was obtained between 4°C and 37°C. Moreover, cross-
linking with bifunctional cysteine-specific reagent MTS-2-MTS gave the same picture. In 
addition, disulfide formation did not change in different states of the transport cycle. 
Therefore, CL1 appears to be highly dynamic since contacts can form even between residues Chapter 4    Results 
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more than 1.5 nm apart as deduced from the 3D homology model (see Figure 4-1). Similar 
rotational and translational freedom of cysteine residues was also reported for other proteins 
such as D-galactose chemosensory receptor (Careaga and Falke, 1992). In conclusion, the 
CLs from TAP1 interact with the X-loop of TAP2, proofing the domain swapping. In 
addition, CL1 seems to be more involved in this interaction than CL2. 
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Figure 4-20. Physical interaction between CL1 of TAP1 and X-loop of TAP2. 
Crude membranes containing different single cysteine variants of the CL1 of TAP1 and TAP2_E602C (500 µg 
of total protein) were incubated in the presence or absence of copper phenanthroline (1 mM Cu
2+) for 1 min at 
4°C. Oxidative cross-linking was terminated by NEM and EDTA, 10 mM each. Samples (20 µg of total protein 
per lane) were subjected to non-reducing SDS-PAGE (6%) followed by immunoblotting against TAP1 (mAb 
148.3, α-TAP1) and TAP2 (mAb 435.3, α-TAP2). 
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Figure 4-21. Physical interaction between CL2 of TAP1 and X-loop of TAP2. 
Crude membranes containing different single cysteine variants of the CL2 of TAP1 and TAP2_E602C (500 µg 
of total protein) were incubated in the presence or absence of copper phenanthroline (1 mM Cu
2+) for 1 min at 
4°C. Oxidative cross-linking was terminated by NEM and EDTA, 10 mM each. Samples (20 µg of total protein 
per lane) were subjected to non-reducing SDS-PAGE (6%) followed by immunoblotting against TAP1 (mAb 
148.3, α-TAP1) and TAP2 (mAb 435.3, α-TAP2). 
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4.3.7  Arresting TAP in a transport incompetent state 
 
  Due to the motional freedom of the loops investigated herein, transport state 
dependent differences in cysteine cross-linking were not observed. However, TAP undergoes 
multiple conformational changes during peptide transport, in which the CLs seems to be 
involved (Reits et al., 2000; Neumann et al., 2002; Herget et al., 2007). Therefore, we 
addressed the interdomain cross-talk by restricting the structural rearrangement by disulfide 
formation between the X-loop and CL1 or CL2. For cysteine cross-linking, we choose 
TAP1_Q277C/TAP2_E602C and TAP1_A381C/TAP2_E602C. These mutations had no 
influence on peptide binding and transport but showed high cross-linking efficiency (Figure 
4-22A). Disulfide formation reduced peptide binding of TAP1_A381C/TAP2_E602C to 5% 
of the reduced state, whereas it had no influence on TAP1_Q277C/TAP2_E602C as well as 
TAP1_Cys-less/TAP2_E602C (Figure 4-22B). However, in the presence of CuPhen, peptide 
transport was decreased by cysteine cross-linking of TAP1_Q277C/TAP2_E602C and 
TAP1_A381C/TAP2_E602C to 10% in comparasion to the absence of CuPhen (Figure 4-
22C). Transport inhibition relies on disulfide formation since transport activity of TAP1_Cys-
less/TAP2_E602C was only slightly reduced under oxidizing conditions. In addition, 
transport inhibition was reversed by reducing disulfide bridges with β-mercaptoethanol. In 
conclusion, cross-linking between CL2 and the X-loop seems to change the structure of the 
peptide binding pocket, whereas the disulfide bridge between CL1 and X-loop destroys the 
interdomain communication most likely by impeding structural rearrangements. 
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Figure 4-22. Differential effects of disulfide bridges on TAP function. 
Crude membranes containing different single cysteine variants of the CL1 and CL2 of TAP1 and TAP2_E602C 
(500 µg) were incubated in the presence or absence of copper phenanthroline (1 mM Cu
2+) for 1 min at 4°C and 
washed twice. (A) Identification of disulfide formation. After cross-linking, samples (20 µg of total protein per 
lane) were analyzed by SDS-PAGE (6%) and immunoblotting. (B) Peptide binding. TAP-containing membranes 
(35 µg of total protein) were incubated with 1 µM radiolabeled RRYQKSTEL at 4°C for 15 min. Specific 
peptide binding to TAP constructs, which were incubated in the absence of copper phenanthroline, were 
normalized to 100%. (C) Peptide transport. Crude membranes (150 µg of total protein) were incubated with 
fluorescein-labeled peptide (1 µM, RRYQNSTC
(F)L) for 5 min at 32°C in the presence or absence of ATP (3 
mM). ATP-specific transport of TAP constructs not incubated with copper phenanthroline were normalized to 
100%. To proof reversibility, cross-linked samples were reduced with 100 mM β-mercaptoethanol for 5 min at 
4°C. The experiments were performed in triplicate. Error bars show the standard deviation. 
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Figure 4-22. continued 
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5.   Discussion 
 
5.1.  CL1 of TAP1 has an important role in substate sensing and signal 
transmission 
 
  As the key component of the MHC class I peptide-loading complex, TAP translocates 
proteasomal degradation products into the lumen of the endoplasmic reticulum. Peptide 
binding is a key step in the overall TAP transport mechanism and in the selection of epitopes 
presented by MHC class I molecules (Uebel and Tampé, 1999; van Endert et al., 2002). ATP 
hydrolysis by the NBDs is tightly coupled to peptide binding to the transmembrane domains 
of TAP (Gorbulev et al., 2001; Chen et al., 2003). However, sterically restricted peptides 
bound to TAP do not trigger ATP hydrolysis and are not transported (Gorbulev et al., 2001). 
It is an open question how the quality of incoming peptides is checked and transmitted to the 
ATPase domains to drive peptide translocation. 
  The identified peptide sensor and transmission interface aligns with the cytosolic loop 
1 of MsbA or the CL1 of the Sav1866. Biochemical and structural studies showed that these 
transmembrane loops are in close contact with the Q-loop and the α-helical domain of the 
NBD (Locher et al., 2002; Dalmas et al., 2005, Ward et al., 2007). Derived from x-ray 
structures, the Q-loop connects the catalytic domain with the α-helical domain of the NBDs 
and is involved in structural rearrangement by sensing bound ATP, which is the initial step for 
dimerization of the NBDs (Smith et al., 2002). The cysteine-scanning approach support the 
function of the CL1 as signal transducer in ABC exporters, because it does not interfere with 
substrate binding but with substrate transport. Interestingly, the most severe effects in 
disrupting the tight coupling between peptide binding and transport and the inter-domain 
communication were found for the most conserved residues in the sensor loop, comprising 
Gly-282, which seems to function as a helix breaker, as well as Ile-284 and Arg-287 of TAP1. 
The later two residues are separated by three residues and therefore face the same site of an α-
helix. Together with Val-288, these residues are essential in sensing the bound peptide and 
interdomain signal transmission. Interestingly, the dual function can also be structurally 
separated to the sensor region at the C-terminal end and the transmission site upstream of the 
α-helix. 
  The peptide contact site is restructured during the ATP hydrolysis cycle. In the 
nucleotide-free state, the strongest cross-linking between peptide and sensor loop is detected. 
Binding of nucleotide weakens this interaction, which could resemble a structural Chapter 5    Discussion 
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rearrangement. For P-glycoprotein such a conformational change by binding AMP-PNP could 
be shown by cryo-electron microscopy (cryo-EM) of two-dimensional crystals (Rosenberg et 
al., 2003). Trapping P-glycoprotein in the ATP hydrolysis state by ortho-vanadate, which 
resembles the same trapped state as AlFx in myosin (Fisher et al., 1995; Smith and Rayment, 
1996), induced a further change in structure. Also TAP showed a structural change trapped in 
the ATP hydrolysis transition state, because direct contact between peptide and the sensor and 
transmission loop is abolished.  
 
5.2.  Cross-talk between TMD/NBD revealed by fluorescence accessibility 
studies 
 
  We have demonstrated that the CL1 is involved in the tight coupling of peptide 
binding and transport (Herget et al., 2007). Further data support the idea that this sensor and 
transmission interface is restructured during the ATP hydrolysis cycle, emphasizing its 
important function in the cross-talk between the transmembrane and nucleotide binding 
domains (Herget et al., 2007). Our modus operandi involves introducing unique cysteine 
residues along the CL1 of TAP1 and the subsequent covalent attachment of fluorescent probes 
to these. The fluorescence labeling has been applied to CL1 in order to decipher the 
topography and to observe whether this region is involved in the cross-talk between TMD–
NBD. Following labeling, two residues (N283C and V288C) were associated with a reduction 
of the ATP-dependent peptide transport activity. Interestingly, the covalent attachment of 
fluorescent probes has no effect on peptide binding. 
  What is the mechanism underlying the effect of covalent modification of CL1 on the 
coupling of peptide binding in the TMDs to ATP hydrolysis by the NBDs? The data 
demonstrated that the perturbation of the ATP-dependent peptide transport process caused by 
covalent attachment of BODIPY-maleimide to CL1 is most likely due to the modification of 
the communication pathway that links the peptide binding event in the TMDs to the 
progression of the catalytic cycle in the NBDs. The communication pathway clearly involves 
CL1, given that mutations or covalent modification within this helix impairs the peptide 
transport activity. 
  What is the nature of involvement of CL1 in the TMD–NBD communication 
pathway? To address this question, the topography of the CL1 was examined in distinct 
conformations of TAP. The conformations reflected the progression of the protein through the 
catalytic cycle and was visualized by the accessibility of engineered cysteines to covalent 
modification by iodoacetamidofluorescein and maleimide probes. This loop region was highly Chapter 5    Discussion 
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accessible to covalent modification, regardless of the physicochemical properties of the 
different probes. In addition, the CL1 displayed different accessibility to probes when the 
protein undergoes distinct conformations (e.g., nucleotide-free state), thereby reflecting 
conformational transitions. 
  The kinetics of fluorescence labeling showed that, except for Q277C, all of the 
residues reflected similar rate constants (kon) for BM labeling in the presence of ATP (Table 
4-3). However, significant differences of the rate constants for BM labeling were observed in 
the absence of nucleotide or in the presence of ADP (Table 4-3). The highest rate constant 
observed was for I284C in the nucleotide-free state, kon = 26 ± 1 (min
-1). Interestingly, in the 
ADP-bound state the highest rate constant was observed for Q277C mutant. The 
communication pathway clearly involves CL1, given that mutations or covalent modification 
within this helix impairs the ATP-dependent peptide transport. On the basis of the 
observations in the present investigation, it appears that CL1 undergoes distinct changes in 
conformation in response to events occurring in the NBDs. A general view along the CL1 
region, indicates important conserved residues which are essential in peptide transport (Gly-
282, Ile-284 and Arg-287; Figure 5-1). Interestingly, among these residues, the mutant I284C 
displayed the greatest propensity for changes in accessibility, indicating important 
conformational changes in this region of the helix. Covalent modification of CL1 induces 
severe effects on peptide transport. For example, BM labeling of V288C mutant induces a lost 
of ATP-dependent peptide translocation. The N- and C-terminal regions of CL1 are oriented 
in different local environments. The N-terminal region has an hydrophilic character, whereas 
the C-terminus is accessible for amphiphilic and hydrophobic probes. 
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Figure 5-1. Residues of CL1 (TAP1) important in TMD-NBD signal transduction. 
Along the CL1 region, conserved residues are required for transport at a step downstream of binding (Gly-282, 
Ile-284 and Arg-287; labeled in squares). The covalent attachment of BM (highlighted in red circle) to cysteine 
residues along the CL1 generated a lost of transport for V288C mutant and a 33% decrease in transport activity 
for N283C (marked by red stars). In the nucleotide-free state the I284C mutant (marked by red circle) is labeled 
very fast, by reacting very rapidly with the fluorescent probe BM. In contrast, in the ATP-bound and post-
hydrolytic states the rate constant is 100- and 36-fold reduced, respectively. The N-terminal region of CL1 is 
accessible for hydrophilic probe (IAF, highlighted in yellow cylinder), whereas the C-terminal region is 
accessible for hydrophobic probe (CM, highlighted in blue cylinder). 
 
  In the absence of a high-resolution structure of TAP, homology models may assist in 
the interpretation of these experimental data. Such an homology model for TAP based on the 
crystal structure of Sav1866 (Dawson and Locher, 2006) has been generated in the group of 
Peter Tieleman (Department of Biological Sciences, University of Calgary). According to this 
model the CL1 residues investigated in the present work are located in the cellular loop 1 of 
TAP1. Along this region, a short helix oriented roughly parallel to the membrane plane, 
named coupling helix 1 (CH1), provides a bulk of contacts to the NBDs of both subunits. 
From this homology model, a trans-contact between Q277-TAP1 and E602-TAP2, as well as 
a cis-contact between E274-TAP1 and Y555-TAP1 is observed (Figure 5-2). The amino acid 
side chains of cysteine, glutamine (Q277C) or glutamate (E274C) in the CL1 of TAP1 can 
build hydrogen bonds, and alternatively, drastical mutagenesis along the CL1 can be 
investigated, and on the other side, the single cysteine mutations could be derivatized with 
methanethiosulfonate reagents (MTS) in order to simulate a positive, negative and 
hydrophobic side chain. From the accessibility studies we can draw the conclusion that the 
CL1 of TAP1 has an amphiphatic character. The putative interaction partners in the NBD are 
Q- and X-loop as well as the vicinity of Walker A motifs, which is supported by a significant Chapter 5    Discussion 
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structural and biochemical amount of data (Dalmas et al., 2005; Dawson and Locher, 2006; 
Zolnerciks et al., 2007). 
 
Figure 5-2. Putative TMD-NBD transmission interface of TAP1. 
Amino acid residues of CH1 (red) are highlighted as stick representation. The putative interaction partners E602 
(TAP2, trans-contact, magenta) and Y555 (TAP1, cis-contact, orange), which are located in the vicinity of CH1, 
are illustrated. The Cα-atom distances between Q277:E602 and E274:Y555 are shown. The presented structure is 
an homology model based on the crystal structure of Sav1866 (Dawson and Locher, 2006), modeled in the group 
of  Peter Tieleman (Department of Biological Sciences, University of Calgary). 
 
In summary, our data support the hypothesis that CL1 is likely involved in the bi-
directional communication between TMDs and NBDs of TAP that is essential for a coupled 
transport process. The present work demonstrates that the topography of CL1 undergoes 
significant reconfiguration between the nucleotide-free, nucleotide-bound and post-hydrolytic 
states of TAP. These results are in good agreement with data of Loo et al., which suggests 
that the binding of ATP to the NBDs can induce long-range conformational changes to alter 
the structure of the TMDs of human P-glycoprotein (Loo et al., 2007). Similar fluorescence 
labeling studies show that nucleotide binding can affect the conformation of TMDs in P-
glycoprotein (Rothnie et al., 2004). Different cysteine crosslinking approaches have shown 
that in the ATP bound state the CL1 and Q-loop are moved away from each other; however, 
crosslinking between these two domains could still be achieved in the presence of ATP-Mg 
plus vanadate when homobifunctional crosslinkers with a length of 13Å were used (Dalmas et 
al., 2005; Daus et al., 2007). 
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5.3.  The role of the X-loop in the transmission interface of TAP  
 
Peptide binding, ATP hydrolysis and peptide transport are tightly coupled within the 
peptide transporter TAP implying signal transduction between TMD and NBD (Gorbulev et 
al., 2001; Herget et al., 2007). In addition to the Q-loop, the newly identified X-loop, present 
in ABC exporters only, was proposed from the X-ray structure of Sav1866 to be involved in 
cross-talk between TMD and NBD (Dawson and Locher, 2006). By substitution of the 
conserved glutamate of the X-loop in TAP2, we first demonstrated that this loop is indeed 
essential for coupling of peptide binding to the subsequent translocation step. We next 
identified critical residues for this event in CL1 and CL2. By using both cysteine scanning 
and cross-linking, we mapped the contact sites of the CLs of TAP1 with the X-loop of TAP2, 
thereby providing direct evidence for domain intertwining in a heterodimeric ABC transport 
complex. It is remarkable that mutations in CL1 almost exclusively disrupt TAP function in a 
step downstream of peptide binding. The inter-domain cross-talk involves structural 
rearrangements, since conformational trapping of TAP by disulfide formation reversibly 
interrupts peptide transport. 
The X-loop is a motif solely found in the NBD of ABC exporters. Substitution of the 
conserved glutamate E602 in the X-loop of TAP2 had no effect on TAP expression and 
peptide binding, demonstrating further that these mutations do not affect membrane insertion, 
folding, and heterodimer assembly. However, peptide transport is impaired by substitution 
with a positively charged residue. The introduction of a short hydrophobic side chain or the 
conservative mutation to aspartate reduced transport activity to 20%, while substitution to 
cysteine decreased transport activity by only 50%. The reduced side chain of aspartate may 
position the negative charge in an unfavored environment. The sulfhydryl group of cysteine is 
largely tolerated. The X-loop appears very flexible since it shows a high B-factor in the X-ray 
structure of ABC exporters as well as of isolated NBDs (Zaitseva et al., 2005; Lewis et al., 
2004). Moreover, this region may be involved in transmitting ATP binding and hydrolysis of 
the NBDs to the TMDs via structural changes because of its close proximity to the C-loop, 
which senses the γ-phosphate of the bound ATP in the NBD-NBD interface. Remarkably, in 
the nucleotide-free and the ATP-bound state of HlyB-NBD (Zaitseva et al., 2005; Schmitt et 
al., 2003) the root-mean-square deviation of the Cα atom of the X-loop glutamate is three-fold 
higher than the entire NBD. However, it should be pointed out that the X-loop is conserved 
only in subfamily B and C of eukaryotic ABC transporters. Whether this region is also part of 
the transmission interface in the other subfamilies, remains to be addressed in future studies. Chapter 5    Discussion 
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  A surprising finding of this study was that each of the CLs of core TAP1 had different 
functions. None of the mutations in CL1 influenced peptide binding, whereas most 
substitutions interfered with the translocation step. These residues are located in coupling 
helix 1 and the peptide sensor (Figure 4-1). The 3D model suggests that the bulky 
hydrophobic phenylalanine residues of the coupling helix (F275 and F276) point into a 
hydrophobic core, thus stabilizing CL1, and substitution of these residues may collapse 
coupling helix 1. Mutations of hydrophilic and charged residues probably affect the 
orientation of CL1 or disrupt inter-domain contacts. The function of CL1 in peptide sensing 
and signaling during the ATP-hydrolysis cycle was proposed recently, with residue 288 of 
TAP1 found to be in direct contact with the bound peptide (Herget et al., 2007). In addition, 
this sensor region is structurally reorganized during the transport cycle. Thus the presence of 
bound peptide may be signaled via the adjacent coupling helix 1 to other parts of the protein 
responsible for downstream events in the transport cycle. 
Surprisingly, substitutions in CL2 of TAP1 only had minor impacts on TAP function. 
By peptide photo-crosslinking and deletion studies, the region comprising CL2 was 
previously identified as part of an overlapping peptide-binding region (Nijenhuis et al., 1996; 
Ritz et al., 2001). Here, we could demonstrate that arginine 378 in TAP1 is essential for 
peptide binding. The 3D model indicates that this residue is part of coupling helix 2. Its side 
chain points into the opposite direction of the X-loop and might stay in direct contact with the 
peptide. It is tempting to speculate that the positive guanidinium group forms a salt bridge 
with the C-terminal carboxyl group of the peptide, which is essential for recognition. 
Interestingly, the P375C substitution disrupted the transport function of TAP leaving peptide 
binding unaffected. Proline 375 caps the coupling helix 2 by a kink, which may be important 
for signal transmission. 
By oxidative cysteine cross-linking, we verified direct contacts between the CLs and 
the X-loop, thus providing evidence for domain swapping and dynamic transmission interface 
in the TAP complex. Based on the number of efficiently cross-linked residues, CL1 was 
found to be more flexible than CL2. However, it should be mentioned that CL1 is in close 
proximity not only to the X-loop of the opposite NBD but also to the Q-loop of the NBD in 
“cis” as demonstrated by chemical cross-linking studies using the multidrug exporter BmrA 
of  B. subtilis (Dalmas  et al., 2005). On the other hand, CL2 does not exclusively form 
contacts with the X-loop but also with the Q-loop of the “trans” NBD as shown by chemical 
cross-linking for P-glycoprotein and CFTR (Zolnerciks et al., 2007; Serohijos et al., 2008; He Chapter 5    Discussion 
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et al., 2008). A similar Sav1866-like inter-domain organization was recently found for the 
yeast ABC exporter Yor1p (Pagant et al., 2008). 
The transmission interface, framed by two CLs and the NBDs, showed considerable 
flexibility as we detected a similar cross-linking pattern in the presence of ATP, ADP or ATP 
plus vanadate or BeFx. A highly dynamic arrangement of the transmission interface was also 
observed for CFTR (Dawson and Locher, 2006; Serohijos et al., 2008; He et al., 2008). The 
need for conformational changes in the transmission interface during the transport cycle is 
supported by transport inhibition through cross-linking of the CLs with the NBDs. In the 
bacterial exporter BmrA, cross-linking of CL1 with the Q-loop of the NBD in “cis” disrupted 
ATP hydrolysis and substrate transport (Dalmas et al., 2005). Arresting CFTR by chemical 
cross-linking of CL2 or CL4 with residues near the Q-loop of the “trans” NBD impaired 
channel activity (Serohijos et al., 2008; He et al., 2008). Furthermore, also the maltose 
permease is fixed by disulfide formation between the “EAA”-motif of the TMD and a surface 
exposed residue in the “cis” NBD in an inactive state (Daus et al., 2007). Here, we 
demonstrate that cross-linking of CL1 with the X-loop in “trans” arrested the TAP complex in 
a transport-incompetent state, which was still able to bind peptides. The transmission interface 
is not restricted to a narrow region of the polypeptide chain but rather is distributed among the 
NBDs and CLs of the TMDs. Notably, cross-linking of CL2 in TAP1 and the X-loop in 
TAP2, impaired not only transport but also peptide binding. Since CL2 is part of the peptide-
binding pocket, it is likely that the disulfide bridge induces a binding-incompetent 
conformation. Thus, the CLs have different functions in substrate recognition, signaling and 
transport binding. 
Besides cross-linked heterodimers of TAP1 and TAP2, covalent coupled homodimers 
of TAP1 and TAP2 were detected under oxidative conditions. TAP2 homodimers were also 
observed by chemical cross-linking using activated NHS esters (Antoniou et al., 2002). In 
addition, TAP1 or TAP2 homodimers are inactive in respect of peptide binding and 
subsequently peptide transport. We believe that the homodimer formation occurs only in cells, 
in which one subunit is in excess. This conclusion is supported by the fact that the 
homodimeric signal in single infected cells was much stronger than in double infected cells. 
Since we coinfected the insect cells by two separate viruses coding for TAP1 and TAP2, 
single infected cells will be present. Importantly, oxidative cross-linking was observed only 
for a few residues. Residues in CL1 and CL2 of TAP1 as well as residue 602 in TAP2 seems 
to be in appropriate conformation for cross-linking of homodimeric as well as heterodimeric 
complexes. However, the natural occurring cysteines at position 197, 209 and 213 of TAP are Chapter 5    Discussion 
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not involved in any disulfide formation although they are accessible for cysteine reactive 
compounds (Baldauf et al., manuscript in preparation ). 
 
5.4.  Different models of coupling mechanisms for importers and exporters 
 
Different models of how ABC transporters might work can be found in the literature. 
Because their substrates and even the direction of transport are distinct, it might seem 
unreasonable to suggest that importers and exporters operate on a similar mechanism. 
However, the structures of full ABC transporters suggest that they indeed share a common 
way of converting ATP binding and hydrolysis to essentially unidirectional transport (Dawson 
et al., 2007). 
In the absence of nucleotide, the NBDs adopt an open conformation, as visualized by 
ModBC-A or HI1470/71 (Hollenstein et al., 2007; Pinkett et al., 2007). Upon binding ATP, 
the NBDs adopt a “closed” conformation, with bound nucleotide sandwiched between the 
Walker A and the LSGGQ motifs, as observed in Sav1866. A comparision of ModBC and 
Sav1866 reveals that the distance between their coupling helices decreases substantially (by 
some 10-15 Å) upon ATP binding (Dawson et al., 2007). In other words, binding of ATP 
brings the two coupling helices closer together (Figure 5-3A). As the coupling helices 
approach, the TMDs flip from the inward-facing to the outward-facing conformation. After 
hydrolysis and dissociation of inorganic phosphate and ADP, the NBDs assume an “open” 
conformation. This increases the distance between coupling helices and flips the transporters 
into an inward-facing conformation. Such a conversion is reminiscent of the “alternating 
access and release” mechanism, postulated half a century ago (Jardetzky, 1966) and still 
providing a useful framework for understanding the mechanism of transporters such as major 
facilitators (Lemieux et al., 2004; Guan and Kaback, 2006).  
However, domain-swapped interactions do not appear to be universal among ABC 
transporters. The structures of bacterial ABC importers reveal that the dimer interface forms 
from the two separate monomers and likely involves a distinct mechanism of transport. One 
limitation of these structural studies is that the full transporters have been crystallized in the 
absence of substrate, making the interpretation of how substrate binding influences 
interdomain interaction and transport difficult. Another key question is how nucleotide 
binding and/or hydrolysis influences domain arrangement and facilitates transport. Although a 
number of different crystal structures have been solved for transporters stabilized by the 
presence of different nucleotides, three structures of ABC exporters in different states, MsbA-
AMP-PNP, MsbA-ADP·Vi, and Sav1866-ADP do not show any striking conformational Chapter 5    Discussion 
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differences (Dawson and Locher, 2006; Dawson and Locher, 2007; Ward et al., 2007). 
Moreover, in vitro characterization of the domain-domain interactions in CFTR suggests that 
the CL4-NBD1 and CL2-NBD2 interfaces do not change in the presence of ATP, ADP, or 
AMP-PNP, suggesting that the formation of these two modules is not influenced by ATP 
binding/hydrolysis. 
On contrary, our results examining the nucleotide dependence of substrate binding to 
CL1 of the TAP complex were suggestive of structural rearrangements during ATP hydrolysis 
(Herget  et al., 2007). Recently, biochemical studies on the eukaryotic drug pump Yor1p 
revealed relatively weak NBD-NBD and CL-CL interactions that may correspond to transient 
sites of crosstalk between domains required for coupling of ATP hydrolysis with substrate 
translocation (Pagant et al., 2008). Based on the data presented in the PhD thesis, a new 
adapted putative model of transmission interface in the TAP complex can be drawn (Figure 5-
3B): 
 
  1.  The peptide transporter is in the “open” conformation. The peptide and nucleotide are 
    not bound, therefore the CHs are not in direct contact with the NBD. 
  2.  Peptide and ATP bind independently to TAP (van Endert et al., 1994; Tomazin et al., 
   1996). 
  3.  TAP is loaded always with ATP, because of the high intracellular ATP concentration 
   (Lapinski  et al., 2003). During the ATP binding, the CL1 adopts a “pre-peptide binding 
   conformation”. 
 4. After  peptide  binding,  the peptide sensor V288 recognizes the peptide binding  
   conformation  (Herget  et al., 2007), which subsequently induces a structural change of 
    the side chain of R287 (see Chapter 5.1 and Neumann et al., 2002). 
  5.  The conformational change of R287 allows formation of the cation-π-complex with the 
    aromatic aminoacids of CH1, which induces a conformational change of the CL1. 
  6.  This conformational change of CL1 facilitates a direct contact between CH1 and NBD. 
    The side chains of E274 and Q277 build a TMD-NBD “signal transduction bridge” with 
    their interaction partners in the NBD, that induces NBD dimerization. 
  7.  The conformational change of NBD act as a power stroke, that will be communicated to 
    the TMD via TMD-NBD “signal transduction bridge”. This leads to a change of the 
    TMD conformation (Loo et al., 2007) and subsequently the peptide will be released in 
   the  ER-lumen. Chapter 5    Discussion 
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  8.  After ATP hydrolysis, the TMD-NBD “signal transduction bridge” will be disconnected 
    and the transporter will return to the “open” conformation.   
 
Peptide pre-bound state
B
Peptide binding
Peptide bound state
A
Coupling
helices
ATP
NBD dimerization
ATP
NBD dimer
ATP hydrolysis
NBD dissociation
Open state
ATP association
ATP
 
Figure 5-3. Dynamic interactions between CHs and NBDs during the translocation cycle. 
(A) Model of interaction based on structural data. According to this model, the CHs stay in contact with the 
NBDs during the translocation cycle (Dawson et al., 2007). (B) Model of interaction based on biochemical 
studies of the present PhD thesis.  Chapter 6    Literature 
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ABCD  ABC transporter subfamily D 
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Crio-EM Cryo-electron  microscopy 
CTL Cytotoxic  T-lymphocyte 
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CuSO4 Copper  sulphate 
Cys-less Cysteine  free 
Da Dalton 
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DMF N,N-Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic  acid 
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DTT 1,4-Dithiothreitol 
E. coli  Escherichia coli 
ECL Enhanced  chemiluminescence 
ECLs Extracellular  loops 
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Elf1p  Elongation-like factor protein 
ER Endoplasmic  reticulum 
ERp57 Protein  disulphide  isomerase-associated 3 
FC-14 Tetradecylphosphocholine 
FCS  Fetal calf serum 
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HI1470/71 Putative  metal-chelate-type transporter ABC complex 
His-tag Histidine  tag 
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IAF Iodoacetamidofluorescein 
ICLs Intracellular  loops 
IgG Immunoglobulin  G 
INF-γ Interferon  γ Abbreviations 
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IPTG Isopropyl-β-D-thiogalactopyranoside 
KCl Potassium  chloride 
Kd Dissociation  constant 
KH2PO4  Potassium dihydrogen phosphate 
Km Kanamycin 
kon  Labeling rate constant 
L  Percent of fluorescence labeling 
LB Luria-Bertani  medium 
LCR  Ligase Chain Reaction 
Lmax  Maximum percent of fluorescence labeling 
LMP Low-molecular-mass  polypeptides 
mAb Monoclonal  antibody 
MalFGK2  Maltose transporter ABC complex 
MDR Multidrug  resistance 
MetNI  Methionine transporter ABC complex 
MgCl2 Magnesium  chloride 
MgSO4 Magnesium  sulfate 
MHC  Major histocompatibility complex 
min Minutes 
MJ0796  Methanococcus jannaschii ABC transporter 
MnCl2 Manganese  chloride 
ModBC-A  Molybdate/tungstate transporter ABC complex 
MOI Multiplicity  of  infection 
MOPS 3-(N-morpholino)propanesulfonic  acid 
MRP  Multidrug resistance protein 
MsbA  Lipid A flippase ABC transporter 
MTS Methanethiosulfonate 
MTS-2-MTS 1,2-Ethanediyl-bis-methanethiosulfonate 
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NaCl Sodium  chloride 
NaF Sodium  fluoride 
Na2HPO4  Disodium hydrogen phosphate 
Na
125I Sodium  iodide Abbreviations 
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NaN3 Sodium  azide 
NaOH Sodium  hydroxide 
Na2S2O5 Sodium  disulfite 
NBD Nucleotide  binding  domain 
NEM N-Ethylmaleimide 
NHS N-Hydroxysuccinimide 
Ni-NTA Nickel-Nitrilotriacetic  acid 
NP-40 Igepal 
OC Obstetric  cholestasis 
PAGE Polyacrylamide  gelelectrophoresis 
PBS Phosphate-buffered  saline 
PCR  Polymerase chain reaction 
PEI Polyethylimine 
PFIC3  Progressive familial intrahepatic cholestasis type 3 
Pgp P-glycoprotein 
pH  Potentia hydrogenii 
PHHI  Persistent hyperinsulinemic hypoglycaemia of infancy 
Pi Inorganic  phosphate 
Pi-Mix Protease-inhibitor  mix 
PLC Peptide  loading  complex 
PMSF Phenylmethanesulfonyl  fluoride 
POPE 1-Palmitoyl-2-oleoyl-phosphatidyl  ethanolamine 
PVDF Polyvinylidene  fluoride 
Rad50 Recombination  mediator  associated with DNA repair 
RbCl Rubidium  chloride 
RMSD Root-mean-square  deviation 
Sav1866  Homologue of multidrug ABC transporters 
SDS  Sodium dodecyl sulphate 
Sf9  Spodoptera frugiperda 
SMC1-6 Structural-maintenance-of-chromosome  proteins 
SPDBV  Swiss-Protein Data Bank Viewer 
SUR  Sulphonyl urea receptor 
t Time 
TAE Tris-acetate  EDTA  buffer Abbreviations 
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TAP  Transporter associated with antigen processing 
TAPL  Transporter associated with antigen processing (TAP)-like 
TBS-T  Tris-buffered saline – Triton X-100 
TEMED N,N,N’,N’-Tetramethyl-ethylendiamine 
TFB Transformation  buffer 
TMD Transmembrane  domain 
TMD0  TMHs of each unique N-domain 
TMHs Transmembrane  helices 
UV Ultraviolet  light 
Vmax  Maximal rate constant 
v/v  volume per volume 
V Volt 
XLSA  X-linked sideroblastic anemia with ataxia 
W Watt 
WHATIF Molecular  modeling  software 
wt Wild  type 
w/v Weight  per  volume 
Yor1p  Plasma membrane ABC transporter Acknowledgements 
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